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Abstract 
Human pre-implantation embryos display a high prevalence of aneuploidy and 
chromosomal mosaicism, unique from any other species.  The decreasing incidence 
of aneuploidy observed between the cleavage and blastocyst stages of pre-
implantation embryo development infers a degree of ‘self-correction’ following 
activation of the embryonic genome.  However, contrary to the previous assumption 
that only euploid embryos should be considered ‘normal’, new evidence has 
confirmed that mosaic embryos can result in the birth of healthy babies.  Thus, 
aneuploidy should be viewed as an intrinsic feature of human pre-implantation 
embryo development, which presents a novel challenge at implantation.  The 
endometrium must implement both positive and negative selection, in order to limit 
maternal investment to only viable embryos.  The ability of the endometrium to act as 
a ‘biosensor’ of embryo quality has been well documented yet there is little direct 
evidence for the key regulators of this process.   
For the first time, we demonstrate a biological context for embryo biosensoring.  
Firstly, we discover novel embryo-secreted proteases that are enhanced at the 
blastocyst stage and relate to implantation outcome upon embryo transfer.  
Secondly, we identify corresponding protease-sensitive receptors in the 
endometrium, heightened during the window of implantation.  By demonstrating the 
cleavage and de-activation of endometrial toll-like receptor 4 (TLR4) by embryo 
conditioned medium, we link successful implantation to a diminished inflammatory 
response.  Furthermore, we demonstrate that TLR4 levels in the endometrium 
constitute a selectivity checkpoint, which is supressed in women suffering from 
recurrent miscarriage (RM). 
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Chapter 1 
Introduction 
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1.1 The Human Endometrium 
The endometrium constitutes the inner, mucosal layer of uterus.  It acts as a lining to 
maintain patency of the uterine lumen by preventing adhesions between the two 
opposing myometrial layers.  The primary reproductive function of the endometrium 
is to provide a nutritive microenvironment which supports viable embryo implantation 
(Tabibzadeh, 1998).  Beyond implantation, the endometrium provides structural and 
nutritional support to the foetus and aids the removal of waste products.  Thus the 
endometrium is an exceptionally adaptable tissue.  Continuous, regular cycles of 
proliferation, differentiation and degeneration occur under the influence of ovarian 
steroid hormones throughout female reproductive maturity.  Shedding of the 
functional endometrial layer takes place in the absence of an implanting embryo yet 
astonishingly the tissue is completely restored within just 2 weeks (Knobil, 2013).  
Re-establishment of the functional endometrial layer and priming of the tissue by 
oestrogen and progesterone restores its receptive state once again.  The means by 
which the endometrium is regenerated is highly intricate and the underlying 
processes have not yet been established.  Yet this process is understood to involve 
proliferation, angiogenesis, differentiation, epithelialization and extracellular matrix 
remodelling (Groothuis et al., 2007).  In recent years, the focus has shifted to the role 
of endometrial stem / progenitor cells in cyclic endometrial regeneration (Gargett et al., 
2015). 
1.2 Structure of the Endometrium 
The endometrium can be subdivided into two key layers; the stratum functionalis and 
the stratum basalis (Figure 1.2.1).  The stratum basalis remains comparatively 
constant from cycle to cycle, whilst the stratum functionalis is dynamic and transient.  
Responsivity to ovarian steroid hormone results in cyclic expansion and 
vascularisation of the stratum functionalis before it becomes sloughed off during 
menstruation.  In the event that an embryo implants, the basalis and the stratum 
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functionalis are maintained and in conjunction with the myometrial junctional zone 
contribute to the maternal fraction of the placenta (Brosens et al., 2002).  Adjacent to 
the uterine lumen a single layer of prismatic epithelial cells coats the apical edge of 
the stratum functionalis.  Yet beneath the basal lamina, stromal cells comprise the 
large majority of this highly vascularised cellular compartment (Rogers, 1996).  The 
myometrium forms an underlying smooth muscle layer, composed predominantly of 
uterine myocytes.  It provides structural and vascular support to the endometrium 
although its primary function is to permit uterine contractions at parturition.  Radial 
arteries situated within the myometrium provide vascular support to the overlying 
endometrium by dividing first into basal arteries which supply the stratum basalis and 
then into spiral arterioles which supply the stratum functionalis.  The 
characteristically coiled spiral arteries are unique amongst the uterine blood vessels 
in that they exhibit selective sensitivity to the cyclic hormonal changes of the 
menstrual cycle.  This was most elegantly observed via the transplantation of 
endometrial fragments into the eye chamber of rhesus monkeys (Markee, 1978).  
The fragments implanted and developed on the iris but soon regressed upon 
progesterone and estradiol withdrawal.  Subsequent coiling of the spiral arterioles 
and venostasis were succeeded by alternating episodes of vasodilation, 
vasoconstriction and bleeding of perivascular cells (Markee, 1978).  The perivascular 
cells surrounding spiral arterioles are also sensitive to progesterone changes and 
produce inflammatory factors including cytokines and prostaglandins (Henriet et al., 
2012).  Although the exact mechanism of tissue breakdown is not yet fully 
understood, spiral arterioles may play a role in menstruation by regulating their own 
vasoconstriction and leukocyte influx (Henriet et al., 2012). 
 The stratum functionalis also contains uterine glands, tubular invaginations, lined 
with columnar epithelial cells.  The primary function of the uterine glands is to provide 
nutrition to a developing conceptus via histotroph secretion (Gray et al., 2001).  Due 
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to their topology within the functional layer of the endometrium, the appearance and 
secretions of the uterine glands fluctuate throughout the menstrual cycle.  During the 
secretory phase of the menstrual cycle the uterine glands become enlarged and 
secretory.   
In developed countries women of reproductive age are thought to undergo, on 
average, 400 menstrual cycles in their lifetime.  Progenitor cells required for the 
regeneration of the stratum functionalis at each menstrual cycle are thought to 
originate from the enduring stratum basalis.  Only recently has evidence for the 
presence of endometrial progenitor (or stem-like) cells with a role in cyclic 
remodelling emerged (Chan et al., 2004, Gargett and Masuda, 2010, Masuda et al., 
2010).  Mesenchymal stem-like cells (MSCs) reside within the endometrium and a 
population of stromal cells have been isolated that display multipotency, 
clonogenicity, immunoprivilege and the ability to contribute to endometrium upon 
transfer into mice via xenograft (Gargett and Masuda, 2010, Miyazaki et al., 2012, 
Wolff et al., 2007).  Various techniques have been adopted in order to isolate 
endometrial stromal cells enriched in MSCs.  Current indications are that endometrial 
stem-like cells are derived from the stratum basalis but may also be found within the 
stratum functionalis due to their identification in menstrual blood (Patel et al., 2008). 
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Figure 1.2.1:  Diagram of the Human Endometrium 
The human endometrium is formed of two components, the stratum functionalis and the stratum basalis.  The stratum functionalis becomes 
remodelled each cycle whereas the stratum basalis remains constant.  The apical surface of the endometrium is covered with a single layer of 
luminal epithelial cells and invaginations from the lumen form the uterine glands.  Underlying stromal cells constitute the majority of the 
endometrium and stem-like cells from the stratum basalis permit the regeneration of the stratum functionalis each cycle.  The endometrium is 
highly vascularised with the spiral arteries in the stratum functionalis originating from blood vessels in the underlying myometrium.  Adapted from 
(Muter, 2015). 
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1.3 The Menstrual Cycle 
Females achieve reproductive fitness due to cyclical modifications that occur in the 
endometrium as a result of fluctuating ovarian steroid hormone levels.  These 
alterations result in distinct phases of proliferation, differentiation, inflammation, 
apoptosis and regeneration, which constitute the menstrual cycle (Figure 1.3.1).  The 
proliferative phase encompasses days 5-13 of a 28 day cycle and results in 
thickening of the endometrial lining from 1-2 to 7-8 mm due to increasing oestrogen 
production by the granulosa cells residing within the ovarian follicle.  The thickening 
results from mitotic proliferation of the endometrial stromal cell compartment, which 
occurs alongside lengthening of spiral arteries and the formation of narrow uterine 
glands by proliferation of endothelial and epithelial cells, respectively (Brosens et al., 
2002, Gray et al., 2001).  The secretory phase is initiated when heightened serum 
oestrogen levels induce a surge of luteinising hormone (LH), which in turn acts upon 
the corpus luteum to promote progesterone production.  This post-ovulatory rise in 
progesterone halts the proliferative process and initiates a highly coordinated 
differentiation process.  The secretory phase endows this newly thickened 
endometrial lining with a receptive phenotype capable of supporting embryo 
implantation and development through vast morphological and physiological 
changes.  The spiral arteries become highly coiled, whilst uterine glands widen, coil 
and exude a glycogen-rich secretion.  Areas of local oedema occur within the stromal 
layer, the extracellular matrix undergoes substantial remodelling and there is an influx 
of specialised innate immune cells termed uterine natural killer cells (uNK) (Gellersen 
and Brosens, 2003, Gellersen and Brosens, 2014, Hanna et al., 2006).  Around day 
23 of the cycle, coinciding with the closure of the putative window of implantation, 
stromal fibroblasts are transformed into specialized decidual cells (see section 1.4).  
In the presence of a viable, implanting embryo trophoblast-derived human chorionic 
gonadotrophin (hCG) maintains the corpus luteum and upholds progesterone 
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production permitting the continuation of this supportive environment.  In the absence 
of a viable embryo the corpus luteum will degenerate, resulting in declining 
progesterone levels which initiates a chain of events culminating in proteolytic 
breakdown and menstruation. 
Humans, fruit bats, elephant shrews and some old world primates are the only 
species who experience menstruation via monthly shedding of the endometrium 
(Emera et al., 2012) and display cyclic decidualization, which occurs spontaneously 
irrespective of the presence of an embryo.  In these mammals menstruation and 
decidualization occur as a result of low and high serum progesterone levels, 
respectively.  Menstruation emulates an inflammatory response highlighted by the 
high numbers of leukocytes within the endometrial compartment which, prior to 
menstruation, make up 40% of the entire cell population (Salamonsen et al., 2002).  
Leukocytes assist the release of pro-inflammatory cytokines, whilst matrix 
metalloproteases (MMP) induce degradation of the extracellular matrix.  Local 
prostaglandins cause sudden constriction of the spiral arteries leading to ischaemia 
and shedding of the superficial endometrial decidual cells. 
Menstruation is widely viewed as a process of re-initiating a cycle of endometrial 
preparations for implantation in the absence of a pregnancy.  There have been 
various theories as to why menstruation would be evolutionarily advantageous.  It 
may be that menstruation alleviates the metabolic pressures of supporting a 
continuously receptive endometrium (Strassmann, 1996) or prevents unnecessary 
maternal investment in a non-viable conceptus (Teklenburg et al., 2010a).  The 
theory of uterine pre-conditioning suggests that exposure to repeated episodes of 
inflammation and oxidative stress associated with cyclic shedding and renewal of the 
endometrium and its vasculature serve to prepare the endometrium for deep 
placentation and protect against hyper-inflammation (Brosens et al., 2009).   
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Figure 1.3.1: The Menstrual Cycle 
The menstrual cycle occurs under the cyclical influence of the ovarian steroid hormones 
estradiol and progesterone.  It can be divided into the follicular and luteal phases.  In the 
follicular phase the endometrium is shed at menstruation and regenerated via the 
proliferation of endometrial stem cells under the influence of E2.  In the luteal phase, 
following ovulation, a rise in progesterone halts the proliferative phase and initiates a 
highly coordinated differentiation process that cumulates in the decidual transformation of 
the endometrium.  Decidualization endows the endometrial stromal cells with migratory 
and selective capabilities required for embryo selection.  Adapted from (Cha et al., 2012). 
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1.4 Decidualization of the Endometrium 
Decidualization denotes the extensive remodeling process that the endometrium 
must undergo to support an implanting embryo. The decidual process is foremost 
characterised by the morphological transformation of elongated stromal fibroblasts 
into rounded, secretory decidual cells.  This process is initiated during the mid-luteal 
phase of the cycle, coinciding with the endometrium transiently acquiring a receptive 
phenotype (Figure 1.4.1), although the characteristic decidual cell morphology in 
vivo becomes more prominent during the late-luteal phase.  This ‘window of 
implantation’ starts approximately 6 days after the surge in luteinizing hormone (LH) 
and is thought to last no longer than 2-4 days.  
Decidualization is induced by sensitization of the oestrogen-primed cells to a post-
ovulatory rise in progesterone and rising intracellular cyclic adenosine 
monophosphate (cAMP) levels during the luteal phase.  This remodeling process is 
first initiated at terminal spiral artery sites before extending throughout the 
endometrium and is accompanied by an influx of specific immune cells (Gellersen 
and Brosens, 2003).   
A complex system of signaling pathways, transcription factors and cross-talk 
underlies this decidual reaction (Christian et al., 2002).  The resulting morphological 
and biochemical changes are dramatic and involve the secretion of prolactin (PRL), 
insulin-like growth factor binding protein-1 (IGFBP-1) and numerous other factors, 
including; the NODAL-signaling pathway inhibitor LEFTY2, BMP2 (bone 
morphogenetic protein 2) and WNT4 (wingless-type MMTV integration site family, 
member 4) (Gellersen and Brosens, 2003, Gellersen et al., 2007, Gellersen and 
Brosens, 2014).  Modifications at the cellular level include; extracellular matrix and 
cytoskeletal remodeling, expansion of cytoplasmic organelles and acquisition of a 
secretory phenotype, transcription factor modulation and altered expression of 
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numerous intracellular enzymes and signalling pathways (Gellersen and Brosens, 
2014).  Importantly, the decidual phenotype is not static. Instead, human 
endometrial stromal cells (HESCs) transit through distinct functional phenotypes, 
characterized initially by an acute pro-inflammatory response, which is followed by 
an anti-inflammatory response and acquisition of the characteristic rounded decidual 
cell morphology. The transient inflammatory stromal response induces the 
expression of receptivity genes, including leukemia inhibitory factor (LIF), 
interleukin-1 beta (IL-1) and heparin-binding EGF-like growth factor (HB-EGF) 
(Salker et al., 2012); whereas acquisition of a mature decidual phenotype coincides 
with closure of the window.  Failure to establish a receptive phenotype or premature 
closure of the receptivity window inevitably leads to implantation failure (Koot et al., 
2016).  Conversely, a disordered and prolonged pro-inflammatory decidual response 
promotes out-of-phase implantation and is associated with miscarriage (Muter et al., 
2015, Salker et al., 2010, Salker et al., 2012). 
The endometrium at implantation is characterized by an abundance of immune cells, 
predominantly uNK cells, macrophages and dendritic cells.  These accumulate 
around the trophoblast cells at the implantation site (Mor et al., 2011).  Yet, rather 
than inducing rejection of the embryo, as in the tissue allograft model, the influx of 
immune cells during decidualization promotes implantation and placentation.   In 
fact, a depletion of immune cells in the decidua results in termination of pregnancy 
(Cha et al., 2012).  The process of implantation may thus be described as 
secondary to the development of a pro-inflammatory phenotype (Cha et al., 2012).  
During implantation, uNK cells are crucial for trophoblast invasion, enabling the cells 
to permeate the stroma and reach the endometrial vascularity (Mor et al., 2011).  
Maternal immunologic tolerance of the embryo is achieved through entrapment of 
dendritic cells by decidual cells (Cha et al., 2012).  This prevents a T cell-mediated 
immunological reaction by preventing contact of maternal T cells with fetal or 
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placental antigens.  Epigenetic changes upon decidualization silence inflammatory 
chemokine genes, restricting chemokine expression within the decidua and 
preventing the recruitment of activated T cells to the sites of inflammation (Cha et 
al., 2012).  Modifications during the transformation of HESCs into decidualized 
endometrial stromal cells (DESCs) also enable the maintenance of progesterone 
signalling and cellular homeostasis under the oxidative stress conditions imposed by 
pregnancy.  Silencing of c-Jun N-terminal kinases (JNK) in DESCs averts 
hypersumoylation in response to reactive oxygen species (ROS) preventing 
transcriptional inhibition of the progesterone receptor (Leitao et al., 2010). 
Errors during decidualization have been connected to adverse events later in 
pregnancy including placental defects, growth restriction and pre-term birth.  Risk 
factors found to induce cellular senescence are also responsible for triggering pre-
term birth.  Furthermore, pre-term birth is more prevalent amongst women of 
advanced maternal age, suggesting a role for senescence in the induction of 
parturition.  Mice with a uterine deletion of transformation-related protein 53 (Trp53) 
display normal implantation accompanied by increased rates of pre-term birth, fetal 
dystocia and death.  Interestingly, these mice also exhibit defective decidualization 
and display higher levels of terminally differentiated, polyploid stromal cells.  More 
recently, recurrent miscarriage (RM) has been associated with increased premature 
senescence of HESCs, resulting in aberrations of the decidual secretome that 
orchestrate early implantation events (Lucas et al., 2015).  
Simultaneous to decidualization, histotrophic support is initiated, ensuring long-term 
growth and survival of the conceptus  (Brosens et al., 2014, Burton et al., 2002).  
Due to the invasive nature of human implantation, perfusion of the developing 
conceptus was thought to provide nutritional support in the early stages of 
pregnancy.  However, plugging of distal portions of the spiral arteries by 
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cytotrophoblast cells restrict significant blood flow to the placenta until 10-12 weeks 
of gestation (Hustin and Schaaps, 1987, Burton et al., 1999).  Histotrophic support 
by uterine glands, HESC secretions and plasma filtrate from the endometrial 
vasculature is thus thought to support embryo and fetal development during the first 
trimester (Burton et al., 2002).  An anaerobic, histotrophic environment is thought to 
be optimal for cellular differentiation during eutherian organogenesis as it minimises 
DNA damage and ROS (Burton et al., 2002).  Uterine gland secretions enrich 
placental development during this phase, producing immunosuppressive cytokines 
that allow maternal tolerance of the placenta and assist remodelling of the utero-
placental vessels (Burton et al., 2002). 
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Figure 1.4.1: Decidual Transformation 
Decidualization occurs in the mid-secretory phase of the menstrual cycle following a post-
ovulatory rise in progesterone. Decidualization of HESCs can be achieved in vitro by 
treatment with a cell permeable cAMP analogue (8-br-cAMP) and a synthetic progestin 
MPA.  Adapted from (Wiley, 2015, Brosens et al., 2014). 
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1.5 Implantation 
Implantation has been historically described as a step-wise process involving (a) 
apposition of a polarised embryo to the maternal luminal epithelium (b) adhesion of 
the embryo to the epithelium at a specific site and (c) invasion resulting from 
migration of both stromal and trophoblastic cell types, until the embryo is fully 
encapsulated within the endometrium.   
In the pre-existing step-wise model of implantation, the embryo was seen as the 
sole determinant of implantation outcome, actively invading a relatively passive 
endometrial matrix.  This was supported by evidence of aggressive invasion of spiral 
arteries by endovascular extravillous trophoblast cells, in a manner likened to 
tumour metastasis (Ferretti et al., 2007).  However, this view has since shifted in line 
with evidence for the endometrium in regulating the timing and extent of embryo 
invasion.   
In humans, cyclical maternal preparations initiated by steroid hormone changes 
prime the endometrium for potential implantation and bestow spatiotemporal control 
over embryo implantation through the instruction of a ‘window of implantation’, as 
discussed previously (Koot et al., 2012, Gellersen and Brosens, 2003).  This phase 
of receptivity occurs between day 20 and day 24 of the menstrual cycle (LH + 6 and 
LH + 10) and acts as a self-limiting time frame to ensure the synchronicity of 
endometrial and embryonic development.  The restriction of endometrial receptivity 
in this way thus acts as a quality control mechanism which reduces the chance of 
maternal investment in non-viable embryos.   
At the embryo-maternal interface during the time of implantation, overlying 
endometrial epithelial cells first make contact with the trophectoderm layer of the 
blastocyst.  The endometrial epithelium has traditionally been viewed as a barrier to 
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implantation following evidence that mouse blastocysts could implant at any stage 
upon damage to this cellular compartment (Cowell, 1969) (Figure 1.5.1).  Whether 
or not the luminal epithelium is a true barrier to implantation in humans has recently 
been challenged (Lucas et al., 2013).  A barrier is essential in polytocous species, 
such as mice, where reproductive success is critically dependent on synchronized 
implantation of multiple blastocysts.  Mouse embryos are capable of temporarily 
suspending development while awaiting the right maternal signals for implantation, a 
process termed embryonic ‘diapause’ (Lopes et al., 2004).  This maternal signal is a 
surge in ovarian estradiol, which triggers synchronized implantation of 
chromosomally stable mouse embryos (Hamatani et al., 2004).  However, human 
embryos do not normally exhibit diapause, are highly invasive and often 
chromosomally unstable (as discussed in section 1.9).  In view of these 
characteristics, it has been argued that human embryos may rapidly breach the 
luminal epithelium unimpeded. Furthermore, recent co-culture studies have 
demonstrated the ability of DESCs to actively migrate towards and engulf hatched 
blastocysts (Grewal et al., 2008, Teklenburg et al., 2010b).  In this model, 
implantation is critically determined by the initial embryo-decidual cell interactions.  
Clues to the mediators of implantation require an understanding of the synchronised 
changes in both the endometrial milieu and the embryo at the time of implantation.  
In vitro cell cultures, animal models and clinical studies have enabled further 
understanding of the key factors involved at implantation (Table 1.5.1).   Yet 
distinguishing between the maternal and embryonic contributions to successful 
implantation, as well as recognising the intra-species differences, provide ongoing 
challenges to this area of research.   
Gene deletions, primarily in mouse models (Table 1.5.2), and expression profiling of 
human endometrial samples propose a preserved network of regulatory genes and 
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factors as critical in establishing a state of endometrial receptivity (Teklenburg et al., 
2010a).  The use of microarray technology has generated a wealth of gene 
expression data that requires further annotation and investigation in order to 
establish key regulators of the implantation process (Koot et al., 2012).  
Transcription factors, growth factors, cytokines and adhesion molecules have all 
been implicated in this pathway but not yet conclusively enough to be applied to the 
therapeutic setting of pregnancy failure.  
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Figure 1.5.1 Cross-talk at Implantation 
The expression of key growth factors, cytokines and hormones at the time of implantation 
highlights that the process involves cross-talk between the embryo, the endometrial 
epithelium and the underlying stromal compartment.  From (Singh et al., 2011). 
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Table 1.5.1 Key Factors at Implantation 
 
 Features Role in Implantation References 
Cadherins Required for calcium dependent cell-to-cell 
adhesions 
P4 dependent expression of E-cadherin via 
calcitonin. 
 
E-cadherin downregulation is thought to be 
involved in embryo invasion. 
 
Li et al., 2002; Achache and 
Revel, 2006 
IL-1 Pro-inflammatory cytokine able to induce a range 
of responses in a variety of cell types 
 
Produced by macrophages, trophoblast and 
stromal cells. 
 
IL-1 agonists, IL-1α and IL-1β, are ubiquitously 
expressed in stromal, epithelial and endothelial 
cells.  Yet IL-1α is expressed more strongly in 
human endometrium and upregulated in LE during 
the secretory phase 
 
Attributed to integrin regulation (increased integrin 
β3 expression seen in HEEC cultures 
supplemented with IL-1) 
 
Thought to mediate embryonic-endometrial cross-
talk at implantation 
 
IL-1 deficient mice are able to achieve pregnancy, 
yet implantation rates fall with injections of an  IL-1 
receptor antagonist 
 
IL-1 secretion by human embryos is quantifiable by 
ELISA in samples of embryo conditioned media, in 
contrast to IL-6 which was undetectable 
 
Levels in ECM are higher from successfully 
implanted embryos compared to those that failed 
to implant 
 
 
Simon et al., 1994; Baranao 
et al., 1997; Simón et al., 
1997; Tabibzadeh and Sun, 
1992 
 
IL-6 Induces an immune response upon secretion by T-
cells and macrophages 
 
IL-6 receptors are detectable in both endometrium 
and blastocyst during implantation indicative of a 
paracrine/autocrine role 
 
IL-6 deficient mice display reduced fertility due to 
implantation defects 
 
Abnormal IL-6 expression has been reported in 
RM patients 
 
Expression higher in HEECs than DESCs and 
induced by IL-1 in DESCs 
Achache and Revel, 2006; 
Lim et al., 2000; Cork et al., 
1999; Von Wolff et al., 
2000; Laird et al., 2003; 
Laird et al., 1994 
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Integrins Transmembrane glycoproteins involved in cell 
adhesion 
 
Identified as regulators of implantation in both the 
human and mouse 
 
v3, 31, 64 and v5 are expressed on the 
outer surface of blastocysts 
 
 
 
 
 
Display steroid activation, up-regulation during the 
receptive phase (αVβ3 expression coincides with 
the WOI) 
 
Widely implicated in endometrial receptivity 
(Aberrant αVβ3 expression in unexplained 
infertility), embryo apposition and adhesion 
 
Proposed role in embryo spacing in mice 
 
Extent of their individual significance, mechanism 
of action and cross-talk in human pregnancy 
remains controversial 
 
Aplin, 1997; Quenby et al., 
2007; van Mourik et al., 
2009; Klentzeris et al., 
1993; Lessey et al., 1995 
Leukaemia inhibitory 
factor (LIF) 
A secreted glycoprotein that affects cell growth by 
regulating differentiation 
 
Promotes trophoblast differentiation toward an 
anchoring extravillous phenotype 
 
 
Co-culture of embryos with LIF expressing 
embryonic trophoblasts and recombinant LIF 
significantly enhanced blastocyst development, 
expansion and hatching 
 
Present in human endometrium and peaks in the 
secretory phase of the menstrual cycle 
 
LIF receptor mRNA has been identified on human 
blastocysts in vitro 
 
Enhanced embryo development in the presence of 
LIF at the late developmental stages (morula and 
beyond) 
 
Increased in uterine flushings of fertile women 
between days LH+7 to LH+12.  Levels were lower 
in women suffering from unexplained fertility (on 
day LH+10) 
 
Basal levels in HEECs differ according to biopsy 
timing, being highest at the late proliferative and 
early secretory phases 
High doses of estradiol and progesterone reduce 
LIF levels in HEECs in vitro 
 
Maternally controlled LIF expression in 
endometrial glands is highest at the time of 
implantation (in mice) 
 
Application of LIF receptor antagonist (PEGLA) to 
timed endometrial biopsies impaired blastocyst 
attachment 
 
Down-regulation of AKT and up-regulation of 
Caspase-3 activation, in the absence of LIF, 
indicate a role in regulating apoptosis at 
Stewart et al., 1992; 
Dunglison et al., 1996; 
Jurisicova et al., 1999; 
Lalitkumar et al., 2013; 
Nachtigall et al., 1996; 
Kauma and Matt, 1995; 
Tsai et al., 1999; 
Arici et al., 1995; Charnock-
Jones et al., 1994; Kojima 
et al., 1994; Bhatt et al., 
1991; Laird et al., 1997 
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Addition to media reported to increase blastocyst 
formation rates from 18.4% to 43.6%, but 
contradictory evidence exists 
 
Stromal secretion of LIF  is enhanced by 
embryonic IL-1, TNFα, PDGF and TGFβ 
implantation 
LIF-/- mice display impaired implantation (partially 
corrected by peritoneal infusion of LIF) yet LIF-/- 
blastocysts implant in wild-type pseudopregnant 
recipients 
 
RIF patients display reduced LIF induction from 
the proliferative to secretory phase 
 
However recombinant LIF administration to RIF 
patients failed to increase 
implantation rates 
 
Micro RNA (miRNA) Involved in post-transcriptional regulation of gene 
expression though regulation of mRNA stability 
 
13 miRNAs (that putatively regulate the expression 
of 3800 genes) were found to be differentially 
expressed in endometrial samples  of RIF patients, 
compared to controls 
 
Revel et al., 2011; 
Kuokkanen et al., 2010 
Mucins Highly glycosylated, large molecules found on 
apical LE cells 
 
Protect the mucosal surface from infection and the 
action of degradative enzymes 
 
Seen as a barrier to implantation as they cover the 
endometrium 
 
Loss of electronegative sulphated glycan from 
MUC-1 in the apical LE should encourage 
apposition of the blastocyst 
 
MUC-1 is cycle dependent and acts as a barrier to 
implantation in mice 
 
Progesterone and estradiol priming induces up-
regulation of MUC1 in receptive endometrium 
 
Human blastocysts express MUC1 in the TE and 
increase MUC1 expression in EEC but induces 
paracrine cleavage at the implantation site 
 
RIF patients display low MUC-1 levels 
 
Aplin et al., 1996; Aplin, 
1997; Meseguer et al., 
2001 
Pinopodes (endometrial 
apical plasma membrane 
protrusions) 
Present on apical surface of LE during WOI 
Progesterone dependent expression 
Involved in endocytosis and pinocytosis 
Expressed throughout the luteal phase and early 
pregnancy 
Originally thought to assist embryo apposition 
No direct role in embryo-endometrial interactions 
High level of inter-patient variation regarding their 
timing within the uterus 
Expression not restricted to the WOI 
Bentin-Ley, 2000; 
Nikas et al., 1995; Nikas 
and Psychoyos, 1997; 
Quinn et al., 2007 
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Prostaglandins Modulators involved in immune cell suppression,  
widely implicated in providing an integral maternal 
contribution to implantation 
 
Possess vasoactive factors which allow access to 
the maternal vascular system 
 
Synthesised by cytosolic phospholipase A2 
(cPLA2), COX-1 and COX-2 enzymes, 
upregulated by P4 
 
Studies of Ptsg2-/- mice highlighted the 
importance of PGI2 and proposed a 
complementary role for prostaglandin-E2 (PGE-2) 
in implantation 
 
PGE2 acts synergistically with estradiol and MPA 
to enhance differentiation of HESCs in a dose 
dependent manner 
 
PGI2 acts via IP (PGI2 receptor) activating 
extracellular signal regulated kinase (ERK1/2) and 
up-regulating pro-angiogenic genes via interaction 
with EGFR 
 
Delayed implantation in cPLA2 knockout mice, 
rescued by exogenous PG administration 
 
Reduced cPLA2α and COX-2 expression in RIF 
patients 
 
Impaired implantation in estrogen stimulated mice 
treated with indomethacin (prostaglandin 
production inhibitor), restored upon PGE2 
treatment (10ug/6ul dose) 
 
PGE2 is increased in endometrial fluid during the 
WOI in humans and in LE during the peri-
implantation period in mice 
 
The exact role at implantation has been 
questioned as PGE-2 receptor (EP2) null mice 
displayed diminished ovulation rather than 
decidualization or implantation defects 
 
Iloprost, a stable PGI2 analogue, enhances 
hatching of murine blastocysts and promotes 
implantation and live birth rates in cattle 
Holmes et al., 1990; 
Holmes and Gordashko, 
1980; Frank, 1994; Vilella 
et al., 2013; Lim and Dey, 
1997; Matsumoto et al., 
2001; Lim et al., 1999; 
Milling Smith, 2006; Huang 
et al., 2004; Song et al., 
2009 
Selectins Single chain transmembrane glycoproteins 
involved in cell adhesion 
Binding of L-selectin on the embryo surface to 
carbohydrate ligands on the maternal epithelium 
was found to generate a physiologically relevant 
interaction which enables orientation of the ICM 
towards the apical epithelium and promotes 
attachment in human implantation 
 
Impaired adhesion results from the application of 
L-selectin antibodies, but L-selectin deficient mice 
were found to be fertile 
Dominguez et al., 2005; 
Genbacev et al., 2003 
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Table 1.5.2 Genes Critical to Implantation: Results of Mouse Knockout Models 
 
Gene Molecule encoded (Putative function) Knockout phenotype in females References 
Bsg Basigin (Immunoglobulin) Defective fertilization; no implantation 
Igakura et al., 1998; Kuno et al., 
1998 
Esr1 Estrogen receptor-α (NR,TF) 
No uterine attachment, but uterine responsiveness to 
decidualization persists with P4 priming 
Lubahn et al., 1993; Paria et al., 
1999 
Fkbp52 
FK506-binding protein-4 (Immunophilin co-
chaperone for steroid hormone NRs) 
Compromised P4 function; no uterine receptivity (ME) Tranguch et al., 2005 
Gp130/Stat 
GP130/Signal transducer and activator of 
transcription (Cytokine-receptor signalling) 
No implantation (ME) Ernst et al., 2001 
Hmx3 H6 homeobox-3 (TF) No implantation (ME) Wang et al., 1998) 
Hoxa10 Homeobox A10 (TF) Defective decidualization; reduced fertility (ME) 
Benson et al., 1996; Lim et al., 
1999b; Satokata et al., 1995 
Hoxa11 Homeobox A11 (TF) Defective implantation and decidualization; infertility Hsieh-Li et al., 1995 
Il11ra1 Interleukin-11 receptor-1 (Cytokine signalling) Impaired decidualization; infertility 
Robb et al., 1998; Bilinski et al., 
1998 
Lif Leukaemia inhibitory factor (Cytokine) No implantation (ME) Stewart et al., 1992 
LpA3 
Lysophosphatidic acid receptor-3 (LPA 
signalling) 
Deferred, on-time implantation; aberrant embryo spacing; post-
implantation defects; small litter size (ME) 
Ye et al., 2005 
Pgr Progesterone receptor (NR,TF) 
No implantation or decidualization (ME); Lack of decidual 
response even after P4 priming 
Lydon et al., 1995 
Pla2g4a 
Phospholipase A2, group IVA [cytosolic Ca
2+
 
dependent] (Arachidonic-acid-releasing enzyme) 
Deferred on-time implantation; aberrant embryo spacing; post-
implantation defects; small litter size (ME) 
Song et al., 2002 
Ppar 
Peroxisome proliferator-activated receptor-δ 
(NR,TF) 
4–6 h delay in initiating embryo attachment; placental defects; 
subfertility 
Lim et al., 1999a; Barak et al., 
2002 
Ptgs2 
Prostaglandin-endoperoxide synthase-2 
(Prostaglandin synthesis) 
Multiple reproductive failures, including defective attachment 
reaction; genetic-background-dependent; Defective 
decidualization; reduced angiogenic response 
Lim et al., 1997; Wang et al., 
2004; Matsumoto et al., 2001 
ME, maternal effect; NR, nuclear receptor; TF, transcription factor (Wang and Dey, 2006) 
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1.6 Pre-Implantation Embryo Development 
Studies of mammalian, predominantly mouse, embryos have supplied fundamental 
insights into early embryo development (Wang and Dey, 2006).  Yet species-specific 
differences mean that these findings are of limited relevance to our understanding of 
pre-implantation embryo development in humans.  The emergence of ARTs 
(assisted reproductive technologies), particularly IVF (in vitro fertilization) to treat 
fertility problems, has since formed the key context of our understanding of human 
pre-implantation embryo development.   
Fusion of oocyte and sperm at fertilization initiates the oocyte to embryo transition 
and is followed by pronuclei migration and fusion.  Relative transcriptional silence 
characterises the first phase of pre-implantation embryo development, whereby 
genetic and epigenetic modifications and a series of cellular divisions occur entirely 
dependent on maternally inherited material.  This phase incorporates the 
downregulation and degradation of over 1000 maternal transcripts in humans and 
terminates with a major wave of embryonic genome activation (EGA).  In human 
embryos this initial phase lasts 3 days, from the 4 to 8 cell stage, and occurs entirely 
independently of cell number (Braude et al., 1988, Dobson et al., 2004).  Timing of 
EGA activation varies markedly between species being undetectable prior to the 2-
cell stage in mice, 4-cell stage in pigs and 8-cell stage in sheep (Braude et al., 1988, 
Braude et al., 1979, Crosby et al., 1988).  Beyond the 8-cell stage human embryos 
undergo compaction, whereby the outer cells of the morula become tightly 
connected by desmosomes and gap junctions.  This provides the first visible 
indication of interrupted radial symmetry and beyond this point morphological 
checkpoints become a function of embryo developmental timing as opposed to cell 
number.  The development of a blastocyst occurs upon subsequent cell divisions 
and the initiation of a blastocoel cavity at the cavitation stage.  A blastocyst may be 
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characterised by a distinct inner cell mass (ICM) and outer trophectoderm (TE) 
layer, which surrounds the fluid-filled blastocoele cavity.  Prior to implantation the 
ICM separates into early epiblast, which will form the fetus, and primitive endoderm, 
which will give rise to extraembryonic endoderm cells which form the yolk sac.  
Human pre-implantation development largely occurs during passage of the embryo 
along the fallopian tube towards the uterine cavity.  By the time the embryo reaches 
the blastocyst stage (day 5) it is thought to emerge from the fallopian tube and make 
contact with the endometrium.  Periodic contractions and expansions between day 6 
and 7 encourage the blastocyst to hatch from its protective, glycoprotein shell (zona 
pellucida).  Successful convergence of the hatched blastocyst and endometrium at 
implantation is required for the subsequent survival and development of the human 
embryo and is thought to occur around day 8.  
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1.7 Species Differences Pre- and Post- Implantation 
Human and mouse embryos similarly undergo cell divisions to form a blastocyst with 
apparent ICM and TE.  Yet despite the morphological resemblance of human and 
mouse pre-implantation embryos, developmental timings have been found to differ 
notably between species with human embryo development lagging behind that of 
the mouse (Figure 1.7.1).  A human blastocyst forms between day 5 and 6 of pre-
implantation embryo development and typically contains around 256 cells.  In 
contrast the cells of a mouse blastocyst, formed between day 3 and 4, are thought 
to undergo one less cell division and comprise around 164 cells (Niakan et al., 
2012).  This delayed embryo development includes a lag in the timing of EGA, 
compaction and blastocyst formation (Figure 1.7.1).   
Species-specific differences extend into the post-implantation period and 
placentation whereby trophectoderm cell fates and invasive capacity are similarly 
divergent.  In both species the ICM gives rise to the epiblast (Epi) and primitive 
endoderm (PE) layers, whilst the TE forms the trophoblast lineage of the placenta.  
The epiblast forms all tissues of the fetus whereas the PE forms the extraembryonic 
endoderm which creates the yolk sac.  In humans the trophectoderm cells form 
placental cytotrophoblast cells which proliferate and differentiate into multinucleated 
syncytial cells and extravillous trophoblast which invade the decidualized 
endometrial cells (Figure 1.7.1) (Norwitz et al., 2001, Moffett and Loke, 2006).  In 
mice, unlike the early invasion seen in humans, TE cells produce a proliferative 
stem cell pool of extraembryonic ectoderm cells that bud off polyploid trophoblast 
giant cells via a process of endoreduplication (Figure 1.7.1) (Simmons et al., 2007). 
The developmental differences observed between human and mouse embryos may 
be explained by key molecular discrepancies, including; unique gene expression 
patterns (Dobson et al., 2004, Wang et al., 2004, Zeng and Schultz, 2005, Bell et al., 
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2008), epigenetic modifications (Beaujean et al., 2004, Fulka et al., 2004), 
predisposition to genetic instability (Vanneste et al., 2009, Vanneste et al., 2011) 
and a protracted period of transcriptional silence in humans (Braude et al., 1988, 
Flach et al., 1982).  
The process of implantation varies markedly between species.  This is evident upon 
comparison of the physical interactions between the embryonic trophoblast, 
endometrial luminal epithelial and stromal cells at the ‘invasion’ stage in key animal 
models (Figure 1.7.2).  In the mouse, the primary animal model used for human 
implantation, around 10 embryos will implant in a single implantation event.  This 
requires a process of maternally controlled embryonic diapause whereby 
suspension of embryo development, via cell cycle arrest and reduced metabolism, 
delays implantation (Lopes et al., 2004).  This permits the coordination of embryo 
development according to endometrial readiness for implantation.   The implantation 
of multiple embryos requires unique mechanisms of embryo spacing throughout the 
uterine horn whilst uterine oedema and luminal closure appear to cause apposition 
of the maternal luminal epithelium to the spatially restricted murine embryos (Wang 
and Dey, 2006).  In contrast, human implantation generally involves the acceptance 
of a single, highly invasive and often chromosomally abnormal embryo, with no 
known maternal control over its development.  In humans the feature of uterine 
closure is entirely absent and the embryo has been described as a ‘free-floating 
body’ within the uterine cavity requiring an entirely distinct process of apposition 
(Genbacev et al., 2003).  Interspecies variation in placentation and pregnancy 
(Table 1.7.2) highlights an evolutionary divergence in the degree of maternal 
investment in the conceptus.  This presents a role for stringent embryo selection at 
the human maternal-embryo interface.   
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Figure 1.7.1 Developmental Timing and Cell Fate Decisions in Human and Mouse Pre-Implantation embryos. 
Embryonic genome activation (EGA), inner cell mass (ICM), epiblast (Epi), primitive endoderm (PE), trophectoderm (TE). 
Adapted from (Niakan et al., 2012).  
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Figure 1.7.2 Distinct Modes of Implantation in Various Species 
The key objective of implantation is anchorage of the trophoblast (T) into the 
stroma (S).  In mice and rats the embryonic endoderm (En) attaches to the 
luminal epithelium (LE), inducing localised apoptosis of the LE and permitting T 
migration into the S.  D = decidual cells.  In guinea pigs focal protrusions of the 
zona pellucida (ZP) by the syncytial trophoblast is followed by embedding of 
trophectoderm into the S.  In rabbits, clusters of trophoblast cells fuse with the LE 
to form symplasma.  In mammals the trophectoderm derived T breaches the LE 
and migrates into the underlying S.  Adapted from (Wang and Dey, 2006). 
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Table 1.7.1 Comparison of pregnancy and placentation in mice and humans 
 
 Mouse Human 
Implantation Secondarily interstitial Primary interstitial 
Yolk sac 
Inverted yolk sac placenta 
functions to term 
Yolk sac floats free in 
exocoelom during first 
trimester 
Trophoblast invasion of 
uterine arteries 
Shallow; limited to proximal 
decidua 
Extensive; reaching 
myometrial vessels 
Transformation of uterine 
arteries 
Dependent on maternal 
factors (uNK cells) 
Dependent on trophoblast 
Area of placental exchange Labyrinthine Villous 
Trophospongium 
Three trophoblast layers; 
outer one cellular, inner two 
syncytial 
Absent 
Interhaemal barrier Extensive 
Single layer of syncytial 
trophoblast 
Placental hormones Placental Lactogens 
hCG, hPL, Placental Growth 
Hormone; major source of 
Progesterone 
Time of Gestation Three weeks Nine months 
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1.8 Challenges of Human Reproduction 
The efficiency of human reproduction is low when compared to other mammalian 
species.  Humans display a monthly fecundity rate (chance of achieving a 
pregnancy in a single menstrual cycle) of ~20-30%, compared to 80% in baboons 
and 90% in rabbits (Chard, 1991, Foote and Carney, 1988, Stevens, 1997).  
Despite medical assistance being available to address fertility problems in humans, 
embryo transfers following ARTs only result in pregnancy in around 50% of cases 
(Boomsma et al., 2009).  Furthermore, over 50% of these conceptions are 
estimated to ultimately end in pregnancy failure due to the additional human 
challenges of embryo wastage and increased pregnancy loss (Macklon et al., 
2002).  The rate of pregnancy loss, in humans, has been estimated as occurring 
most commonly during early pregnancy, prior to 6 weeks gestation (Figure 1.8.1).  
Yet the clinical pregnancy loss at 12 weeks gestation is estimated to be 10-15 % 
(Chard, 1991, Macklon et al., 2002).  RM, defined as 3 or more consecutive losses, 
affects 1-2% of fertile couples (Jauniaux et al., 2006, Rai and Regan, 2006).  Pre-
clinical pregnancy loss therefore presents an additional reproductive challenge in 
humans and is distinct from subfertility (Koot et al., 2010).   
Pregnancy loss, whether sporadic or recurrent, is thought to originate from 
aberrations either of the embryo (chromosomal or developmental) or the uterine 
environment.  Yet no specific anatomical, immunological, endocrine or genetic 
aetiologies have been predominantly linked with RM.  Rather, an association 
between decreased time to pregnancy (TTP) and RM has been observed.  The 
anecdotal notion of superfertility, determined by a TTP <3 months, is estimated to 
affect 3% of the population (Macklon et al., 2002).  A retrospective analysis of 560 
patients affected by RM revealed that 40% could be defined as ‘superfertile’ (Salker 
et al., 2010).   In association with a decreased TTP, the superfertile population 
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experience fewer pre-clinical pregnancy losses, but greater post-clinical losses 
(Figure 1.8.1).  These findings have led to the development of a ‘receptivity versus 
selectivity’ paradigm (Figure 1.8.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
     
  32 
 
 
Figure 1.8.1 The Embryo Wastage Iceberg 
The outcome of conceptions in fertile and superfertile populations, whereby the 
‘sea-level’ distinguishes pregnancy losses before the missed menstrual period 
and clinically recognised pregnancies.  Adapted from (Teklenburg et al., 2010a). 
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1.9 Embryo Selection or ‘Biosensoring’ 
The need for embryo receptivity to be coupled with selectivity in humans is in line 
with the characterisation of pre-implantation human embryos as highly invasive and 
frequently chromosomally abnormal.  Human pre-implantation embryos were first 
characterised in the 1950s, where they were extracted from volunteers undergoing 
elective hysterectomy (Hertig et al., 1954, Hertig et al., 1956).  Even during this 
early work, it was hypothesised that developmental abnormalities affect up to 50% 
of all human embryos, in vivo.   Subsequent genetic studies have confirmed that 
human embryos exhibit chromosomal aberrations at a rate ten times that of other 
mammalian species (Macklon and Brosens, 2014, Vanneste et al., 2009, Wells and 
Delhanty, 2000, Voullaire et al., 2000).  Cytogenetic analysis of oocytes and 
embryos, via array-based comparative genomic hybridization (aCGH), revealed a 
diverse array of chromosomal abnormalities, which have not been observed later in 
pregnancy (Fragouli et al., 2013).  In this study, only 26% of 420 oocytes examined 
were found to be haploid after the completion of meiosis II, with errors being largely 
attributable to premature separation of sister chromatids.  A transient increase in 
aneuploidy rate, reaching 83%, was observed amongst 754 embryos at the 
cleavage stage with 20-25% of these embryos displaying complex chromosomal 
abnormalities (Fragouli et al., 2013).  Yet 58% of 1046 blastocysts were found to 
contain aneuploidies with 10% being highly abnormal (Fragouli et al., 2013).  These 
findings suggest that chromosomal abnormalities are tolerated during the first 
embryo divisions, where a reliance on maternal transcripts and proteins persists.  
EGA around the 4-8 cell stage is then thought to cease further division or activate 
cell-regulatory mechanisms that enable clearance of abnormal cells.  However, this 
method of ‘self-correction’ from cleavage to the blastocyst stage is by no means 
unanimous as the resulting majority of embryos exhibit mosaicism, despite 
appearing morphologically normal (Mertzanidou et al., 2013, Fragouli et al., 2013).  
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Although aneuploidy affects around 5% of clinical pregnancies, most of which result 
in miscarriage (Hassold and Hunt, 2001), the prevalence of abnormalities amongst 
embryos is far greater.  This paradigm suggests a loss of abnormal embryos, via 
selection, around the time of implantation.   
Recently, theories have emerged regarding the evolution of aneuploidies amongst 
human embryos and suggest that rather than being entirely detrimental, they may in 
fact confer an implantation advantage, comparable to cancer cells (Brosens et al., 
2014).  Nevertheless the sheer variation observed amongst human embryos calls 
for selectivity in order to restrict maternal investment to only viable embryos.  Thus 
the high rates of implantation failure and pre-clinical pregnancy losses in humans 
may in fact reflect a stringent selection mechanism imposed by maternal tissues.    
Evidence for a discerning endometrium originated from studies in cattle, whereby 
embryos of differing origins induced differential endometrial gene expression 
patterns upon pregnancy (Sandra and Renard, 2011).  This work introduced the 
concept of the endometrium as a biosensor of embryo quality, which has since 
been extended to humans.  Adequately decidualized HESCs not only sense 
embryo quality but also respond selectively in order to eliminate compromised 
embryos (Weimar et al., 2012a, Salker et al., 2010, Brosens et al., 2014).  The 
observation that HESCs from women suffering from RM are unable to discriminate 
between human embryos according to embryo quality (Weimar et al., 2012b) 
indicates that biosensoring by the endometrium is a pre-requisite to successful 
pregnancy. 
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1.10 Embryo-Derived Signals 
Human embryonic signals have been shown to differentially regulate maternal gene 
expression when separated into two groups representing good and poor quality 
embryos (Brosens et al., 2014).  Signals from embryos deemed unsuitable for 
transfer (developmentally incompetent embryos (DIE)) were found to alter the 
expression of 447 human and 544 murine genes when cultured with HESCs or 
flushed through the uterus of a mouse, respectively.  In stark contrast only 13 
human genes and 90 murine genes were affected by the presence of signals from 
successfully implanted embryos (developmentally competent embryos (DCE)) 
(Figure 1.10.1).  This work highlights the prescence of a conserved embryo-derived 
signal, able to convey develomental potential to the maternal cells in order to 
actively promote or prevent implantation.  In addition, this signal appears to be 
preserved within human embryo culture supernatants.   
A recent study investigated how embryo-derived signals might control chemical 
signals within the endometrium in order to influence decidualization of the stromal 
cell compartment, despite the lack of direct cell-cell contact (Ruan et al., 2012).  
Although it has long been considered a barrier to implantation in humans, the 
endometrial epithelium is a crucial pre-requisite for decidualization in the mouse 
(Lejeune et al., 1981).  In mice, in the presence of an intact endometrial epithelium, 
decidualization may be induced purely by mechanical stimuli, such as oil or air 
intraluminal injection (Finn, 1966) or endometrial scratching (Lejeune et al., 1982).   
Serum and glucocorticoid-inducible kinase (SGK1), known to regulate epithelial ion 
transport and cell survival, was found to be upregulated particularly in the luminal 
epithelium of mid-secretory endometrial biopsies from women with unexplained 
infertility (Salker et al., 2011).  Furthermore, SGK1 was downregulated in biopsies 
from women with RM and DESCs from these patients were sensitized to oxidative 
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cell death (Salker et al., 2011).  Sgk1-/- mice showed unaffected implantation rates 
but exhibited pregnancy complications including bleeding at the decidual-placental 
boundary, fetal growth retardation and compromised induction of pregnancy-
specific genes involved in oxidative stress defences (Salker et al., 2011).  These 
findings suggest that SGK1 in the luminal epithelium plays a protective role against 
oxidative damage at the feto-maternal interface required for successful implantation 
and the prevention of pregnancy complications. 
Epithelial Na+ channel (ENaC) channels, located in the apical epithelium, have been 
shown to be up-regulated at the peri-implantation period in mice (Kellenberger and 
Schild, 2002).  They play a role in water and electrolyte resorption, with potential to 
influence uterine closure seen at implantation in mice, and are known to be 
activated by mechanical stimuli and serine proteases (Kleyman et al., 2009, Vallet 
et al., 1997, Fronius and Clauss, 2008).  Serine proteases, such as trypsin, are 
known to be abundant at the embryo-endometrial interface, released by murine 
embryos and essential for implantation, although there are as yet no reports 
implicating embryo-derived trypsin proteases in human implantation (Salamonsen 
and Nie, 2002, Sawada et al., 1990). 
Ruan et al. (2012) found that the treatment of murine endometrial cell cultures with 
trypsin (20ug ml-1) induced morphological changes that mimicked decidualization 
(Ruan et al., 2012).  The group illustrated that trypsin acted via ENaC in epithelial 
cells, to produce a sustained [Ca2+]i
 rise which facilitated a cyclooxygenase-2 (COX-
2) dependent increase in prostaglandin E2 (PGE2) release (Figure 1.10.2).  These 
findings are significant as the activities of voltage sensitive calcium channels, which 
can be activated by membrane depolarization, have been implicated as a pre-
requisite for decidualization in the mouse (Sakoff and Murdoch, 1996).  
Furthermore, PGE2, formed from the enzymatic conversion of Phospholipase A2 
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(PLA2)-derived arachidonic acid by cyclooxygenases at the endometrial stromal-
epithelial interface, is known to be essential for decidualization (Ruan et al., 2011) 
and Ca2+ mobilisation has been shown to enable COX2-dependent PGE2 production 
(Ruan et al., 2008). 
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Figure 1.10.1 Human embryo signals elicit a conserved gene response in human 
DESCs and whole mouse uterus.  Quantitative Venn Diagram to show the number of 
transcripts significantly (P <0.01) regulated in DESC (Human) and whole mouse uterus 
(Mouse) by exposure to signals from succesfully implanted embryos (DCE) versus 
poor quality embryos (DIE).  (Brosens et al., 2014) 
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Figure 1.10.2 Embryo derived proteases are capable of mounting an 
implantation response in the endometrial stromal cells via activation of the 
epithelial sodium channel (ENaC).  a) ENaC channels are transmembrane ion 
channels which contain 3 structurally related subunits ,  and .  The  and  
subunits, in particular, are targets of proteolytic processing with cleavage by 
proteases, such as trypsin, facilitating transepithelial Na+ transport causing epithelial 
cell membrane depolarization.  b) Epithelial cell membrane depolarization resulting 
from cleavage and activation of ENaC activates L-type Ca2+ channels resulting in 
Ca2+ influx and up-regulation of COX-2 expression in endometrial epithelial cells.  
The resulting release of PGE2 activates cAMP-related pathways contributing to 
decidualization in stromal cells.  Adapted from (Ruan et al., 2012) and (Wikimedia, 
2015) 
 
 
 
 
     
  40 
 
1.11 ARTs 
A prolonged time-to-pregnancy coupled with a far higher rate of pregnancy losses 
in humans compared to alternate species has led to the development of many 
ARTs in order to address the fertility-related challenges (Wilcox et al., 1989).  As of 
2012, it was reported that the use of ARTs has now given rise to over 5 million 
offspring (European Society of Human Reproduction and Embryology, 2012).   
ARTs were first introduced in order to increase the chances of conception in cases 
of severe subfertility and studies first began in animal models.  Artificial 
insemination was first performed, in dogs, as early as 1785 (Spallanzani, 1785).  
Between 1950 and 1970 animal oocyte and sperm retrieval were routine and, in 
some species, optimised embryo culture conditions had even been established 
(Reviewed by; Jones, 2003, Clarke, 2006).  The breakthrough in human ARTs 
came in 1969 when IVF was first described using human oocytes (Edwards et al., 
1969).  Human embryo culture, at the cleavage stages, was subsequently reported 
in 1970 and by 1978 the first IVF conceived baby, Louise Brown, was born 
(Edwards et al., 1970, Steptoe and Edwards, 1978, Edwards et al., 1980). 
Increasing patient demand, rather than enhanced understanding, led to the 
emergence of ARTs as a newly recognised medical practice.  The increasing 
popularity of subfertility treatments has resulted in numerous technological 
advances in the field namely; improved culture conditions of pre-implantation 
embryos, intra-cytoplasmic sperm injection (ICSI) and enhanced gamete and 
embryo cryopreservation techniques  (e.g. vitrification).  However, it has been 
calculated that only 5% of oocytes collected in a fresh IVF cycle and only 36.5% of 
top quality embryos transferred will actually result in a live birth (Patrizio and 
Sakkas, 2009, De Neubourg et al., 2004).   
     
  41 
 
It is not yet fully understood whether this high rate of gamete and embryo wastage 
reflects the in vivo human condition or the limitations of our in vitro laboratory 
techniques.  Animal work would suggest that in vitro culture detriments embryo 
gene expression, morphology, metabolic activity and developmental kinetics but the 
effect in humans is undetermined (Knijn et al., 2006, Corcoran et al., 2006, 
Lonergan and Fair, 2008, McHughes et al., 2009, Holm et al., 2002, Lopes et al., 
2007).  
Our incomplete understanding of human pre-implantation embryo development, 
and reliance on divergent animal models, thus continues to limit IVF success rates.  
The development of ex vivo human models of early- and post-implantation events 
would undoubtedly promote ART success yet these remain restricted by ethical 
limitations and a scarcity of research embryos. 
An apparent need remains for increased understanding of implantation in humans, 
which involves both embryo and endometrial counterparts.  Assessing in vitro 
embryos, which are known to differ from their in vivo derived equivalents, 
independently from the implantation environment fails to contextualise the 
challenge of human reproduction.  As a result the treatment of reproductive 
difficulties via IVF, despite continual technological advances, commonly leads to a 
failed pregnancy. 
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1.12 Hypothesis and Aims 
Despite decades of intense investigation, the search for clinically useful markers of 
embryonic competence and endometrial receptivity continues to be the Holy Grail of 
Reproductive Medicine.  This journey, which promises to eliminate IVF failure and 
early pregnancy loss once and for all, has so far been disappointing.  At the heart of 
the current malaise lies the prevailing belief that reproductive success depends on 
binary drivers, such as ‘good and bad’ embryos and ‘receptive and non-receptive’ 
endometria.  
I hypothesize that human implantation is much more dynamic and adapted to deal 
with a highly invasive and genetically diverse blastocyst.  Furthermore, I speculate 
that effective strategies to prevent implantation failure and early pregnancy loss 
must be based on an in-depth understanding of the mechanisms that control 
embryo selection at implantation.  
The specific goals of my study were: 
- Identification of embryonic signals that enable uterine biosensoring at 
implantation. 
- Characterisation of endometrial receptors involved in embryo selection and 
rejection.
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Chapter 2 
Materials and Methods 
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2.1 Materials 
2.1.1 Cell Culture Media and Materials 
Media 
Reagent Manufacturer Catalogue No. 
Antibiotic-Antimycotic  
Penicillin (10,000 μg/ml)- 
Streptomycin (10,000μg/ml) 
GIBCO®, Invitrogen 15240 
 L-Glutamine (200mM) 100x  GIBCO®, Invitrogen 25030 
 Β-Estradiol>95%  Sigma-Aldrich E8875 
Charcoal Sigma-Aldrich O5105 
Collagenase   Sigma-Aldrich C9891 
Deoxyribonuclease I (DNase 1)  Roche 11284932001 
Dextran Fisher Scientific  
Dulbecco’s Modified Eagle Medium (DMEM)/F12 (1:1)  
with L-glutamine, no phenol red 
GIBCO®, Invitrogen 11039 
Dulbecco’s Modified Eagle Medium (DMEM)/F12 (1:1)  
with L-glutamine, with phenol red 
GIBCO®, Invitrogen 31330 
Fetal Bovine Serum (FBS)  
heat inactivated 
GIBCO®, Invitrogen 10500 
Insulin (Recombinant, Human)  Sigma-Aldrich 91077C 
L-Glutamine Gibco 25030-081 
Primocin (500mg) Source Bioscience UK 
Limited 
ant-pm-1 
 
 
Materials 
Reagent Manufacturer Catalogue No. 
6-well plates  Corning® Costar®,  T-3506-6 
Cell culture flask (25cm
2
) CellStar® 690160 
Cell culture flask (75cm
2
) CellStar® 658170 
Cell scraper, small, Corning APPLETON WOODS BC323 
Glass bottomed petri dishes (35mm) MatTek Corporation P35GCol-1.5-14.C 
Immuno 96-well plate  NUNC 442404 
Luer lok™ Syringe (50ml) BD Plastipak™ 300865 
Sterile Filter Tips (0.1-10µl) Alpha Laboratories ZP1010S 
Sterile Filter Tips (1-40µl) Alpha Laboratories ZP1204S 
Sterile Filter Tips (1-100µl) Alpha Laboratories ZP1200S 
Sterile Filter Tips (1-300µl) Alpha Laboratories ZP3300S 
Sterile Filter Tips (100-1000µl) Alpha Laboratories ZP1250S 
Syringe (10ml) BD Plastipak™ 302188 
Syringe Filter (0.2µm) Minisart® 16534 
 
 
 
Cell Lines 
Ishikawa Cell Line human, endometrial adenocarcinoma, Sigma-Aldrich, 99040201-1VL  
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2.1.2 Cell Culture Treatments 
Hormone Concentration Manufacturer 
8-br-cAMP (cAMP) 0.5mM Sigma-Aldrich 
Medroxyprogesterone acetate (MPA) 1µM Sigma-Aldrich 
 
Reagent Concentration Manufacturer Catalogue No. 
Trypsin (0.22µ filtered) 10nm to 1uM Worthington LS003734 
Lipopolysaccharides (LPS)  
from Escherichia Coli 0111:B4 
1ug/ml Sigma-Aldrich L4391 
TLR4 inhibitor Peptide set 50uM Novus Biologicals NBP2-26244 
Soybean trypsin inhibitor 1mg/ml Worthington LS003570 
 
2.1.3 siRNA 
 
SiRNA Manufacturer Catalogue No. 
siGENOME Non-Targeting siRNA Control Pool GE HEALTHCARE UK LTD D-001206-13-05 
PRSS8 Silencer® Select Pre-designed siRNA, 5 nmol Fisher Scientific 10782097  
2.1.4 Antibodies 
Primary 
Antibody Manufacturer Catalogue No. Raised in  Dilution 
AMBP Novus Biologicals H00000259-M01 Mouse mAb 1:100 
-actin Abcam AB8277 Rabbit pAb 1:100,000 
COX2 Cell Signalling 4842 Rabbit pAb 1:1000 
Cytokeratin 18 Abcam AB668 Mouse mAb 1:100 
PAR2 Abcam AB180953 Rabbit mAb 1:250 
PRSS8 Antibodies Online ABIN761891 Rabbit pAb 1:100~ 
1:250* 
SCNN1A Sigma-Aldrich HPA012939-100UL Rabbit pAb 1:100~ 
1:250* 
SCNN1G Proteintech 13943-1-AP Rabbit pAb 1:100~ 
1:250* 
SPINT1 Sigma-Aldrich SAB1409704-50UG Mouse pAb 1:100 
TLR4 Cell Signalling 
Technology 
NB100-56566 Mouse mAb 1:250* 
1:100~ 
TMPRSS2 Antibodies Online ABIN716876 Rabbit pAb 1:100 
TMPRSS15 Novus Biologicals NBP1-55616 Rabbit pAb 1:100 
Vimentin Dako M7020 Mouse mAb 1:100~ 
Vimentin Cell Signalling SG3F10 Mouse mAb 1:1000* 
*Western blotting, ~Immunocytochemistry 
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Secondary 
Antibody Manufacturer Catalogue No.  Dilution 
Goat IgG-Alexa Fluor 488 Molecular Probes A21222 Rabbit 1:2000* 
1:100~ 
Mouse IgG-Alexa Fluor 555 Molecular Probes A21424 Goat 1:6000* 
1:100~ 
*Western blotting, ~Immunocytochemistry 
Antibody Blocking Peptides 
Blocking Peptide Manufacturer Catalogue No. 
AMBP Blocking Peptide Fitzgerald 33R-9450-FIT 
SCNN1G Fusion Protein Proteintech ag5286  
2.1.5 Chemical Reagents 
 
Reagent Manufacturer Catalogue No. 
30% Acrylamide/Bis Solution, 37.5:1 500ml BIO-RAD LABORATORIES LTD 161-0158 
Ammonium persulfate (APS) Sigma-Aldrich A3678-25G 
Chloroform Fisher Scientific C298-4 
Ethanol Fisher Scientific BP2818-4 
Ethylenediaminetetraacetic acid (EDTA) Roche 11 836 170 001 
Glycerol Sigma-Aldrich G5516-100ML 
Glycine Fisher Scientific G/P460/53F 
Isopropanol Fisher Scientific BP2618-4 
Methanol Fisher Scientific M/4000/17F 
Mineral Oil Sigma-Aldrich M-8410 
N,N,N,N’-tetramethyl-ethane-1,2-diamine (TEMED)  Sigma-Aldrich T9281-25ML 
Non-fat dried milk powder VWR International Ltd.  A0830.1000 
PageRuler Plus Pre-stained Protein Ladder  ThermoScientific 26619 
Paraformaldehyde (PFA) Sigma-Aldrich P-6148 
Pierce® ECL Plus Western Blotting Substrate ThermoScientific 32132 32134 
Power SYBR® Green PCR Mastermix  Fisher Scientific VY4368702 
Protein Assay Dye Reagent  BioRad #500-0006  
RIPA Lysis Buffer 10x  Upstate [Millipore] 20-188 
RNA STAT-60 Amsbio CS110 
siRNA Universal Buffer 5x Fisher Scientific 11821924 
Sodium chloride (NaCl) Fisher Scientific S/3160/60F 
Sodium dodecyl sulfate Sigma-Aldrich L4390-25G 
Triton X-100 Sigma-Aldrich T-8787 
Trizma®Base Sigma-Aldrich T1503-1KG 
Trypan Blue ThermoScientific 15250-061 
Tween®20 Fisher Scientific BP337-500F 
Vectashield Mounting Medium with DAPI Vector Laboratories H-1200  
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2.1.6 Miscellaneous Reagents 
Reagent Manufacturer Catalogue No. 
10kDA Spin Column Abcam PLC ab93349 
5X siRNA Universal Buffer 100mL Fisher Scientific 11821924 
7500 Real Time PCR system Applied Biosystems  
Amersham Hybond™ PVDF membrane GE HEALTHCARE RPN 303F 
Amersham Hyperfilm™MP GE HEALTHCARE 28906844 
Gel Casting Cassettes NOVEX® by Life 
Technologies 
NC2015 
MicroAmp® Optical 96-well Reaction Plate Life Technologies N8010560 
Mineral Oil Sigma M-8410 
Multiskan Ascent  ThermoScientific 51118300 
PageRuler Plus Pre-stained Protein Ladder  ThermoScientific 26619 
Pierce® ECL Plus Western Blotting Substrate ThermoScientific 32132 32134 
Power SYBR® Green PCR Mastermix  Fisher Scientific VY4368702 
Protein Assay Dye Reagent  BioRad #500-0006  
RNA STAT-60 Amsbio CS110 
RNAse Zap Invitrogen AM9780 
ThermalSeal RT2RR 50-µm-thick Sealing Films Applied Biosystems TS-RT2RR-100 
Vectashield Mounting Medium with DAPI Vector Laboratories H-1200 
WellWash  ThermoScientific 4 MK2 220/240V 
XCell SureLock® Mini-Cell and XCell II™ Blot Module Invitrogen EI0002  
2.1.7 Kits 
Kit Manufacturer Catalogue No. 
ECL Prime Western Blotting Detection Kit Scientific Laboratory Supplies Ltd. RPN2232 
EnzChek Protease Assay Kit  
(Green fluorescence) 
Life Technologies E6638 
Factor D  ELISA Kit ABCAM ab99969 
Human HAI-1 ELISA Kit Raybio® ELH-HAI1 
Human Prostasin ELISA Kit Raybio® ELH-Prostasin 
Human TMPRSS2 ELISA Kit ELABSCIENCE BIOTECH CO. E-EL-H1418 
JetPRIME® Polyplus transfection 114-07 
Proteome Profiler™  
Human Phosph-MAPK Array 
R&D Systems® ARY002B 
QIAquick® Gel Extraction Kit  Qiagen 28704 
Quantitect Reverse Transcription Kit  QIAGEN 205311 
Trypsin Activity Assay Kit (Colorimetric) Abcam AB102531 
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2.1.8 Buffers and Solutions  
2.1.8.1 General 
 
Phosphate Buffered Saline (PBS) 
140 mM NaCl 
2.5 mM KCl 
1.5 mM KH2PO4, pH 7.2 
1.5 mM Na2HPO4, pH 7.2 
 
Tris Buffered Saline (TBS) 
130mM NaCl 
20mM Tris 
pH 7.6 
 TBS-Tween 20 (TBS-T) 
0.2% Tween 20 in TBS (1x) 
 
RIPA Buffer 
50mM Tris HCl pH 7.4 
1% NP40 
0.5% deoxycholate 
0.1% SDS 
150mM NaCl 
2mM EDTA 
50mM NaF 
 
DNA Loading Buffer 
0.2% (w/v) Bromophenol blue 
40% (v/v) glycerol 0.25M EDTA pH8.0 
 
Laemmli Buffer 
50mM Tris-HCl, pH 6.8 
1% (w/v) SDS 
10% (v/v) glycerol 
2% (v/v) β-mercaptoethanol 
0.002% (w/v) Bromophenol blue 
 
 
2.1.8.2 Immunohistochemistry  
 
4% PFA Solution 
4% PFA (W/v) in PBS  
pH 9.2 with NaOH  
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Cell Permeabilisation Solution 
0.1% Triton-x (w/v) in PBS 
 
Blocking Solution and Antibody Incubation Solution 
1% (w/v) BSA in PBS 
 
 
2.1.8.3 Western Blotting 
 
SDS Tris-Glycine Running Buffer 10X  
250mM Tris Base 
1.9M Glycine 
pH 8.3 
1% (w/v) SDS 
 
SDS Tris-Glycine Transfer Buffer 10X  
0.05M Tris-HCl (pH 6.8) 
0.4M Glycine 
20% (v/v) Methanol 
1% SDS 
 Stripping Buffer 
15g Glycine 
1g SDS 
10ml Tween®20 
Adjust pH to 2.2 
Bring volume to 1.0 L 
 
Western Blocking Buffer and Antibody Incubation Solution 
5% (w/v) non-fat milk in TBS-T 
2.1.8.4 SDS Polyacrylamide Gels 
 
Resolving Gel 
375mM Tris (pH 8.8) 
0.1% (w/v) SDS 
0.1% (w/v) APS 
10% Acrylamide Bis Solution (37.5:1) 
TEMED added at 1 in 1000 
 
Stacking Gel 
80mM Tris (pH6.8) 
0.1% (w/v) SDS 
0.1% (w/v) APS 
5.8% Acrylamide Bis Solution (37.5:1) 
TEMED added at 1 in 1000 
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2.1.8.5 Calcium Profiling 
Krebs’-Heinselet Buffer 
133mM NaCl 
4.7mM KCl 
11.1mM Glucose 
1.2mM MgSO4 
1.2 KH2PO4 
2.5mM CaCl 
10mM TES pH 7.4 
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2.2. Methods 
2.2.1 Human Endometrial Biopsies 
Endometrial biopsies were acquired from patients attending the research-led 
Implantation Clinic at University Hospital Coventry and Warwickshire.  Informed 
written consent was obtained from all patients and the study was approved by the 
NHS National Research Ethics Committee of Hammersmith and Queen Charlotte’s 
Hospital NHS Trust.  Biopsies were taken in the mid-secretory phase, 5 to 11 days 
after the post-ovulatory LH surge, and all patients were withdrawn from any hormonal 
treatment at least 3 months prior to the biopsy appointment.  Each biopsy, where 
appropriate, was processed in three stages.  Biopsy addition to 7ml DMEM-F12 
supplemented with 10% dextran-coated charcoal treated foetal bovine serum (DCC-
FBS) (v/v) allowed direct isolation of endometrial stromal cells.  Snap freezing of 
biopsies in liquid nitrogen provided a sample for protein analysis, which was 
subsequently stored at -80°C.  Immersion of biopsy tissue fragments in RNA later 
followed by storage at -80°C provided material for RNA studies. 
2.2.1.2 Ishikawa Cells 
Ishikawa cells were purchased from Sigma (99040201-1VL) and thawed according to 
manufacturer’s protocol.  The cells were routinely cultured and passaged (as in 
section 2.2.2.5) in a continuous cell culture laboratory.  Cells were closely monitored 
and regularly tested for mycoplasma contamination.  Mycoplasma-free cells were 
stored according to section 2.2.2.7. 
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2.2.2 Cell Culture 
2.2.2.1 Dextran-Charcoal Stripping of FBS 
FBS contains endogenous steroids hormones which may mask the effect of 
exogenously applied ligands.  Therefore DCC treatment was used to strip serum of 
small molecules.  FBS was defrosted for 24 hours at 4°C.  1.25 g charcoal, 125 mg 
Dextran and 500 ml FBS were thoroughly mixed and incubated at 57°C for 2 hours, 
inverting every 30 minutes.  Following centrifugation at 400 x g for 30 minutes the 
supernatant was filter sterilised using a 0.2µm filter and stored in aliquots at -20 °C.  
The DCC-FBS aliquots were defrosted either at 4°C overnight or at room 
temperature (RT) on the day required. 
2.2.2.2 Cell Growth Medium 
 
DMEM:F12 supplemented with 10% DCC-FBS (v/v) 
500 ml DMEM:F12 (with phenol red and L-Glutamine) 
50 ml DCC-FBS  
5 ml L-Glutamine 
5 ml Antibiotic-Antimycotic  (100x) 
100 µl Insulin (10mg/ml stock) 
5 µl Estradiol (10-4 stock) 
 
DMEM:F12 supplemented with 2% DCC-FBS (v/v) 
500 ml DMEM:F12 (without phenol red) 
10 ml DCC-FBS 
5 ml L-Glutamine 
5 ml Antibiotic-Antimycotic  (100x) 
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The thawed DCC was supplemented with L-Glutamine, AB/AM solution, Insulin and 
Estradiol (as above) and added to DMEM:F12 by sterile filtration.  The media was 
stored at 4 °C for up to 4 weeks, filter sterilised and warmed to 37°C prior to use. 
2.2.2.3 Preparation of Isolated Endometrial Stromal Cells 
Endometrial biopsies were collected in DMEM:F12 supplemented with 10% DCC-
FBS (v/v).  Biopsies were decanted into a petri dish, isolated by removal of 
media/mucus and mechanically minced for 5 minutes with sterile scalpels.  
Enzymatic digestion was achieved using 10ml of additive free DMEM:F12 
supplemented with 0.5mg/ml Collagenase and 0.1mg/ml DNase 1 for 1 h at 37°C 
with vigorous shaking every 20 minutes.  The collagenase acts to digest the ECM 
and the DNase removes viscous DNA produced after apoptosis of some of the cells 
during digestion.  10ml of DMEM:F12 supplemented with 10% DCC-FBS (v/v) was 
applied to deactivate the enzyme action and the sample was centrifuged at 400 x g 
for 5 min.  Following aspiration of the supernatant the pellet was resuspended in 
12ml DMEM:F12 supplemented with 10% DCC-FBS (v/v) , transferred to a 75cm2 
culture flask and incubated at 37°C with 5% (v/v) CO2 overnight to allow attachment.  
Aspiration of the media the following day removed blood, epithelial and unattached 
cells whilst replenishment using 12ml of DMEM:F12 supplemented with 10% DCC-
FBS (v/v) every 2 days maintained the proliferating HESC culture.  Upon confluency, 
HESCs were passaged (as previously described) and cultured at an appropriate 
dilution.  Experiments were performed in DMEM:F12 supplemented with 2% DCC-
FBS (v/v) and decidualization was induced by supplementation with 0.5mM Bromo-
cAMP and 1mM MPA.  All experiments were performed prior to the fourth passage.   
     
  54 
 
2.2.2.4 Isolation of Endometrial Epithelial/Stromal Cells 
Biopsies were collected from consenting patients and processed immediately as 
above but; Following culture in 10ml of additive free DMEM:F12 supplemented with 
0.5mg/ml Collagenase and 0.1mg/ml DNase 1 for 1 h at 37°C the sample was 
passed through a 40nm filter, fitted above a 50ml tube (Falcon) to isolate the stromal 
cells.  The filter was then moved to a fresh tube and backwashed with 20ml 
DMEM:F12 supplemented with 10% DCC-FBS (v/v) to extract the epithelial cells.  
The cells were spun by centrifugation for 5 minutes at 1000 x RPM, supernatant 
aspirated and pellet re-suspended in DMEM:F12 supplemented with 10% DCC-FBS 
(v/v) with progesterone (P4)10
-4 and placed into culture. 
 
2.2.2.5 Routine Mammalian Cell Culture 
Mammalian cells were routinely grown in monolayers using 75cm2 culture flasks 
maintained at 37°C in a humid atmosphere containing 5% (v/v) carbon dioxide (CO2) 
using a Heracell incubator.  Cells were maintained in DMEM:F12 supplemented with 
10% (v/v) DCC-FBS which was changed every other day and passaged when near 
confluent (1-2 times per week depending on growth rate).   
In brief, the media was aspirated using a vacuum, cells washed using 5 ml PBS and 
1ml pre-warmed Trypsin-EDTA added.  Following incubation for 5 minutes at 37   ͦC 
the cells were loosened by tapping (confirmed by inspection under the microscope).  
9ml of DMEM:F12 supplemented with 10% DCC-FBS (v/v) were added to neutralize 
the Trypsin and cells transferred to a 14ml Falcon tube.   The cell suspension was 
centrifuged at 400 x g for 5 minutes, supernatant aspirated and the pellet re-
suspended in DMEM:F12 supplemented with 10% DCC-FBS (v/v) at a suitable 
dilution (Usually 1:3). 
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Culture media in all cases was pre-warmed to 37°C in a water bath and syringe 
filtered using a 0.2µm filter and all work was carried out in a Class I safety cabinet. 
2.2.2.6 Preparation of Whole Tissue Samples for RNA Extraction 
Endometrial biopsies were stored in RNA later.  Around 1 mm of tissue was chopped 
using sterile scalpels and transferred into STAT 60 (1 ml) within a 2 ml RNase-free 
tube.  The sample was homogenised using a Kinematica POLYTRON® PT 1200 E 
homogenizer, thoroughly cleaned using the following wash steps; 1 x RNAse zap, 3 
x nuclease free water, 1 x 70% (v/v) ethanol, 1 x STAT 60.  The homogenised 
sample was left at RT for 5 minutes and 200 µl chloroform added before placing it 
onto dry ice and storing overnight at -80 ˚C.  RNA extraction was subsequently 
performed according to protocol.     
2.2.2.7 Storage of Cell Stocks 
A cryoprotectant solution (2x) was prepared by adding 20% DMSO to DCC-FBS and 
filter sterilised.  Cells were harvested and pelleted as described above and then re-
suspended in DCC-FBS (1ml per vial).  The cryoprotectant was added drop-wise 
with gentle tapping (1ml/vial) to give a final concentration of 10% DMSO.  The cell 
suspension was then aliquotted into labelled cryovials (1.8ml/vial) transferred to an 
isopropanol filled freezing container and placed at -80 °C overnight, before 
transferring into a liquid nitrogen tank for long-term storage.  Cells recovered from 
liquid nitrogen were thawed rapidly at 37°C, pelleted as before and re-suspended in 
a 75cm2 culture flask containing 12ml pre-warmed DMEM:F12 supplemented with 
10% DCC-FBS (v/v).   
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2.2.2.8 Hormonal treatment 
Confluent monolayers of cells were cultured in DMEM:F12 (without phenol red) 
supplemented with 2% DCC-FBS (v/v) overnight and hormonal treatments were 
applied the following day. For routine decidualization treatment, HESCs were treated 
in DMEM:F12 (without phenol red) supplemented with 2% DCC-FBS (v/v), 0.5mM 8-
bromo-cAMP (cAMP) and 1µM medroxyprogesterone acetate (MPA). All cell 
treatments were carried out before the fourth passage. 
2.2.2.9 Cell Treatment Protocol 
Endometrial cells were cultured in DMEM:F-12 supplemented with 10% DCC-FBS 
(v/v) (2ml/well).  Cells were monitored and passaged (1:4) when at 80-90% 
confluence into 6-well plates (2ml cell suspension/well) in DMEM:F-12 supplemented 
with 10% DCC-FBS.  Plates were monitored for cell growth and media replenished 
daily until 80-90% confluence.  Cells were then down-regulated overnight in DMEM 
(with no phenol red, supplemented with 2% DCC-FBS (v/v)).  At time of treatment the 
prepared aliquots were thawed, vortexed and diluted to a working stock in serum 
free, additive free DMEM.   
ECM was diluted 1:100, Soybean trypsin inhibitor with diluted to 1mg/ml, Trypsin was 
diluted from 1mM stock, LPS was diluted to 1ug/ml, TLR4 inhibitor (VIPER) and the 
accompanying control peptide were diluted to 50M.  All media was aspirated from 
the cells prior to treatment, cells were washed with PBS (1ml/well) and treatments 
were applied in triplicate (0.5ml/well).  Serum free DMEM was used as the control.  
Cells were incubated at 37°c with 5% CO2 for the course of treatment.  After the 
exposure time the treatment was aspirated, cells washed with PBS (1ml/well) and 
either harvested or cultured further at 37°c with 5% CO2 in DMEM:F12 supplemented 
with 2% DCC-FBS 2ml/well. 
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2.2.3 Transient Transfections 
Transfections of primary HESCs were performed at 80% confluence in DMEM:F12 
supplemented with 10% DCC-FBS (v/v) in 6-well plates.  Transfections were 
achieved using the Lipofectamine®RNAiMAX Transfection Reagent, a cationic, lipid 
formulation.  50nM of siRNA was diluted in opti-MEM® Medium and incubated with 
Lipofectamine®RNAiMAX Reagent at an appropriate volume for 5 minutes.   The 
transfection solution was added dropwise to cells to give a final volume of 250µl/well. 
Cells were incubated at 37 °C and harvested 24 hours post-transfection.  
siGENOME Non-Targeting siRNA Pool 1 was used as a control. 
2.2.4 Protein Analysis 
2.2.4.1 Protein Extraction 
HESCs were harvested from 6-well plates using RIPA buffer supplemented with 
protease inhibitors (60µl/well) following a PBS wash (1ml/well).  Cell Scrapers were 
used to collect the lysates which were then pipetted into 0.6 µl eppendorfs and 
centrifuged at 13,200 RPM for 10 min at 4°C.  The supernatant was transferred to a 
fresh eppendorf and stored at -80°C.  Protein concentration was determined and 
between 10 and 20µg was combined with loading buffer, boiled at 95°C for 10 
minutes (in order to denature the proteins allowing the antibody to access the 
epitope) and loaded into SDS-polyacrylamide gels. 
 
 
2.2.4.2 Determination of Protein Concentration 
The Bradford Assay was used to quantify the concentration of protein in the cell 
lysates preceding Western blot analysis.  This method employs a Coomassie Blue 
dye which binds to the protein and enables quantification by comparison with a 
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standard curve generated by known concentrations of a standard (BSA). 
A series of BSA dilutions from 0 to 20 µg of protein were prepared in a final volume 
of 800 µl.  All lysates were diluted for analysis (2µl in 798µl dH2O) and vortexed.  
200µl of Protein Assay Dye Reagent was added to all standards and samples, which 
were vortexed and incubated at RT for 15 minutes.  Standards and samples were 
loaded in duplicate into a flat-bottomed optically clear 96-well plate (200µl/well) and 
absorbance measured at 595 nm (Multiskan Ascent).   
2.2.4.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Proteins were resolved on discontinuous polyacrylamide gels using the Invitrogen 
XCell SureLock® Mini-Cell apparatus.  Gels were prepared by adding two solutions 
to a Novex Gel Casting Cassette, one to form a resolving gel and the other to form a 
stacking gel.  The resolving gel typically contained 8% acrylamide, 1% SDS and 375 
mM Tris-HCL pH 8.8.  The stacking gel consisted of 5% acrylamide, 1% SDS and 
125mM Tris-HCl pH 6.8.  TEMED and APS were used to induce polymerization of 
the gels.  First the resolving gel was added to the cassette reaching 1.5cm from the 
top and isopropanol was overlaid to prevent evaporation during polymerization.  
Once polymerization was achieved the isopropanol was rinsed away, the resolving 
gel was overlaid with the stacking gel and a comb was inserted.   Once set, the comb 
and tape were removed from the cassette and it was clamped into place within the 
electrophoresis tank, overlaid with Running Buffer.  Equal volumes of the prepared 
protein samples were then added to the wells, typically 20 µl/well, alongside 10 µl of 
Pre-stained Protein Ladder.  Gels were run at 125 V for up to 2 hours until the dye 
front had migrated to the base of the gel, at which time the cassettes were opened 
and the gels used for Western blot. 
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2.2.4.4 Western Blotting 
The protein samples were resolved using SDS-PAGE and transferred onto a PVDF 
membrane, activated in methanol, using a wet blotting method.  The PVDF 
membrane, filter paper and pads were pre-equilibrated in Transfer Buffer (1x) and 
used to assemble a ‘sandwich’ within the cathode shell.  This consisted of layering 
pads, filter paper, SDS-PAGE gel, PVDF membrane, filter paper and pads to give 
good contact between the electrodes.  The electrode assembly was then fitted into 
the tank with the membrane towards the anode and the gel towards the cathode.   
Transfer Buffer was poured onto the blot module until full and into the tank until half 
full and the transfer was performed at 230 mA for 2 hours.  The membrane was then 
transferred onto filter paper and left to dry.  The membrane was reactivated in 
methanol, rinsed in 1 x TBS and incubated in Blocking solution (5% Milk in TBS-T for 
1 hour at RT) to prevent non-specific binding.  The membrane was then washed 
once in TBS-T for 15 minutes and three times in TBST for 5 minutes before 
incubation with the primary antibody, diluted in Western Antibody Incubation Solution 
at 4 °C overnight (unless specified otherwise on the datasheet).  The dilutions used 
were as follows: SCNN1A, SCNN1G, TLR4, PRSS8, PAR2 at 1: 250; β-actin at 1: 
100 000.  The TBS-T wash step was repeated before incubation with the HRP-
conjugated antibody, raised against the primary antibody, diluted in Western 
Antibody Incubation Solution for 1 hour at RT.  The TBS-T wash step was repeated, 
before a 5 minute wash in TBS following which protein bands were visualised using 
enhanced chemiluminescence with ECL Western blot detection system according to 
the manufacturer’s instructions. 
2.2.4.5 Stripping Membranes for Western Blotting 
To re-probe membranes with alternative primary antibodies, membranes were 
incubated in Stripping Buffer for 10 minutes, twice before washing in TBS-T (as 
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above).  Alternatively membranes were incubated in boiling water for 3 minutes and 
then placed into cold TBS-T.   
2.2.5 Assessment of proteases in embryo conditioned medium (ECM) 
Embryo conditioned medium was obtained from two IVF units;   
The Centre for Reproductive Medicine (CRM) Coventry & Warwickshire NHS 
Trust with approval from the Ethics committee and the couples’ written, informed 
consent.  Embryos were cultured in individual 20µl drops of ISM1™ (Origio) and 
BlastAssist™ (Origio).  During this study the CRM changed their culture method to 
include the ORIGIO® Sequential Series™ (Fert™, Cleav™, Blast™). 
The Brussels Centre for Reproductive Medicine (Vrije Universiteit Brussel, 
Brussels) with the approval of the Institutional Committee of the University Hospital 
Brussels.  Embryos were cultured individually in 25µl drops of Q1 (Quinn’s Protein 
Plus Cleavage Medium) and Q2 (Quinn’s Advantage™ Protein Plus Blastocyst 
Medium) (Sage In Vitro Fertilization).   During this study the unit changed their 
culture method to include the ORIGIO® Sequential Series™ (Fert™, Cleav™, 
Blast™). 
If the embryos were suitable for culture to the blastocyst stage embryo drops were 
collected on Day 6 following embryo transfer on Day 5.  If embryos were transferred 
on Day 2 the embryo drops were collected at the time of transfer.  All drops were 
stored at -80°C and thawed on day of use.  Empty drops, incubated alongside the 
drops used for embryo culture, were used as a control. 
2.2.5.1 Protease activity assay 
Protease activity was measured using the EnzChek Protease Assay Kit for green 
     
  61 
 
fluorescence (E6638, Life Technologies) according to manufacturer’s protocol. This 
kit contains a casein derivative that has been extensively labelled with the pH-
insensitive, green-fluorescent BODIPY® FL dye, which results in a quenching of the 
fluorescent dye. Protease-catalysed hydrolysis releases the highly-fluorescent 
BODIPY® FL dye-labelled peptides, allowing for quantitative detection of protease 
activity in solution. The green-fluorescent BODIPY® FL dye has excitation and 
emission spectra similar to those of fluorescein. Samples were thawed, warmed to 
room temperature and diluted as follows; 7.5µl ECM + 92.5µl 1x Digestion Buffer per 
well. Samples and standards were applied in duplicate and incubated for 24 hours at 
room temperature, protected from light.  Fluorescence was measured at 505/513 nm 
and concentrations determined by comparison to the standard curve. 
2.2.5.2 Trypsin Activity Assay 
The Trypsin Activity Assay Kit (Colorimetric) (ab10253, ABCAM) was used according 
to the manufacturer’s instructions to accurately measure trypsin activity in ECM.  The 
cleavage of a given substrate, by trypsin, generates p-nitroaniline (p-NA) which is 
detected at ʎ=405nm and the resulting colour intensity is thus proportional to p-NA 
content.   
Reagents were added to 0.6ml nuclease-free tubes prior to plating as follows; 
Positive Control: 90µl Trypsin Assay Buffer and 10µl Positive Control Solution.  pNA 
Standards: 0, 4, 8, 12, 16, 20µl p-NA Standard (2 mM) with corresponding volumes 
of Trypsin Assay Buffer to give a final volume of 100µl per tube (to generate 0, 4, 8, 
12, 16, and 20 nmol/well of the p-NA standard).  All reagent tubes were inverted to 
mix and samples applied to an Immuno 96-well plate (442404, NUNC) in duplicate.  
Undiluted ECM/control media was added directly to the plate.  A mastermix of 48µl 
Trypsin Assay Buffer and 2µl Trypsin Substrate (in DMSO) per well was prepared, 
vortexed and 50µl applied to each well.  1µl of 10mM Chymotrypsin Inhibitor Solution 
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(N-tosyl-L-phenylalanylchloromethyl ketone or TPCK) was added to each well and 
incubated at room temperature for 10 minutes.  1µl of 20 mM Trypsin Inhibitor 
Control (Tosyllysine Chloromethyl Ketone hydrochloride or TLCK) was added to 
TLCK control wells only and incubated for 5 minutes at room temperature.  
Absorbance was measured at 405nm using a Multiskan Ascent (51118300, 
ThermoSceintific) at 0, 1, 2, 3 and 4 hour time points.  The plate was incubated at 
25°c and protected from light for the duration.   
The results were calculated as follows: For the colour generated at each time point: 
A405nm = (A2 – A2C) – (A1 – A1C), where A1 = absorbance at zero hours, A1C = 
trypsin inhibitor control at zero hours, A2 = absorbance at subsequent time point, 
A2C = trypsin inhibitor control at subsequent time point.  The zero p-NA standard 
was subtracted from all readings and standard curves generated from the p-NA 
values at each time point.  A405nm was applied to the standard curve to give the 
nmol of p-NA generated in the reaction wells.  Trypsin activity was determined by 
applying the values to the following equation: Trypsin Activity = B/((T1-T2)xV) x 
Sample Dilution Factor = nmol/min/ml = mU/ml. Where B is the p-NA calculated from 
the Standard Curve (in nmol), T1 and T2 are the times of the first and second 
readings (in minutes) and V is the sample volume added into the reaction well (in 
ml).   
2.2.5.3 PRSS8 (Prostasin) ELISA 
The total abundance of prostasin in ECM samples was measured using RayBio® 
Human Prostasin ELISA Kit (ELH-Prostasin, RayBiotech, Inc.) according to the 
manufacturer’s protocol.  Samples were thawed, warmed to room temperature and 
diluted as follows; 7.5µl ECM + 92.5µl Assay Diluent D per well. Samples and 
standards were applied to the 96-well plate (mounted with immobilised antibody) in 
duplicate and incubated overnight at 4°c, with gentle shaking.  Following incubation 
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with HRP-conjugated streptavidin and the addition of a TMB substrate solution, the 
kit provides a colour change from blue to yellow according to the quantity of 
prostasin present in the sample.  The absorbance was read at 450nm and the 
sample concentrations were determined by comparison to the standard curve.  
2.2.5.4 TMPRSS2 ELISA 
The total level of Tmprss2 in the samples was determined using the Human 
TMPRSS2 ELISA Kit (E-EL-H1418, Elabscience) according to the manufacturer’s 
protocol. Samples were thawed, warmed to room temperature and diluted as follows; 
7.5µl ECM + 92.5µl Reference Standard & Sample Diluent  per well. The samples 
and standards were loaded, in duplicate, into the 96 well plate, pre-coated with an 
antibody specific to TMPRSS2.   Next, Avidin conjugated to Horseradish Peroxidase 
(HRP) was added to each well and incubated. After the addition of TMB substrate 
solution only those wells that contain TMPRSS2, biotin-conjugated antibody and 
enzyme-conjugated Avidin will exhibit a colour change. The enzyme-substrate 
reaction was terminated by the addition of sulphuric acid solution and the colour 
change was measured at 450nm. The concentration of TMPRSS2 in the samples 
was then determined by comparing their optical density (OD) to the standard curve. 
 
 
2.2.6 Gene Expression Analysis by qRT-PCR 
 
 
2.2.6.1 Quantitative Real-time Polymerase Chain reaction (qRT-PCT) 
Gene expression was determined by qRT-PCR.  qRT-PCR involves the detection of a 
fluorescent signal which is generated relative to the amount of PCR product 
generated each cycle, i.e. in real time in contrast to endpoint detection. 
The SYBR Green detection system was used.  The SYBR® Green dye, fluorescently 
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undetectable in its unbound form, binds to all dsDNA molecules resulting in the 
emission of a fluorescent signal proportional to amplicon quantity.  The fluorescence 
can then be read by a sequence detector in real time, in this instance a 7500 Real 
Time PCR system (Applied Biosystems).  Amplification of the fluorescent signal, at 
each cycle, indicates the increasing accumulation of dsDNA resulting from the 
annealing and subsequent polymerisation of the cDNA.  The change in fluorescence 
intensity (∆Rn) resulting from amplification is calculated as follows; ∆Rn = Rn+ - Rn-, 
where Rn+ is the fluorescence emission of the product at each time point and Rn- is 
the fluorescence emission at the baseline.  The baseline represents background 
fluorescence where there is no detectable increase resulting from amplification of 
PCR products.  The 7500 Real Time PCR software generates amplification plots of 
∆Rn vs cycle number.  During the initial cycles the ∆Rn does not exceed the baseline 
but as the reaction progresses the fluorescence intensity reaches a threshold defined 
as a statistically significant point above the baseline.  Based on the variability within 
the baseline an arbitrary threshold is selected at a point in the linear phase of 
exponential amplification, usually defined as 10 times the standard deviation of the 
baseline, within cycles 3 to 15.  The cycle threshold (Ct) is subsequently calculated by 
determining the point at which the fluorescence crosses the chosen threshold limit 
relative to the initial amount of target.  Thus Ct values decrease linearly with 
increasing target quantity.  The number of PCR cycles undertaken in order for the 
level of fluorescent signal to cross the given threshold is used to allocate a Ct value 
which enables the determination of dsDNA quantity. 
 
 
2.2.6.2 RNA Extraction 
RNase ZAP, RNase-free plasticware and DEPC-treated water were routinely used to 
minimize degradation of RNA.  Total RNA was extracted from cells cultured in 6-well 
plates by direct lysis using STAT-60 (200 µl/well), following a PBS wash (1ml/well).  
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Cell Scrapers were used to harvest the RNA into pre-cooled eppendorfs which were 
placed on ice.  0.2 volumes of chloroform was added to samples which were shaken 
vigorously for 15 seconds then centrifuged at 12,000 x g for 15 minutes at 4˚C.  This 
separates the sample into an aqueous, organic and interphase.   The RNA resides 
exclusively in the upper, colourless aqueous phase which is then transferred to a fresh 
Eppendorf.  To encourage precipitation 0.5 volumes of cold isopropanol are added to 
the RNA before vortexing and storing at -80 ˚C for at least 30 minutes.  The tubes 
were then centrifuged at 12,000 x g for 10 minutes at 4˚C.  The supernatant was 
discarded and pellet washed with 1 volume of 75% (v/v) ethanol by repeat re-
suspension and centrifugation at 7500 x g for 5 minutes at 4˚C.  The purified RNA was 
air-dried for 2 minutes in a clean, undisturbed environment before adding a suitable 
volume of nuclease free water and storing at – 80 ˚C.  RNA concentration was 
determined using a spectrophotometer (Nanodrop 1000).  Pure RNA has an A260/ A280 
ration of 1.9-2.1 and lower ratios indicate contamination.  Samples were diluted to 
1µg/µl with nuclease free water and stored at -80 °C.   
 
2.2.6.3 cDNA Synthesis 
Quantitect Reverse Transcription Kit (QIAGEN) was used to produce complementary 
deoxyribonucleic acid (cDNA) from the RNA, according to the manufacturer’s 
instructions. 
Reagents were placed on ice to thaw and the work area was cleaned with IMS and 
RNase Zap.  The heating block was set to warm to 42˚c whilst nuclease free tubes 
(0.6ml) were prepared and labelled (two per RNA sample, one labelled ‘-RT’).  Once 
thawed all reagent tubes were vortexed to prevent concentration gradients, spun and 
placed back on ice. 
Two nuclease free tubes for each RNA sample were prepared as follows; 
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2µl (7x) gDNA Wipeout Buffer, 1µg Template RNA and RNAse-free water to give a 
final volume of 14µl.  Tubes were gently spun to mix and then heated at 42°c for 2 
minutes before placing on ice.  This step removes any traces of contaminating 
genomic DNA. 
Two separate mastermixes were then prepared with a final volume 10% greater than 
required. 
(1) Reverse Transcription Reaction;  
1µl Quantiscript RT, 4µl Quantiscript RT Buffer (5x), 1µl Primer Mix 
(2) Reverse Transcriptase Negative Control; 
1µl nuclease free water, 4µl Quantiscript RT Buffer (5x), 1µl Primer Mix 
These were vortexed and 6µl of (1) was added to one of the duplicate tubes 
containing 14µl of RNA whilst 6µl of (2) was added to the remaining 14µl of RNA, 
labelled ‘-RT’.  Tubes were spun to mix and heated at 42˚c for 30 minutes before 
heating at 95˚c for 3 minutes to inactivate the Reverse Transcriptase reaction.  The 
resulting cDNA was diluted in nuclease free water and stored at -20˚c. 
2.2.6.4 Primer Design 
The NCBI database was used to access gene sequences in order to design primers 
by hand.  The Roche probe library’s qRT-PCR Assay Design feature was utilised as 
a starting point. 
The melting temperature (Tm) was calculated with the formula Tm = 
69.3+(41(GC/L))- (650/L) where GC is the number of G and C bases in the primer 
and L is the length of the primer.   
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Primers were amended by length and G/C content to fulfil the following 
requirements; 
- Sequences should be exon spanning to distinguish between cDNA and 
gDNA 
- Primer length between 18-24 base pairs 
- Tm between 58.0°c -59.9°c 
- Amplicon length between 75-110 bases 
- Tms of forward and reverse primer within 1°c of one another 
- At the 3’ end of the primer two of the last five bases should be G/C 
- No more than four of the same base in succession 
- Amplicon Tm = 64.9+(0.41x(((C+G)/L)x100)-(500/L) 
- Sequences entered into the Nucleotide BLAST program (NCBI) should show 
100% accuracy and specificity with no other genes with over 85% match for 
that transcript, where possible 
All primer sequences are provided in Appendix 1. 
2.2.6.5 Primer Preparation 
Primers were supplied lyophilised and re-suspended according to the manufacturer’s 
instructions.  To avoid any risk of contamination primers were prepared in the PCR 
hood and primer tubes were first centrifuged to ensure collection at the bottom of the 
tube.  The lyophilised primers were diluted in nuclease-free water to give a final 
concentration of 100µM.  Tubes were vortexed and centrifuged to ensure thorough 
mixing.  Working stocks (to prevent repeat freeze-thawing of primers) were prepared 
for each primer by adding 20µl of diluted primer with 180µl of nuclease free water, in 
nuclease free tubes, to give a final working concentration of 10µM.  Primers were 
stored at -20°c until required.   
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2.2.6.6 Primer Optimization 
All reagents and samples were thawed on ice and thoroughly vortexed and 
centrifuged at each step of the procedure to ensure thorough mixing.   
Working in the PCR hood to prevent contamination, a mastermix was prepared for 
each primer pair to be tested (with a final volume 10% greater than that required to 
allow for pipetting error).  Forward and reverse primers were used at 300nM in a total 
volume of 19μl in a SYBR Green master mix per well.  The mastermix was added to 
a MicroAmp® Optical 96-well Reaction Plate (19µl/well) followed by 1µl/well of 
pooled cDNA (or nuclease free water for controls), in triplicate, according to a pre-
prepared template.  The plates were sealed (using ThermaSeal RT2 film) and 
centrifuged for 3 minutes at 3000 RPM before placing in the 7500 Real Time PCR 
system (Applied Biosystems) covered with a mask.   
RT-qPCR was performed for 40 cycles (95 °C for 15 seconds, 60 °C for 1 min), after 
an initial incubation at 95 °C for 10 minutes.  L19, a non-regulated ribosomal 
housekeeping gene, was employed as an internal control.  Upon cycle completion 
the contents of the wells were aliquotted into 0.6ml RNA free tubes (combining 
triplicates) and stored at -20˚c. 
 
 
 
2.2.6.7 Agarose Gel Electrophoresis 
1g of powdered Agarose and 100ml of (1x) TBE solution combined and heated by 
microwaving until totally dissolved. 2µl of Ethidium Bromide (an intercalating dye that 
binds non-specifically to DNA/RNA and fluoresces in UV light) was added to the gel 
solution upon cooling and solution swirled to mix.  The gel solution was poured into a 
prepared gel tray, fitted with comb, and left to set.  The gel was then positioned 
within the gel electrophoresis machine (comb removed) and covered with 1xTBE up 
to the fill line.   The PCR samples were combined with loading dye, mixed and 
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pipetted carefully into the wells, in duplicate. 2µl of an appropriate ladder (e.g. 
Hyperladder™ V (BIO-33031, Bioline)) was added to wells either side of samples in 
order to determine size of the product.  Gels were run at 10V per 1cm of gel. 
 
 
2.2.6.8 Agarose Gel Extraction 
A pre-weighed sample pot was prepared for each sample.  DNA bands were 
visualised under UV light, cut from the gel using sterile scalpels and placed into the 
sample pots.  Samples were weighed to determine volumes of reagents required for 
each sample (100mg ~ 100µl).  Three volumes of Buffer QG were added per volume 
of gel and samples incubated at 50°c for 10 minutes.  Once dissolved one volume of 
isopropanol (to precipitate DNA) was added, samples pipetted onto the provided 
QIAquick columns and centrifuged for 16,000G for 1 minute (at room temperature).  
The flow through was discarded (as the DNA remains bound to the membrane of the 
QIAquick columns) and this process repeated until the entire sample has been 
used.500µl of Buffer QG was applied to each column, centrifuged (as before) and 
flow through discarded. 750µl Buffer PE (to wash the sample) was added, column 
centrifuged (as before) and flow through discarded. 
The columns were moved into 1.5ml nuclease free tubes, 30µl Buffer EB/nuclease 
free water added and samples left to incubate for 3 minutes before centrifuging (as 
before) to elute the DNA. 
Samples were stored at 2°c until assessed using a Nanodrop to determine DNA 
concentration.  DNA then diluted to 1ng/µl in nuclease free water. 
 
2.2.6.9 Standard Curve Analysis 
 
8 serial 1/10 dilutions were created in labelled nuclease free tubes per primer pair as 
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follows; 10µl cDNA + 90µl nuclease free water.  These were vortexed, centrifuged 
and the process repeated for each dilution to give final concentrations ranging from 
100pg/μl to 10ag/μl.  qRT-PCR was performed using 300nM of the designed primers 
in a SYBR green mastermix (as before) and serial dilutions applied in triplicate.  Ct 
Values were measured and primer efficiencies were calculated from the resulting 
data. 
The log of the cDNA concentration was plotted against the mean Ct values and the 
primer efficiency calculated as follows: Primer Efficiency = -1/(10^gradient of the 
line). 
2.2.7 Intracellular Calcium Profiling 
Cells were grown to ~90% confluence in 35mm glass-bottomed petri dishes (MatTek, 
US).  Cells were incubated with physiological saline solution (PSS) containing 5µM 
Fura-2/Flou-4 AM for 40 minutes at room temperature.  Pluronic F127 (0.025%, w/v) 
non-ionic detergent was added to assist with dye loading.  Cells were then washed 
with PSS and the dish was positioned on the stage of a confocal microscope (LSM 
510 META, Carl Zeiss, UK) and temperatures were maintained at 37oC with a peltier 
unit.  Krebs’-Heinselet, warmed to 35°C, was superfused for 20-30 minutes to ensure 
de-esterification of Fura-2/Flou-4 AM was complete.  Perfusion was stopped and the 
volume of solution in the dish altered to 200µl in order for image acquisition. On the 
stage of a Zeiss Axiovert 200M inverted microscope and visualized with a 40x 
objective lens, Fura-2/Flou-4 AM fluorescence was excited using a krypton/argon laser 
at 488nm and emitted light was collected above 510nm (LSM 510 META, Carl Zeiss, 
UK).  Images were captured at 1 frame per second via the C-Apochromat 63×/1.20 W 
objective lens.   
For the ECM experiments, two time sequences were assimilated for each dish.  The 
     
  71 
 
first time sequence recorded baseline activity for 2 minutes, 10ul of embryo 
conditioned medium was applied (to give a 1/20 dilution) and images were recorded 
for the following 5 minutes.  After a 10 minute interval the second recording was 
initiated using the same viewing field in order to detect longer term [Ca2+]i signals.   10 
μl of unconditioned ECM was added as a control and experiments with trypsin and 
trypsin inhibitor were conducted in a similar manner.  A cooled charge-couple device 
camera at a rate of approximately one frame per second was used to capture the 
fluorescence which was used to indicate [Ca2+]i fluxes. Within each field of view 
regions of interest (ROI) were drawn around a selected cell. The Multi Measure 
function in the ImageJ ROI Manager was used to mine intensity profiles for each ROI 
over time. Origin 8.5 (OriginLab Corporation, USA) was used for further processing, 
graphing and statistical analysis of the imported intensity profiles. Traces were 
normalised to their corresponding baseline to give a self-ratio trace (F/F0). [Ca
2+]i 
signaling was quantified for the first and last five minute time periods by area under the 
curve (AUC) calculated above the baseline (F/F0).  Data was analysed and plotted to 
show oscillatory frequency, peak response and area under the curve. 
 
 
2.2.8 Microscopy 
2.2.8.1 Immunohistochemistry 
Paraffin-embedded, formalin fixed endometrial specimens were immunostained 
using the Novolink polymer detection system.  A microtome was used to create 5µm 
sections which were dewaxed in histoclear, rehydrated in descending ethanol 
solutions before rinsing with water.  Sections were exposed to 30% (v/v) hydrogen 
peroxide for 5 minutes and then rinsed with TBS.  Slides were then placed in a 
humidified chamber for 5 minutes at room temperature with immunohistochemistry 
blocking solution, which contained serum matched to the species in which the 
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secondary antibody was raised.  Immunostaining with primary antibodies was carried 
out in a humidified chamber overnight at 4 °C.  The primary antibody was omitted 
and replaced by the corresponding immunoglobulin isotype in the case of negative 
controls.  Slides were washed twice in TBS and incubated with a post primary 
solution for 30 minutes.  Slides were washed in TBS and incubated with Novolink 
Polymer for 30 minutes, to achieve visualisation of mouse/rabbit immunoglobulin 
primary antibodies.  Slides were washed in TBS and peroxidase activity was 
developed using a diaminobenzidine (DAB) solution which produces a visible brown 
precipitate at the antigen site.  Sections were counterstained with Hematoxylin and 
overlaid with coverslips. 
2.2.8.2 Immunofluorescence 
Human and mouse embryos were collected at various stages of development and 
stored in 4% Para-formaldehyde/PBS at 2-8 °C.  HESCs were cultured in 35mm glass-
bottomed petri dishes.  They were fixed in 4% Para-formaldehyde/PBS for 1 hour at 
room temperature, following removal of media and a PBS wash, then stored at 2-8 °C.  
Samples were first washed in PBS and permeabilised (where appropriate) for 1 hour in 
0.01% (v/v) Triton X-100 in PBS at room temperature.  Following a PBS wash 
incubation in 1% w/v BSA in PBS for 1 hour at 4 °C, with rocking, was performed to 
prevent non-specific antibody binding.  Samples were then incubated in the primary 
antibodies (diluted as stated in ‘Materials 2.1.4’) overnight at 4 °C, with rocking.  1% 
w/v BSA in PBS without primary antibody was used for the negative control.  The 
following day samples were washed in 1% w/v BSA in PBS for 10 minutes at 4 °C and 
then incubated in the secondary antibodies (diluted as stated in ‘Materials 2.1.4’) for 2 
hours at 4 °C, with rocking.  For visualisation embryos were washed in 1% w/v BSA in 
PBS and mounted onto 35mm glass-bottomed petri dishes in 10µl Vectashield® with 
DAPI for nuclear counterstain and overlaid with a glass coverslip.  Visualisation was 
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achieved using a Zeiss LSM 510 confocal imaging system. 
 
2.2.9 Data Mining 
In silico analysis was performed on the following publicly available datasets from the 
Gene Expression Omnibus (Edgar et al., 2002): 
Pre-implantation embryonic development (Homo sapiens): GDS3959  
Pre-implantation embryonic development (Mus musculus): GDS813 
Endometrium through the menstrual cycle (Homo sapiens): GDS2052 
Data were exported to Microsoft Excel for analysis and graphs were generated using 
GraphPad Prism® Software.  Statistical analysis was performed using SPSS 
Software, IBM and GraphPad Prism® Software. 
2.2.10 Statistical Analysis 
Differences amongst three or more group means were determined using the one-
way analysis of variance (ANOVA) followed by the Games-Howell post-hoc test.  
Variables that did not fit a normal distribution were analysed using the Mann-Whitney 
U test. Correlative analysis was performed using the Spearman’s rank test.  Results 
were expressed as means ± standard error of the mean (SEM). Values of P<0.05 
were considered statistically significant. 
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Chapter 3 
 
 Embryo-derived Trypsin-like 
Proteases in Implantation 
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3.1 Introduction 
Human pre-implantation embryos are known to be distinctively invasive and 
unpredictable in terms of their developmental competence and chromosomal 
composition (Vanneste et al., 2009, Wells and Delhanty, 2000, Voullaire et al., 2000).  
Humans display correspondingly high rates of pregnancy loss, affecting up to 50% of 
conceptions.  Although 50% of miscarriages result from aneuploidies, the specific 
and complex chromosomal rearrangements seen in blastocysts have not been 
detected in clinical miscarriage samples (Fragouli et al., 2013).  The genetic diversity 
observed in human embryos may render implantation events adaptable to a 
changing environment and aneuploidy could in fact infer an implantation advantage, 
as in cancer cells (Macklon and Brosens, 2014, Vanneste et al., 2009).  However this 
diversity also poses a requirement for a selective human endometrium that impedes 
implantation of developmentally incompetent embryos, in order to safeguard the 
mother against prolonged investment in a non-viable conceptus (Macklon and 
Brosens, 2014). 
In order to develop a receptive yet selective phenotype the functional endometrial 
compartment undergoes vast morphological and biochemical remodeling, including 
decidualization, which occurs cyclically and spontaneously in humans.  Insufficient 
decidual preparation of the endometrial stromal cell layer results in out of phase 
implantation and pregnancy loss (Teklenburg et al., 2010b).  Although the embryo is 
thought to make initial contact with the upper endometrial epithelium, the role of this 
cellular compartment in implantation is still under debate and may differ between 
species (Lucas et al., 2013).  The interaction between epithelial and stromal cells, 
however, is thought to orchestrate the implantation process, creating a dynamic 
micro-environment capable of reacting and adapting to local requirements.  In this 
way the endometrium may be seen as a biosensor of embryo quality, a feature 
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illustrated by differential endometrial gene expression patterns upon exposure to 
embryos of altered origins or varying quality (Sandra and Renard, 2011, Brosens et 
al., 2014, Salker et al., 2010).  In addition to supporting implantation of viable 
embryos, HESCs specifically target and eliminate compromised embryos  (Brosens 
et al., 2014) and thus malfunction of the endometrial biosensor may lead to a 
prolonged maternal investment in non-viable embryos (Weimar et al., 2012b, Salker 
et al., 2010).  This theory has been substantiated by the observation that HESCs 
from women suffering with RM fail to discriminate between viable and non-viable 
embryos (Teklenburg et al., 2010a).   
In order for the endometrium to function as a biosensor, human embryos must 
produce mechanical or chemical signals that convey their developmental potential to 
the maternal cells.  It is expected that such signals would be heightened at the 
blastocyst stage, when the embryo implants.  Various factors have been studied and 
implicated in the process of implantation (Table 1.5.1), mainly using gene deletion 
studies in rodent models, but none have been shown to result in a defined human 
maternal response in line with the biosensoring theory.  However a recent study, 
focusing on the mouse, has comprehensively implicated a role of embryo-derived 
serine proteases, notably trypsin, in regulating the decidual response through 
cleavage of the epithelial sodium channel (ENaC) (Ruan et al., 2012).   
In this chapter I use a variety of methods, ranging from a comprehensive literature 
search, analysis of microarray databases, protein measurements and co-culture 
experiments, in order to identify candidate embryo-derived signals involved in 
maternal embryo recognition and biosensoring. 
I demonstrate that tryptic proteases play an important role in the implantation 
process in the human.  Both evolutionarily conserved and non-conserved pathways 
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contribute to the generation of a complex protease signal that act on specific 
receptors in human decidualising stromal cells.  Furthermore, the embryo-derived 
protease signals fluctuate between human embryos according to their ability to 
implant in vivo. 
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3.2 Results 
3.2.1 Trypsin literature search 
As discussed in Chapter 1, a key role for embryo-derived trypsin-like proteases has 
been described in murine implantation (Ruan et al., 2012).  I performed an electronic 
literature search using the PubMed database focusing on a role of trypsin and 
trypsin-like proteases in embryo development and/or implantation. The keywords 
‘trypsin’ or ‘protease’ in conjunction with ‘embryo’, ‘implantation’ or ‘reproduction’ in 
the title or abstract, were used.  I restricted the search to articles published in the 
English language between 1970 and December 2015.  This literature search 
identified 1456 articles and implicates embryo-derived trypsin activity as an important 
mediator of implantation across, at least, ten different species (Table 3.2.1).   
The results of the literature search reveal that trypsin-like proteases are involved in 
early/pre-implantation embryo development of the salmon louse, tiger mosquito, 
marine crab, Xenopus frog and mouse (Table 3.2.1).  Furthermore, the search 
directly implicates trypsin-like proteases in regulating zona lysis and embryo hatching 
in rabbit, mouse, rat, sheep and hamster embryos (Table 3.2.1).  The literature even 
details a role for protease activity beyond hatching, promoting embryo attachment 
and penetration of endometrial cells in mice and rats, and placental development in 
Rhesus monkeys (Table 3.2.1).  Implantation-related trypsin activity in mice is 
reported to encompass a complex system of at least two types of proteolytic activity, 
either locally secreted or located at the cell surface.  In this species, trypsin and 
protease inhibitors were found to reduce the number of implantation sites, promote 
fetal loss and reduce fetal birth weight in vivo (Table 3.2.1).  No study to date has 
designated a role for trypsin in either human blastocyst development or implantation.   
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Table 3.2.1 The Role of Trypsin-like Proteases in Implantation: A Review of the Literature 
 
 
Species Experimental Details Conclusions Reference 
Aedes 
Albopictus 
- Analysis of trypsin-like serine peptidase profiles in eggs, 
larvae and pupae by zymography and SDS-page.  
- Differing proteolytic bands were observed at each 
stage, and could be inhibited by a serine protease 
inhibitor (phenyl-methyl sulfonyl-fluoride/PMSF) and 
trypsin-like serine protease inhibitor (Nα-Tosyl L-lysine 
chloromethyl ketone hydrochloride/TLCK), in larvae and 
pupae. 
 
- Trypsin-like serine proteases are 
important in early mosquito 
development. 
(Saboia-Vahia 
et al., 2013) 
Hamster - Measured the effect of various proteases on zona 
pellucida (ZP) dissolution. 
- Cysteine protease inhibitors completely inhibited ZP 
escape whereas trypsin inhibitors had a reduced effect. 
- Cysteine proteases may mediate 
blastocyst hatching in hamsters. 
- This differs from previous evidence 
which demonstrated a role of trypsin-like 
proteases in this process. 
 
(Mishra and 
Seshagiri, 2000) 
L.Salmonis - Trypsin-like LsTryp10 mRNA was found to be evenly 
distributed in ovaries and oocytes and produced both 
maternally and by embryos. 
- Maternally deposited and embryonic LsTryp10 appear 
to be translated from dissimilar pools of mRNA; one 
being maternally transcribed and the other being 
transcribed post- fertilization. 
- Maternally derived LsTryp10 is thought to regulate the 
yolk degradome. 
 
- A trypsin-like protease, of both maternal 
and embryonic sources, was detected in 
oocytes. 
- The protease was differentially regulated 
and had different functions according to 
its origin.  
(Skern-
Mauritzen et al., 
2009) 
Marine 
Crab 
- Biochemical composition and digestive enzyme activity 
was analysed throughout embryonic development. 
- Trypsin activity is detectable during early 
and late embryonic development. 
(Xu et al., 2013) 
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- Increased trypsin activity was detected in the early and 
late stages. 
 
Mouse - Tested a range of enzymes and their effects on the ZP. 
- Lysis of ZP in vitro could only be achieved by trypsin or 
pronase. 
 
- The lysin secreted by the embryo prior to 
implantation must be a proteolytic 
enzyme.  
(Bowman and 
McLaren, 1970) 
Mouse - Embryos were cultured on monolayers of decidual cells 
and exposed to soybean trypsin inhibitor and 
nitrophenol-p-guanidino benzoate (NPGB). 
- NPGB alone had the greatest inhibitory effect on 
blastocyst development compared to alternative trypsin 
inhibitors alone.  
- However when inhibitors were combined the inhibitory 
effect was even greater.   
 
- Suggests a complex system of at least 
two types of proteolytic activity is 
required for implantation and embryo 
attachment in mice. 
 
  
(Kubo et al., 
1981) 
Mouse - Applied a trypsin assay to homogenised embryo pellets 
and embryo culture supernatants. 
- Tested the effect of inhibitors on in vitro embryos.   
- The most significant results were found when using 
trypsin inhibitors which were too large to enter the 
blastocyst, suggesting a cell surface or secreted 
enzyme.  
 
- Strypsin is a membrane associated 
trypsin-like protease involved in 
blastocyst hatching.  
(Perona and 
Wassarman, 
1986) 
Mouse - Enzymatic activity measured in embryo culture medium  
- Embryo protease activity increased during hatching and 
could be strongly inhibited following administration of 
trypsin inhibitors.   
- Only weak inhibition was observed with non-trypsin 
specific inhibitors.   
 
 
- Protease activity of hatching blastocysts 
results from trypsin and/or trypsin-like 
serine proteases.  
(Sawada et al., 
1990) 
 81 
 
Mouse - Pregnant mice were injected, intraperitoneally, with 
Ascaris trypsin inhibitor on day 12 to 15 of pregnancy.  
- On day 19 implantation sites, early resorptions and 
living and dead foetuses were counted. 
- Ascaris trypsin inhibitor leads to maternal deaths, 
abortions, increased fetal deaths and decreased mean 
fetal weight of living fetuses  
 
- Implicates a role for trypsin in both 
uterine and embryonic development.  
(Blaszkowska, 
2005) 
Mouse  
- Intrauterine injection of serine protease inhibitor 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride 
(AEBSF) on day 3 of pregnancy. 
- Mice were sacrificed and uterine horns harvested on 
day 8 to count the number of implantation sites. 
- The number of implantation sites was reduced in 
response to increasing AEBSF concentration.  
- This effect was reversible and AEBSF has cytotoxic 
effect on the uterine epithelia. 
 
 
- AEBSF impairs implantation, possibly 
due to interference in extracellular matrix 
remodelling. 
(Sun et al., 
2007) 
Mouse - Used liquid chromatography/mass spectrometry to 
analyse secreted proteins from recently activated 
oocytes.  
- Prss1 was the most abundant of all 18 proteins found in 
the ZP free group. Only 6 proteins were found in ZP 
intact group. 
- Prss1, Trypsinogen 7, Trypsin 4 and 
Trypsin 10 are secreted from recently 
activated oocytes suggesting a direct 
role in regulation of fertilisation and 
embryonic development. 
 
(Peng et al., 
2012) 
Rat  
- Intrauterine injections of protease inhibitors (of 
chymotrypsin-like, thiol-, metallo- and trypsin-like 
proteases) on day 5 of pregnancy.   
- 5 to 6 hours later embryos were flushed from the uterine 
horns and examined.  
 
- A number of proteases play specific 
roles in embryo development and 
hatching in rats; 
- Trypsin-like and metallo- proteases are 
implicated in zona lysis.  
(Ichikawa et al., 
1985) 
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- Chymotrypsin-like proteases and thiol 
proteases are implicated in growth and 
development of the embryo. 
 
Rat - Cervical dislocation of pregnant mice on day 3 of 
pregnancy. Uterine horns dissected and endometrial 
cells collected.   Blastocysts collected prior to dissection 
via uterine flushing and co cultured with endometrial 
cells and AEBSF. 
- AEBSF containing wells showed abnormal aggregation 
of endometrial cells and inner mass shrinking of the 
blastocyst leading to blastocyst and cell death. 
 
- Protease activity is required for 
blastocyst hatching and penetration of 
endometrial cells in vitro.  
(Jiang et al., 
2011) 
Rabbit - The effect of various proteases, including trypsin, were 
measured on the development and hatching of 
blastocysts.  
- Trypsin was one of the enzymes sufficient in low 
concentrations to result in blastocyst complete hatching. 
 
- Rabbit blastocyst hatching in vivo may 
involve trypsin-like proteases. 
(Kane, 1986) 
Rhesus 
Monkey 
- ISH (In situ hybridisation) experiment investigating 
mRNA localisation of and PN-1 (protease nexin-1). 
- Intense localisation of mRNAs was observed in 
trophoblastic shell and column, glandular epithelium 
and placental villi on day 12-18.  
- PN-1 mRNA levels increased significantly on day 26. 
- Prss8 is implicated in endometrial 
epithelial morphology establishment, 
tissue remodelling, and trophoblastic 
invasion during early pregnancy.  
- The cognate Serpin, PN-1, was not 
reciprocally expressed, generating a 
tissue environment supporting the 
proteolytic activities of Prss8 throughout 
early pregnancy. 
(Lin et al., 2006) 
 
Sheep 
 
- Enzymatic removal of the ZP in vitro of both fertilised 
and unfertilised eggs using various proteases.  
 
 
- Pronase may have a greater effect than 
trypsin on the lysis of the ZP prior to 
implantation in sheep. 
 
(Moor and 
Cragle, 1971) 
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- Pronase was the major protease showing a lytic effect 
on fertilised egg ZP however trypsin and chymotrypsin 
had a significant effect after a prolonged period of time.  
- However greater sample numbers were used for 
pronase analysis.  
 
Xenopus 
Laevis 
- A secreted trypsin-like oviducal protease, oviductin, 
renders Xenopus eggs fertilizable by the conversion of 
glycoproteins gp43 to gp41. 
- Isolated, unfertilised egg envelopes were incubated with 
trypsin, chymotrypsin, p-aminobenzamindine and 
leupeptin. 
- A sperm binding assay revealed that trypsin treatment 
dramatically increased sperm binding to egg envelopes. 
 
- Trypsin activity renders Xenopus eggs 
penetrable by sperm and capable of 
fertilization by selectively cleaving gp43 
on the egg envelope mimicking oviductin 
action. 
(Lindsay and 
Hedrick, 1998) 
Xenopus 
Laevis 
- Cloning of cDNA from Xenopus embryos using RT-PCR 
and comparison against human membrane type serine 
protease 1 (MT-SP1) and trypsin. 
- Overexpression of Xenopus embryonic serine protease 
2 (XESP-2) and the Xenopus homolog of MT-SP1 
(XMP-SP1) had significant defects to embryo 
development.   
- Injecting XESP-2 inhibited progression through to 
blastophore closure.  
- XESP-2 has a cysteine rich scavenger receptor, similar 
to the protease encoded by TMPRSS2. 
 
- Isolated three embryo-derived TTSPs 
cDNAs with distinct patterns of 
regulation during embryogenesis.  
- XESP-2 and XMP-SP1 were found to 
play a role in regulating embryo 
development. 
 
(Yamada et al., 
2000) 
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3.2.2 Trypsin activity in human embryos  
In order to determine a role for trypsin activity in human implantation, embryo culture 
media (ECM) drops, in which embryos were cultured for IVF treatment, were routinely 
collected and stored at -80°C.  These culture drops were tested for the presence of 
protease and trypsin activity in order to identify whether such activity may be as 
important in human implantation as observed in other species.  The ECM either 
contained a number of co-cultured embryos from a single patient (‘pooled’), or 
embryos that were cultured individually for time-lapse imaging (‘individual’). 
Protease activity was measured using the Enzchek® assay.  This assay measures 
protease catalysed hydrolysis of a casein derivative, which causes release of the 
quenched fluorescently labelled peptides (BODIPY FL dye).  The level of 
fluorescence measured is proportional to protease activity.  Trypsin activity was 
measured using an assay that employs a trypsin-specific substrate, which upon 
cleavage by trypsin generates p-nitroaniline (p-NA) detectable at OD = 405.  The 
colour change is thus proportional to p-NA content.  
To determine if trypsin activity is generated by human embryos, ECM of 163 pooled 
embryos from 16 individuals were analysed using the trypsin assay (Figure 3.2.2.1a).  
As shown, trypsin activity was detectable, although the level of activity varied widely 
between culture droplets (median: 20.9 mU/ml; range: 0.7 to 45.4 mU/ml). 
In order to obtain more precise measurements of protease and trypsin activity, ECM 
of 87 individually cultured embryos from 21 individuals were analysed using the 
Enchek® and trypsin assays (Figure 3.2.2.1b,c).  Embryos were divided into two 
groups according to the day of pre-implantation embryo development at the time of 
ECM collection (day 2 or day 5).  Data were normalised to activity in unconditioned 
medium (UCM) droplets, which were not used for embryo culture, and mean values 
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are displayed. 
Protease activity was measured in 47 individual ECM droplets and was increased in 
the ECM of day 5 embryos (median: 247.7 % change from control; range: 0.0 to 
806.6 % change from control) compared to day 2 embryos (median: 38.3 % change 
from control; range: 0.0 to 546.1 % change from control) (Figure 3.2.2.1b).   
Trypsin activity was measured in 40 individual ECM droplets and similar to protease 
activity, was increased in the ECM of day 5 embryos (median: 34.7 % change from 
control; range: 2.1 to 76.7 % change from control) compared to day 2 embryos 
(median: 10.3 % change from control; range: 0.0 to 46.4 % change from control) 
(Figure 3.2.2.1c).   
The recorded levels of protease and trypsin activity varied markedly between 
individual ECM droplets (range: 0 to 806.6 % change from control; range: 0 to 76.7 % 
change from control, respectively) (Figure 3.2.2.1b,c).  This variation is partly, but not 
entirely, explained by increased activity from embryos at day 5.   
A high rate of attrition is observed during in vitro culture of human embryos with a 
majority of embryos arresting before the blastocyst stage.  Therefore separation of 
ECM according to the day of development does not accurately reflect the 
developmental stage of the embryo.  In our unit embryo transfers are conducted 
according to developmental day rather than embryo developmental stage.  To 
determine whether trypsin activity reflected embryo developmental stage, 39 ECM 
droplets from day 5 transferred embryos were separated according to the 
developmental stage of the embryo (morula, cavitating, blastocyst) and subjected to 
the trypsin assay (Figure 3.2.2.2).  Although the majority of embryos included in this 
analysis had reached the blastocyst stage (n = 24), this data shows a close trend 
towards increasing trypsin activity in line with developmental maturation. 
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Day 5 transferred blastocysts are routinely graded according to the Gardner grading 
system (Gardner et al., 2000), which assigns values to the level of blastocoel 
expansion in combination with the morphological quality of two polarised cell 
compartments that comprise the blastocyst.   The outer shell-like TE that will give rise 
to the extraembryonic membranes and the inner cluster of cells that will give rise to 
the fetus, the ICM.  These compartments are graded independently by an 
embryologist just prior to embryo transfer and the grades have been shown to reflect 
embryo implantation potential (Gardner et al., 2000).   
Blastocoel expansion is graded as follows:  
1, the blastocoel is less than half of the volume of the embryo; 
2, the blastocoel is half of or greater than half of the volume of the embryo;  
3, the blastocoel completely fills the embryo;  
4, the blastocoel volume is larger than that of the early embryo, with a thinning zona; 
5, the trophectoderm is starting to herniate though the zona;  
6, the blastocyst has completely escaped from the zona.   
 
For fully formed blastocysts (with a blastocoele grading of 3-6) the inner cell mass is 
graded as follows: 
A, tightly packed, with many cells;  
B, loosely grouped, with several cells;   
C, very few cells.   
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For fully formed blastocysts (with a blastocoele grading of 3-6) the trophectoderm is 
graded as follows: 
A, many cells forming a cohesive epithelium; 
B, few cells forming a loose epithelium; 
C, very few large cells.  
To determine if trypsin activity varies between high and low quality embryos, 21 
individual ECM drops from blastocysts transferred on day 5 were measured using 
the trypsin assay, and separated according to their morphological grading via the 
Gardner scale (Figure 3.2.2.3).  In brief, groups A and B denote good to average 
quality embryos whereas group C denotes poor quality embryos.  Though numbers 
are limited, this analysis revealed that increased trypsin activity was detectable in 
ECM drops from embryos with poorer quality trophectoderm.  This may be explained 
by a propensity of trypsin, produced by the embryo, to leak out between the cells 
within the trophectoderm layer in cases where the cells are more loosely packed.  
The result may be decreased trypsin levels within the blastocyst itself potentially 
impairing the ability of the blastocyst to adequately undergo the hatching process, a 
prerequisite for implantation. 
This work provides novel evidence of trypsin activity being produced by human 
embryos, which complements the wealth of literature designating a role for trypsin 
during the implantation process (Table 3.2.1).  Although the exact role of trypsin in 
human implantation requires further investigation I speculate that it may mirror that of 
other species and contribute to blastocyst hatching, embryo attachment, invasion and 
maternal recognition.   
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Figure 3.2.2.1 Protease and Trypsin activity in ECM a) Trypsin activity in day 
5 pooled ECM (n = 16). b) Protease activity in individual ECM (n = 49, P = 
0.006) using the Enzchek® assay.  c) Trypsin activity in individual ECM (n = 38, 
P = 0.0015).  All measurements were performed in duplicate, normalised to 
UCM and are displayed as mean values.  Mann Whitney statistical analysis was 
applied.  *P < 0.05; **P < 0.01; ***P < 0.001. 
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Figure 3.2.2.2 Trypsin activity and pre-implantation embryo development.  
Trypsin activity in individual ECM (n = 39).  All measurements were performed in 
duplicate, normalised to UCM and are displayed as mean values.  Median values are 
displayed for each group.  ANOVA statistical analysis was applied (F = 1.569, P = 
0.2133) with Brown-Forsythe test (P = 0.0757). 
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Figure 3.2.2.3 Trypsin activity and morphological grade.  Trypsin activity in 
individual ECM from blastocysts transferred on day 5 (n = 21) and separated 
according to morphological grade (A = good, B = satisfactory, C = poor).  All 
measurements were performed in duplicate, normalised to UCM and are displayed 
as mean values.  Median values are displayed for each group.  Mann Whitney 
statistical analysis was applied (ICM P = 0.0622, TE P = 0.0355). 
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3.2.3 Trypsin induces calcium Ca2+ oscillations in Ishikawa cells 
A recent study illustrated that trypsin could induce morphological changes that 
mimicked decidualization in murine endometrial cell cultures via a sustained rise in 
intracellular calcium ions ([Ca2+]i)
 (Ruan et al., 2012).  The authors speculated that 
embryo-derived trypsin activity may similarly regulate implantation in humans (Ruan 
et al., 2012).   
Ca2+ coordinates various physiological and biochemical processes, acting as 
widespread secondary messengers in signal transduction pathways.   To establish 
whether trypsin induces Ca2+ signaling in human endometrial cells, we monitored 
Ca2+ oscillations in individual Ishikawa cells, a well-studied human endometrial 
adenocarcinoma cell line, by confocal microscopy.  Ishikawa cells were first pre-
loaded with fura-2 (0.5 µg/ml), a sensitive, high affinity, ratiometric indicator dye that 
is widely used for accurate [Ca2+]i measurements around basal concentrations.  A 
shift in the excitation spectrum of fura-2 upon binding to Ca2+ permits ratio 
measurements, which overcome problems associated with uneven dye loading, 
leakage, photobleaching and unequal cell thickness.  Upon treatment with trypsin 
(10 nM) [Ca2+]i oscillations were observed and persisted for around 10 minutes 
(Figure 3.2.3.1a).   
Ca2+ may enter the cytoplasm from external sources via calcium channels in the cell 
membrane, or from emptying of internal stores, i.e. mitochondria and endoplasmic 
reticulum.  To determine the nature of the Ca2+ response to trypsin, the previous 
experiment was repeated in the absence of extracellular Ca2+.  This resulted in a 
single [Ca2+]i transient, followed by a decline in [Ca
2+]i to below the baseline level 
(Figure 3.2.3.1b).  Re-addition of Ca2+ to the extracellular solution resulted in 
resumption of oscillations (Figure 3.2.3.1b).   The data indicate that a single initial 
increase in [Ca2+]i upon trypsin application originates from the emptying of an 
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intracellular store, whilst store-operated Ca2+ entry channels (SOCE) are crucial to 
the sustained calcium signalling response to trypsin. 
Sarco/Endoplasmic Reticulum Ca2+ ATPase (SERCA) resides in the sarcoplasmic 
reticulum (SR) where it transfers Ca2+ from the cell cytosol to the SR lumen via ATP-
hydrolysis.  The “Ca2+ re-addition” protocol  (Bird et al., 2008) was used in order to 
determine the existence of SOCE in Ishikawa cells.  SERCA was inhibited, in the 
absence of extracellular Ca2+, using cyclopiazonic acid (CPA), which resulted in 
depletion of Ca2+ content from the ER due to passive Ca2+ leakage (Figure 3.2.3.1c).  
The amplitude and rate of rise of [Ca2+]i  upon re-addition of extracellular Ca
2+ 
demonstrates SOCE activation in Ishikawa cells.  Furthermore, an increased rate 
and amplitude of the [Ca2+]i rise upon application of CPA in addition to trypsin (10 
nM) suggests that trypsin potentiates SOCE (Figure 3.2.3.1d). 
These findings clearly demonstrate that trypsin can induce sustained, SOCE-
dependent Ca2+ oscillations in human endometrial (Ishikawa) cells. 
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Figure 3.2.3.1 Trypsin-induced Ca2+ oscillations in Ishikawa cells.  a) 10 nM 
trypsin application in the presence of extracellular Ca2+. b) 10 nM trypsin 
application in the absence of extracellular Ca2+ followed by re-addition of 
extracellular Ca2+ after 5 minutes.  c) Inhibition of the SERCA pump via CPA and 
activation of SOCE via the “Ca2+ re-addition protocol” (Bird et al., 2008).  d) As 
(c) but in the presence of trypsin (10 nM).  Fluorescence intensity for fura-2 (0.5 
µg/ml) is shown as the 340/380 ratio, calculated from excitation at 340 nm (high 
calcium) and 380 nm (low calcium) with emission set at 510 nm (LSM 510 
META, Carl Zeiss, UK).  Work done in collaboration with Dr Anatoly Shmygol. 
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3.2.4 Trypsin-dependent gene expression in Ishikawa and HEECs 
Ca2+ signaling, mediated by embryo-derived trypsin, has been shown to induce 
Ptgs2 expression, which codes for COX-2, a key mediator of prostaglandin 
synthesis in mouse implantation (Ruan et al., 2012). 
In order to assess whether trypsin impacts this prostaglandin synthesis pathway in 
humans, trypsin (10 nM) was applied to confluent cultures of Ishikawa cells and 
human endometrial epithelial cells (HEECs).  Trypsin was withdrawn after 15 
minutes and RNA was harvested for qRT-PCR 24 hours later.  This brief exposure 
to trypsin was sufficient to induce PTGS2 expression 5-fold in Ishikawa cells (Figure 
3.2.4.1a,) and 1.8-fold in HEECs (Figure 3.2.4.1b). 
To determine whether increased PTGS2 expression upon trypsin exposure 
correlates with COX-2 levels, Ishikawa cells were exposed to increasing 
concentrations of trypsin (0 to 100 nM) for 15 minutes.  Protein was harvested after 
24 hours and COX-2 protein levels were measured via SDS-PAGE and Western 
blot (Figure 3.2.4.1c).  The findings indicate that induction of PTGS2 in response to 
a tryptic signal is paralleled by the induction of COX-2 at protein level. 
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Figure 3.2.4.1 PTGS2 and COX-2 expression upon trypsin exposure.  
a) Ishikawa cells exposed to trypsin (10 nM, 15 minutes).  b) Pooled HEECs 
exposed to trypsin (10 nM, 15 minutes).  RNA was harvested at 24 hours and 
PTGS2 transcript levels analysed, in triplicate, via qRT-PCR.  Data are 
normalized to L19 and shown as mean values (+SD).  c) Ishikawa cells exposed 
to increasing trypsin concentrations (0 to 10 nM) for 5 minutes.  Protein was 
extracted at 24 hours and COX-2 levels measured via western blot.  Β-actin was 
used as a loading control. 
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3.2.5 Embryo-derived trypsin induces Ca2+ signaling in Ishikawa cells 
To determine whether embryo-derived trypsin activity could induce Ca2+ signaling in 
endometrial cells, Ishikawa cells were treated with ECM (diluted 1:20).  In order to 
monitor Ca2+ concentrations, cells were pre-loaded with fluo-4 AM (5 µM), a non-
fluorescent acetoxymethyl ester, which is cleaved intracellularly to give the single-
wave, green-fluorescent calcium indicator fluo-4.  Despite possessing lower affinity 
for Ca2+ than fura-2, fluo-4 permits measurements of greater rises in calcium levels, 
accurately detecting Ca2+ concentrations from 100 nM to 1 µM (Gee et al., 2000).  
Following application of ECM, the cells were subsequently monitored for 15 minutes 
(Figure 3.2.5.1a,b).    
ECM induced Ca2+ oscillations in Ishikawa cells that varied markedly according to 
embryo quality (Figure 3.2.5.1a,b).  ECM from competent embryos, i.e. successfully 
implanted, induced a sharp but transient rise in [Ca2+]i, lasting 3.5 minutes (Figure 
3.2.5.1a).  In contrast, ECM from embryos deemed unsuitable for transfer (‘poor 
quality’) induced a sharp initial rise in [Ca2+]i followed by sustained, repetitive, Ca
2+ 
oscillations, which persisted for the entire observation period (Figure 3.2.5.1b).  This 
data suggest that embryo-derived signals can induce Ca2+ in the endometrium.  
Crucially ‘good quality’ and ‘poor quality’ embryos induce differential endometrial 
responses. 
To determine whether the observed Ca2+ responses in Ishikawa cells resulted from 
trypsin activity in ECM, cells were pre-loaded with soybean trypsin inhibitor (1 
mg/ml) before adding ECM (Figure 3.2.5.1c).  This resulted in a dramatic reduction 
in the initial [Ca2+]i rise in response to ECM addition (Figure 3.2.5.1a,b) and entirely 
abolished subsequent Ca2+ oscillations (Figure 3.2.5.1c).  These findings indicate 
that embryo-derived trypsin activity is required for the Ca2+ signaling responses 
observed upon treatment of Ishikawa cells with ECM. 
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To further characterize the Ca2+ signaling responses observed upon application of 
ECM, Ishikawa cells were treated with trypsin (10 nM) (Figure 3.2.5.1d).  Sustained, 
repetitive Ca2+ oscillations were detected following exposure to trypsin (Figure 
3.2.5.1d), which mimicked the response to ECM from poor quality embryos (Figure 
3.2.5.1b).  As expected, the magnitude of the Ca2+ peaks were greater upon trypsin 
application, compared to ECM, but the pattern and duration of the Ca2+ oscillations 
were comparable (Figure 3.2.5.1b,d).  Pre-treatment of the Ishikawa cells with 
soybean trypsin inhibitor (1 mg / ml) diminished the response to trypsin and curtailed 
the prolonged Ca2+ oscillations observed previously (Figure 3.2.5.1e).   
These findings confirm a role for trypsin as a potential embryonic signal, detectable 
by endometrial cells and containing intrinsic information on embryo competency. 
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Figure 3.2.5.1 [Ca2+]i oscillations in Ishikawa cells with ECM and trypsin.  
a) ECM (1:20 dilution) from successfully implanted embryos applied at 2 
minutes. b) ECM (1:20 dilution) from poor quality embryos applied at 2 minutes. 
c) Cells pre-treated with soybean trypsin inhibitor (1 mg/ml), ECM (1:20 dilution) 
added at 2 minutes.   d) 10 nM trypsin applied at 2 minutes e) Cells pre-treated 
with soybean trypsin inhibitor (1 mg/ml), 10 nM trypsin added at 0 minutes.   
Ishikawa cells were loaded with 5μM fluo-4-AM, excitation achieved at 488 nm 
and emitted light collected above 510 nm. Images were captured by confocal 
microscopy at 1 frame per second via the C-Apochromat 63 ×/ 1.20 W objective 
lens (LSM 510 META, Carl Zeiss, UK).  Traces show fluorescence within 
individual cells expressed as a fold increase over fluorescence at time 0 (F/F0).  
Data are representative of 4 replicates.  Work done in collaboration with Dr 
Anatoly Shmygol. 
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3.2.6 Embryo-derived trypsin induces Ca2+ signaling in DESCs 
The endometrial epithelium is largely regarded as a barrier to implantation in the 
mouse, which embryo(s) must breach in order to make contact with the underlying 
stromal cells and initiate decidualization.  In humans, the stromal compartment 
undergoes cyclic decidualization, in the absence of an embryo, and co-operation 
between the stroma and overlying epithelial compartments is thought to orchestrate 
implantation.  Consequently we speculated that, in humans, the maternal response 
induced by embryo-derived trypsin activity would extend beyond the epithelial layer 
and encompass the DESCs.  
ECM was previously shown to induce differential calcium signalling responses in 
Ishikawa cells according to the quality of the cultured embryos (‘poor quality’ 
embryos compared to successfully implanted embryos).  To more accurately assess 
whether embryo-derived trypsin activity determines implantation outcome, we 
compared ECM from day 5 transferred embryos according to the resulting pregnancy 
outcome (P = Pregnant, NP = Not Pregnant).  In this way embryos were 
morphologically and developmentally alike and Ca2+ signaling responses could be 
directly attributed to implantation outcome.   
To determine whether trypsin-dependent Ca2+ signalling extends to the stromal 
compartment, primary DESCs were pre-loaded with fura-2 and treated with ECM 
(diluted 1:50).  The cells were subsequently monitored for 15 minutes.   
ECM from transferred embryos was found to induce Ca2+ signalling responses in 
DESCs that varied strikingly according to their implantation competence (Figure 
3.2.6.1a,b).  ECM from successfully implanted embryos (P) induced a sharp initial 
rise in [Ca2+]i followed by a suppression of subsequent Ca
2+ oscillations (Figure 
3.2.6.1a).  In contrast, ECM from embryos which failed to implant (NP) induced 
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sustained Ca2+ oscillations (Figure 3.2.6.1b).   
After 15 minutes of ECM treatment, trypsin (10 nM) was applied to the DESCs in 
order to identify whether ECM and trypsin induced Ca2+ signaling via a common 
pathway.  Trypsin application following ECM treatment induced an initial rise in 
[Ca2+]i (Figure 3.2.6.1a,b) but the Ca
2+ oscillations were short lived and greatly 
reduced when compared to the control (Figure 3.2.6.1c).  This data implicates trypsin 
as the embryo-derived signal inducing Ca2+ oscillations in DESCs. 
These findings are very similar to those observed in epithelial cells (Figure 
3.2.5.1a,b) suggesting that Ca2+ signalling in response to embryo-derived trypsin also 
encompasses the stromal compartment in the human endometrium.  Overall the Ca2+ 
transients appear to be less prominent in DESCs compared to Ishikawa cells.  
However, this difference may be explained by the higher ECM dilution used (1:50 
compared to 1:20) and the difference in Ca2+ sensitive probes (fura-2 compared to 
fluo-4). 
The data further confirm a role for trypsin as an embryo-derived signal and indicate 
that biosensoring is not confined to the pre-implantation embryo but continues upon 
breaching of the luminal epithelium.  
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Figure 3.2.6.1 [Ca2+]i oscillations in DESCs.  a) ECM (1:50) from successfully 
implanted embryos (P, pregnant), then 10 nM Trypsin at 15 minutes.  b) ECM 
(1:50) from embryos which failed to implant (NP, not pregnant), then 10 nM 
Trypsin at 15 minutes.  c) 10 nM Trypsin.  Cells were collected from mid-luteal 
endometrial biopsies, loaded with 5μM fura-2 and imaged by confocal microscopy.  
Fluorescence intensity for fura-2 (0.5 µg/ml) is shown as the 340/380 ratio, 
calculated from excitation at 340 nm (high calcium) and 380  nm (low calcium) with 
emission set at 510  nm (LSM 510 META, Carl Zeiss, UK).  Traces show 
fluorescence within individual cells.  Data are representative of 4 replicates.  Work 
done in collaboration with Dr Anatoly Shmygol. 
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3.2.7 Trypsin biosynthesis pathway  
Trypsin is formed by enzymatic degradation of trypsinogen and its activity may be 
modulated by the action of numerous trypsin and protease inhibitors. A simplified 
regulatory pathway of trypsin production has been described in the pancreas (Figure 
3.2.7.1) (Ir et al., 1996, Itoh et al., 1996).  Enteropeptidase (encoded by TMPRSS15) 
is deemed the ‘master regulator’ of trypsin activity due to its role in cleavage and 
activation of the trypsin zymogen, trypsinogen (Ir et al., 1996).  This activation initiates 
a cascade of trypsin release, which is able to auto-activate trypsinogen, further 
increasing trypsin production. Alpha-1 microglobulin/bikunin precursor (AMBP), on the 
other hand, encodes a complex plasma glycoprotein which, upon proteolytic 
processing, produces bikunin which is a urinary trypsin inhibitor (Itoh et al., 1996).   
I analysed microarray data in both human and murine embryos at differing pre-
implantation developmental stages in order to identify the expression patterns of 
genes implicated in the trypsin pathway.   
The gene encoding trypsinogen itself, PRSS1, is not regulated during pre-
implantation development (Figure 3.2.7.2).  However, in line with a role for trypsin in 
implantation, TMPRSS15 expression is markedly increased beyond the 8-cell stage in 
human embryos (Figure 3.2.7.2).  This pattern was not reciprocal in the mouse where 
there is no change in Tmprss15 expression with embryo development (Figure 
3.2.7.3).  Concurrently, AMBP expression is decreased beyond the 8-cell stage in 
human embryos whereas expression is unchanged in mouse embryos (Figures 
3.2.7.2 and 3.2.7.3).   
The Inter-alpha trypsin inhibitor (II) family contains serine protease inhibitors formed 
from three of the four II heavy chains (ITIHs).  Transcriptional regulation of the ITIH 
genes during pre-implantation development could thus potentially influence embryo-
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derived trypsin activity.  Interestingly ITIH expression patterns are clearly distinct 
between mouse and human embryos.  Itih1 decreases from the 1-cell stage to the 
blastocyst stage in mice but conversely, ITIH1 increases in human embryos beyond 
the 4-cell stage (Figures 3.2.7.2 and 3.2.7.3).  Whilst Itih4 expression peaks at the 2-
cell stage and Itih2 and Itih3 expression levels appear analogous between 
developmental stages in mouse embryos (Figure 3.2.7.3) ITIH2, ITIH3 and ITIH4 all 
gradually decrease beyond the 2-cell stage in human pre-implantation embryos 
(Figure 3.2.7.2).  These findings indicate decreasing trypsin inhibition at later stages 
of human pre-implantation embryo development, strengthening a role for trypsin as a 
vital embryonic signal at implantation. 
Microarray analysis of these classical trypsin pathway genes in pre-implantation 
embryos highlights a human-specific mechanism of trypsin activity at the blastocyst 
stage, whereby increased expression of the trypsinogen activator, TMPRSS15, is 
coupled with decreased expression of the trypsin inhibitors, AMBP and ITIH2-4. 
Immunocytochemistry was used to confirm the presence of the TMPRSS15 and 
AMBP proteins at four different pre-implantation embryonic stages in both human and 
mouse embryos (Figures 3.2.7.4 and 3.2.7.5).  The presence of TMPRSS15 and 
absence of AMBP in the inner cell mass of the human blastocyst, suggest a net 
increase in trypsin activity at this stage (Figures 3.2.7.4 and 3.2.7.5).  The staining for 
both proteins is less distinct in the mouse blastocyst, in line with lack of conserved 
TMPRSS15/AMBP regulation between species. 
These findings demonstrate an intricate, and previously unidentified, regulation of 
trypsin production and activity by pre-implantation embryos.  Importantly, the gene 
expression patterning responsible for regulating tryptic activity appears to vary notably 
between human and mouse embryos. 
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In summary, advancing stages of human pre-implantation embryos appear to display 
enhanced trypsin regulation through increased conversion of trypsinogen and 
reduced trypsin inhibition.  This evidence presents an alternative method of trypsin 
biosynthesis in human embryos, which may have compensated for the loss of 
implantation-specific trypsin proteases, such as Prss28, in the mouse (O'Sullivan et 
al., 2001).   
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Figure 3.2.7.1 The Trypsin regulatory pathway.  TMPRSS15 encodes the enzyme 
Enterokinase which has been deemed the master regulator of trypsin activity.  
Enterokinase is required to convert the inactive trypsin precursor (trypsinogen) into its 
active state.  Trypsin is then able to auto-activate trypsinogen causing a cascade of 
trypsin release (Kunitz, 1939).  AMBP encodes a complex plasma glycoprotein which, 
upon proteolytic processing, produces bikunin, which is a urinary trypsin inhibitor. 
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Figure 3.2.7.2 In vivo expression of trypsin regulatory genes during human pre-implantation embryo development.  Analysis of microarray 
data from the Gene Expression Omnibus  [accession numbers GSD3959 (Edgar et al., 2002)] shows the up-regulation of TMPRSS15 and down-
regulation of AMBP, ITH2, ITH3 and ITH4 with human pre-implantation embryo development.  Transcripts were measured at the 1 cell, 2 cell, 4 
cell, 8 cell, morula and blastocyst stages of embryonic development from 18 samples using Affymetrix Human Genome U133 Array.  Data are 
presented as means ± S.D and One-way ANOVA statistical analysis was applied. *P <0.05; **P <0.01; ***P <0.001. 
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Figure 3.2.7.3 In vivo expression of trypsin regulatory genes during mouse pre-implantation embryo development.  Analysis of microarray 
data from the Gene Expression Omnibus  [accession number GDS813 (Edgar et al., 2002)] shows the up-regulation of Prss28 with pre-
implantation embryo development but a lack of regulation of Tmprss15 and Ambp, Itih2 and Itih3.  Murine transcripts were measured at the oocyte, 
1 cell, 2 cell, 8 cell and blastocyst stages of embryonic development from 20 samples using Affymetrix Human Genome U133 Array.  Data are 
presented as means ± S.D and One-way ANOVA statistical analysis was applied. *P <0.05; **P <0.01; ***P <0.001. 
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Figure 3.2.7.4 TMPRSS15 expression in human and murine pre-implantation 
embryos.  Immunoflourescent labelling of human and murine embryos at different 
pre-implantation developmental stages (1 cell, 2-4 cell, 4-6 cell, blastocyst).  
Embryos were fixed in 4% w/v PFA/PBS at 2-8 °C.  Polyclonal antibodies against 
TMPRSS15 were purchased from Novus Biologicals, NBP1-55616.  1% w/v BSA in 
PBS without primary antibody was used for the negative control.  Embryos were 
mounted onto 35mm glass-bottomed petri dishes in 10ul Vectashield® with DAPI.  
Visualization was achieved using a Zeiss LSM 510 confocal imaging system. 
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Figure 3.2.7.5 AMBP expression in human and murine pre-implantation 
embryos.  Immunoflourescent labelling of human and murine embryos at different 
pre-implantation developmental stages (1 cell, 2-4 cell, 4-6 cell, blastocyst).  
Embryos were fixed in 4% w/v PFA/PBS at 2-8 °C.  Monoclonal antibodies against 
AMBP were purchased from Novus Biologicals, H00000259-M01.  1% w/v BSA in 
PBS without primary antibody was used for the negative control.  Embryos were 
mounted onto 35mm glass-bottomed petri dishes in 10ul Vectashield® with DAPI.  
Visualization was achieved using a Zeiss LSM 510 confocal imaging system. 
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3.2.8 Evolutionarily conserved proteases  
Human embryonic signals were previously shown to regulate maternal gene 
expression in a manner conserved between human DESCs and whole mouse uterus 
(Brosens et al., 2014).  In addition, ECM from DCE has been shown to induce the 
expression of numerous implantation genes when flushed through the mouse uterus.  
According to this concept, the origin of the embryo-secreted protease activity, which 
imparts embryo developmental potential to the endometrium, may be partly 
conserved between humans and mice (Brosens et al., 2014).   
Gene Expression Omnibus (GEO) data mining was used to identify any protease 
encoding trancripts that displayed conserved up-regulation from the oocyte/1 cell 
stage to the blastocyst stage in both human and mouse pre-implantation embryos.  
In total 581 human and 588 mouse protease genes were identified (Puente et al., 
2003), for which 505 and 434 had available microarray data, respectively.  In each 
case, differences between the pre-implantation developmental stages were first 
identified using one-way ANOVA statistical analysis via SPSS software.  The 
Games-Howell post-hoc test was applied on genes differentially expressed between 
2 or more developmental stages (P <0.05, one-way ANOVA).  As I aimed to identify 
specifically blastocyst regulated genes, I also calculated the fold change in transcript 
level from each developmental stage compared to that of the blastocyst stage.  The 
results are listed in Appendix 2.   
The most highly regulated serine protease genes in human and mouse embryos 
between the 8 cell stage and blastocyst stage were Tmprss2 and Prss8 (Figure 
3.2.8.1).  TMPRSS2 and PRSS8 transcripts were also significantly up-regulated at 
the blastocyst stage in human embryos (Figure 3.2.8.2). 
Immunocytochemistry was used to confirm the presence of the PRSS8 and 
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TMPRSS2 proteins throughout pre-implantation development in both human and 
mouse embryos (Figures 3.2.8.3 and 3.2.8.4).  Staining is strongest at the blastocyst 
stage and particularly high in the TE compartment, compared to the ICM (Figures 
3.2.8.3 and 3.2.8.4).  
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Figure 3.2.8.1 Microarray analysis of genes significantly up-regulated at the 
blastocyst stage in humans and mice.  Out of 194 and 228 serine protease genes, 
respectively, just 2 were conserved, PRSS8 and TMPRSS2.  In silico analysis was 
performed on publicly available datasets from the Gene Expression Omnibus (Edgar 
et al., 2002), accession number GSD3959 (homo sapiens) and GDS813 (mus 
musculus).  SPSS Software (IBM) was used for statistical analysis.  One-way ANOVA 
was used for statistical analysis followed by the Games Howell post hoc test (P 
<0.05). 
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Figure 3.2.8.2 PRSS8 and TMPRSS2 transcript levels in human and mouse pre-
implantation embryo development.  Analysis of microarray data from the Gene 
Expression Omnibus  [accession numbers GSD3959, GDS813 (Edgar et al., 2002)].  
a) Murine transcripts measured at the oocyte, 1 cell, 2 cell, 8 cell and blastocyst 
stages of embryonic development from 20 samples using Affymetrix Human Genome 
U133 Array.  n =20, P <0.0001 [Tmprss2]) n =20, P <0.0001 [Prss8].  b) Human 
transcripts measured at the 1 cell, 2 cell, 4 cell, 8 cell, morula and blastocyst stages 
of embryonic development from 18 samples using Affymetrix Human Genome U133 
Array.  n =18, P <0.0001 [TMPRSS2], n =18, P <0.0001 [PRSS8].  Data are 
presented as means ± S.E.M and One-way ANOVA followed by Games Howell post 
hoc analysis was applied. 
 
 
 
 
 
 
 
 
 114 
 
Figure 3.2.8.3 PRSS8 expression in human and mouse pre-implantation 
embryos.  Immunoflourescent labelling of human and murine embryos at different 
stages of pre-implantation embyo development.  Embryos were fixed in 4% w/v 
PFA/PBS at 2-8 °C.  Polyclonal antibodies against PRSS8 were purchased from 
Antibodies Online, ABIN761891.  1% w/v BSA in PBS without primary antibody was 
used for the negative control.  Embryos were mounted onto 35mm glass-bottomed 
petri dishes in 10ul Vectashield® with DAPI.  Visualization was achieved using a 
Zeiss LSM 510 confocal imaging system. 
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Figure 3.2.8.4 TMPRSS2 expression in human and mouse pre-implantation 
embryos.  Immunoflourescent labelling of human and murine embryos at different 
stages of pre-implantation embyo development.  Embryos were fixed in 4% w/v 
PFA/PBS at 2-8 °C.  Polyclonal antibodies against TMPRSS2 were purchased from 
Antibodies Online, ABIN716876.  1% w/v BSA in PBS without primary antibody was 
used for the negative control.  Embryos were mounted onto 35mm glass-bottomed 
petri dishes in 10ul Vectashield® with DAPI.  Visualization was achieved using a 
Zeiss LSM 510 confocal imaging system 
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3.2.9 Embryo-derived proteases and implantation  
 
A key aim of my study was to characterise the nature of embryo-derived soluble 
factors that enable maternal recognition and selection at implantation. Defining such 
signal(s) may improve the selection of IVF embryos, enhance pregnancy rates after 
transfer, provide new insights into the mechanisms responsible for implantation failure 
and early pregnancy loss, and – potentially – lead to new strategies to enhance or 
prevent implantation.  
 
To evaluate whether the proteases identified over the course of this chapter may 
serve as indicators of embryo implantation potential, levels of trypsin activity, PRSS8 
and TMPRSS2 were measured in ECM from individual day 5 single embryo transfer 
(SET) embryos.  The criteria for SET in our unit are; maternal age < 37 years, at least 
one good quality blastocyst (ICM and TE grade BB or above), and no previous failed 
IVF cycles.  Therefore selecting ECM from SETs controlled for patient age, embryo 
quality, embryo developmental stage and prognosis, meaning that the protease 
levels detected in ECM could be directly related to pregnancy outcome.   
 
Trypsin activity was measured using the trypsin assay as described previously 
(Chapter 3.2.2).  PRSS8 and TMPRSS2 levels were quantified using custom 
designed enzyme-linked immunosorbent assays (ELISAs), in a 96-well format.  All 
assays were carefully optimised using ECM in order to establish optimal experimental 
conditions and dilution factors.   
 
Due to the limited volume of individual ECM drops (20µl), loss resulting from embryo 
carry-over and the use of a paraffin oil overlay, 15µl was deemed the maximum 
usable volume of ECM.  As ECM drops were applied to the assays in duplicate, for 
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accuracy, the final dilution of ECM was 1:13.3 and UCM (also diluted 1:13.3) was 
included as a control.  In each case, values were normalised to the UCM and values 
falling below the UCM or outside the standard curve were excluded from the analysis.  
In total 328 ECM drops were applied across the three assays, 71 of which met the 
selection criteria (day 5 SET). 
 
Interestingly, trypsin activity was found to be significantly higher in ECM from embryos 
that failed to implant following SET when compared to successfully implanted 
embryos (median: 49.5 % change from control (NP), 20.6 % change from control (P); 
range: 11.5 to 76.7 % change from control (NP), 2.1 to 39.8 % change from control 
(P)) (Figure 3.2.9.1).  Total TMPRSS2 levels were similarly increased in ECM from 
embryos that failed to implant (median: 57.2 % change from control (NP), 0.0 % 
change from control (P); range: 0.0 to 154.6 % change from control (NP), 0.0 to 11.5 
% change from control (P)) (Figure 3.2.9.1).  Conversely, total PRSS8 levels were 
shown to be significantly higher in ECM from embryos that successfully implanted 
following SET (median: 0.0 % change from control (NP), 67.8 % change from control 
(P); range: 0.0 to 211.9 % change from control (NP), 0.0 to 338.7 % change from 
control (P)) (Figure 3.2.9.1).   
 
These intriguing results suggest that protease levels in embryo culture supernatants 
may provide an indication of implantation potential prior to transfer.  Further 
understanding and refinement of such analysis could potentially provide a novel 
supplementary means of embryo grading and selection for IVF treatment, in addition 
to morphology. 
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Figure 3.2.9.1 Proteases in ECM related to implantation outcome.  Trypsin activity and total abundance of TMPRSS2 and PRSS8 were 
measured in day 5 ECM from SETs.  Outcome was determined by hCG test result following embryo transfer (P = pregnant, NP = not pregnant).   
Trypsin: n = 20, P = 0.0015.  TMPRSS2:  n = 19, P = 0.0007.  PRSS8: n = 32, P = 0.0071 [PRSS8].  Data are presented as mean values and the 
median of each group is shown.  The Mann Whitney test was used for statistical comparison.  *P <0.05; **P <0.01; ***P <0.001. 
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3.3 Discussion 
Embryo derived trypsin-like proteases have been implicated as crucial at 
implantation in  mice (Ruan et al., 2012).  By performing a literature search I show 
that a wealth of evidence supports a role for trypsin and trypsin-like proteases at 
implantation in various species, but not humans. 
By measuring protease, specifically trypsin, levels in embryo culture droplets from 
IVF patients, I demonstrate that trypsin activity is produced by human embryos and 
enhanced at the implantation stage of embryo development.  Trypsin activity was 
detectable even in ECM from individually cultured human embryos and found to be 
related to the day and stage of embryo development.  This novel finding establishes 
embryo-derived trypsin-like activity as a conserved feature of implantation and 
implicates trypsin-like activity as a marker of embryo implantation potential. 
It was suspected that embryo-derived trypsin activity may regulate Ca2+ signalling 
and gene expression in a similar mechanism to that identified in mice (Ruan et al., 
2012).  We show that human ECM and trypsin induce [Ca2+]i oscillations in Ishikawa 
cells via a mutual signal transduction pathway.  Crucially the [Ca2+]i oscillations 
observed in Ishikawa cells were highly divergent between embryo signals from 
successfully implanted embryos and poor quality embryos.  This data shows that 
embryo signals convey embryo developmental potential to the endometrium and 
induce long-lasting cellular changes that actively determine implantation outcome.  
The abolition of [Ca2+]i oscillations by pre-treatment of cells with soybean trypsin 
inhibitor prior to embryo conditioned medium validates a role for trypsin as crucial to 
this embryo-endometrial crosstalk.  Importantly, trypsin and ECM were able to induce 
similar responses in DESCs.  In addition, consistent with the hypothesis proposed by 
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Ruan et al., this data demonstrates that trypsin modulates PTGS2 transcript 
expression and COX-2 protein levels in Ishikawa and HEECs. 
In order to identify a species-specific mechanism of trypsin production in human 
embryos, I analysed microarray data of key genes involved in trypsin regulation 
throughout pre-implantation embryo development.  An up-regulation of the 
trypsinogen activator, TMPRSS15, and a down-regulation of a urinary trypsin 
inhibitor gene, AMBP, were observed and confirmed using immunocytochemistry of 
embryos at different pre-implantation stages.  These findings show a human specific 
mechanism of trypsin regulation during pre-implantation embryo development which 
may explain the increased trypsin activity detected at the blastocyst stage. 
Evidence from a previous study suggested that the embryonic signal at implantation 
may be partly conserved between humans and mice (Brosens et al., 2014).  This 
data identifies two conserved trypsin-like serine proteases, TMPRSS2 and PRSS8, 
which are specifically up-regulated at the blastocyst stage during both human and 
mouse pre-implantation embryo development.   
A main aim of this research was to identify key embryo secreted factors which may 
provide a non-invasive marker of implantation potential.  This data confirms that 
trypsin, PRSS8 and TMPRSS2 levels in ECM, from individually transferred embryos 
on day 5, differ according to pregnancy outcome.  Interestingly trypsin and 
TMPRSS2 levels were noticeably higher in embryos that failed to implant, whilst 
PRSS8 levels were higher in successfully implanted embryos.   
Taken together, this novel data demonstrates that embryo-derived trypsin-like 
proteases are produced by human embryos and can regulate human implantation.  
This enhances our understanding of human implantation and presents candidate 
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proteases for a novel, non-invasive method of embryo selection that, with further 
advancement, may enhance pregnancy rates following IVF. 
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Chapter 4 
 
Endometrial Recognition 
of Embryo-derived Proteases 
 123 
 
4.1 Introduction 
In the previous chapter, human embryos were shown to produce specific proteases 
at the blastocyst stage that can induce Ca2+ signalling and regulate the expression of 
key implantation genes and proteins in endometrial cells. These embryo-derived 
proteases may play a central role in maternal biosensoring, as the levels detectable 
in ECM were found to reflect implantation outcome upon single embryo transfer. 
In this chapter, I describe the characterisation of endometrial receptors that may be 
responsive to embryo-derived proteases. 
I demonstrate that several protease-sensitive receptors are present in the 
endometrium, more highly expressed in stromal cells, and that expression peaks 
during the window of implantation.  Furthermore, I show that proteases in ECM 
rapidly cleave TLR4 expressed on decidualizing cells, which abolishes the induction 
of pro-inflammatory genes, such as IL-8, upon activation of the receptor. My data 
reveal that human embryos imbue maternal tolerance upon implantation by 
dampening innate immune responses in the decidua.  Additionally, preliminary data 
show that suboptimal cleavage of TLR4 by ECM of individually cultured embryos is 
associated with subsequent implantation failure. Conversely, I also demonstrate that 
suboptimal expression of TLR4 in the endometrium, which arguably impairs active 
disposal of developmentally compromised embryos, is associated with recurrent 
miscarriage. 
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4.2 Results 
4.2.1 Putative receptors responsive to embryo-derived TMPRSS2 and 
PRSS8  
A systematic literature search of putative targets of TMPRSS2 and PRSS8 led me to 
focus on the following receptors and target proteins: ENaC, TLR4 and PAR2. These 
transmembrane receptors all possess extracellular domains which, upon proteolytic 
activation by extracellular proteins, regulate cell signalling. 
ENaC facilitates the bulk movement of Na2+ across the epithelium, maintaining 
electrolyte and water homeostasis (Garty and Palmer, 1997).  The channels contain 
three of the four structurally related subunits, ,  and  or   and , though the 
latter is less well-studied (Kleyman et al., 2009).  Proteolytic cleavage sites within the 
extracellular finger domains of the  and  subunits can be activated by various 
proteases to regulate ENaC function (Kleyman et al., 2009). Several studies have 
shown that ENaC can be activated by trypsin (Chraïbi et al., 1998, Caldwell et al., 
2004, Kleyman et al., 2009).  PRSS8 cleaves the  subunit at a defined site and is 
capable of activating ENaC in mice and Xenopus oocytes (Bruns et al., 2007, Vallet 
et al., 1997).  A study of human airway epithelium described opposing roles for 
PRSS8 and TMPRSS2 in ENaC regulation, increasing and decreasing ENaC 
currents, respectively (Donaldson et al., 2002). 
The protease-activated receptor (PAR) family contains four G-protein-coupled 
receptors (GPCRs); PAR1, PAR2, PAR3 and PAR4.  PARs are uniquely activated by 
serine proteases, with trypsin primarily activating PAR2 and to a lesser extent PAR4.  
Proteolytic activation of PARs occurs at the extracellular amino terminus (N 
terminus), where cleavage exposes tethered peptide ligands, which facilitate self-
activation (Déry et al., 1998).  PAR2 has been identified in the stromal and epithelial 
compartments of the endometrium and has been implicated in tissue remodeling, 
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inflammation and repair (Hirota et al., 2005).  Activation of PAR2 by trypsin or 
TMPRSS2 induces elevated [Ca2+]i, due to Ca2+ release from intracellular stores, 
making it a candidate endometrial receptor for embryo-derived protease activation 
(Nystedt et al., 1995, Wilson et al., 2005).   
The family of toll-like receptors (TLRs) are highly conserved, pathogen-recognition 
receptors involved in activation of innate immunity (Liu et al., 2014, Lu et al., 2008).  
TLRs were first identified in Drosophila, where drosophila Toll receptor (the 
homologue of mammalian TLR4) was found to be essential for dorso-ventral pattern 
establishment in developing embryos.  TLRs are present in HESCs and HEECs and 
have been shown to be regulated during the menstrual cycle (Hirata et al., 2007).  
The best studied TLR interaction is the activation of TLR4 by its endogenous ligand 
lipopolysaccharide (LPS), found on the outer cell wall of Gram-negative bacteria.  
TLR4-LPS binding occurs via accessory molecules, cluster of differentiation 14 
(CD14) and myeloid differentiation factor 2 (MD-2), to mediate the production of pro- 
and anti- inflammatory cytokines, as demonstrated in uterine epithelial cells of 
oestrous mice (Robertson et al., 2011).  Trypsin, TMPRSS2 and PRSS8 have been 
shown to regulate TLR4 activity.  Isoforms of the TMPRSS2-ERG fusion gene 
differentially up-regulate Nuclear Factor Kappa-B (NF-B) associated genes, 
including TLR4 (Wang et al., 2011).  Trypsin downregulates TLR4 activity via 
degradation of the TLR4 accessory molecules CD14 and MD-2 in murine peritoneal 
macrophages (Komatsu et al., 2012).  By contrast PRSS8, the only embryo-derived 
protease found to be increased in ECM from successfully implanting embryos, can 
directly cleave and de-activate TLR4 in the liver (Uchimura et al., 2014).   
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4.2.2 Endometrial expression of ENaC, PAR2 and TLR4 
GEO data mining was used to analyse the expression of transcripts encoding these 
key protease-regulated receptors during different phases of the menstrual cycle 
(Figure 4.2.2.1).  Well-characterised samples were collected by pipelle or curetting of 
the endometrium from normo-ovulatory women with regular cycles.  Phases were 
assigned to the samples according to the criteria of (Noyes et al., 1950) via 
independent analysis by up to four pathologists (Talbi et al., 2006). 
A three-fold increase in SCNN1A expression (encoding the ENaC  subunit) is 
observed during the early- and mid- secretory phases compared to the proliferative 
and late secretory phases (Figure 4.2.2.1).  However, this pattern is not analogous to 
the corresponding ENaC  subunit, SCNN1G (Figure 4.2.2.1).  F2RL1, which 
encodes PAR2, is significantly up-regulated throughout the luteal phase of the cycle 
(Figure 4.2.2.1).  Yet, of all 42,203 genes measured, TLR4 was among the most 
highly up-regulated upon transition from the early- to the mid- secretory phase 
(Figure 4.2.2.1) (Talbi et al., 2006).   
Immunofluorescence and Western blot analyses were used to compare the 
expression of the aforementioned candidate receptors in purified HESCs and 
HEECs.  Cytokeratin 18 and vimentin were used to demonstrate enrichment of 
HEECs and HESCs, respectively.  The expression levels of PAR2 were comparable 
between HEECs and HESCs (Figure 4.2.2.2a,b).  Using immunofluorescence, TLR4 
expression was seemingly equivalent between the two cell types (Figure 4.2.2.2a), 
yet Western blot analysis demonstrated higher levels of this receptor in primary 
HESC cultures (Figure 4.2.2.2).  Despite ENaC being designated an epithelial 
channel, both methods show that the expression of  and  ENaC subunits is 
constitutively higher in cultured HESCs when compared to purified HEECs (Figure 
4.2.2.2a,b).   
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Following confirmation that these protease-regulated receptors are expressed in the 
stromal compartment, I measured their protein levels in HESCs undergoing 
decidualization in vitro, for 2, 4 or 8 days.  Interestingly, all three protease-sensitive 
receptors demonstrated a biphasic expression pattern upon decidualization, 
characterized by rising expression that peaks on day 4 of the differentiation process, 
and declining levels at day 8 (Figure 4.2.2.3).   
In summary, expression profiling, both in vivo and in vitro, points towards a potential 
role for ENaC, PAR2 and TLR4 in deciphering embryo-derived proteases at the time 
of implantation.  Furthermore, the discovery that ENaC and TLR4 are more 
abundantly expressed in HESCs when compared to HEECs, at least in culture, 
suggests a role for these receptors in regulating implantation once the blastocyst has 
breached the luminal epithelium. 
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Figure 4.2.2.1 Expression of key protease-regulated receptor genes 
during the menstrual cycle.  GEO profile microarray of protease 
activated receptors; SCNN1A ( ENAC), SCNN1G ( ENAC), TLR4 and 
F2RL1 (PAR2) during the proliferative (P), early secretory (ES), mid-
secretory (MS) and late secretory (LS) phases of the menstrual cycle, 
using Affymetrix Human Genome U113 array.  Data are presented as 
means + S.E.M of 22 samples.  One-way ANOVA statistical analysis was 
applied, followed by Games-Howell post-hoc test.  *P < 0.05. 
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Figure 4.2.2.2 Candidate protease-regulated receptor expression in 
HESCs and HEECs purified from mid-luteal endometrial biopsies.  a) 
Immunoflourescent labelling of purified HESC and HEEC cultures.  
Images are representative of 3 samples.  b) Western blot analysis of 
purified HESC and HEEC lysates.  -actin was used as a loading control.  
Blot is representative of 3 replicates.  Purity of the epithelial and stromal 
cells was assessed by cytokeratin (CYK18) and vimentin expression, 
respectively. Dr Flavio Barros assisted with the isolation and culturing of 
HEECs. 
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Figure 4.2.2.3  In vitro expression of key protease-regulated 
receptors during the decidualization of HESCs. Western blot analysis 
of total cell lysates of undifferentiated or decidualized HESCs (2-8 days).  
Protein was harvested after 0 (D0), 2 (D2), 4 (D4) or 8 (D8)  days of 
cAMP/MPA treatment.  -actin was used as a loading control.  Western 
blots are included in Appendix 8. 
 
 
 
 
 131 
 
4.2.3 Embryo-derived proteases cleave and inactivate TLR4 in 
decidualizing stromal cells 
 
Putative protease-responsive receptors are most highly expressed on day 4 of 
decidualization.  To test if these receptors are cleaved by embryo-derived signals, 
decidualized cultures were exposed to either ECM or UCM, both diluted 1:100.  The 
dilution factor was pragmatic as it enabled assessment of endometrial cell responses 
to ECM of individually cultured embryos.  After 15 minutes, the cells were harvested 
and total protein lysates subjected to Western blot analysis.  Unexpectedly, I found no 
evidence of either PAR2,  ENaC or  ENaC cleavage.  Lack of cleavage could 
reflect insufficient protease activity in diluted ECM samples or, alternatively, the 
secretion of specific protease inhibitors by decidualizing cells.  By contrast, there was 
a conspicuous loss of TLR4 in decidual cells exposed to ECM (Figure 4.2.3.1a).  The 
kinetics of this response, within 15 minutes, can only be accounted for by the sudden 
loss of the epitope, located in the extracellular domain of the receptor (amino acids 
542 - 631) (Panter and Jerala, 2011).  
 
In a preliminary experiment, ECM from 8 individually cultured and transferred 
embryos was separated according to implantation outcome, diluted 1:100 and applied 
to day 4 DESCs for 15 minutes.  Embryo-derived proteases from successfully 
implanted embryos had a greater inhibitory effect on TLR4 than those from embryos 
which failed to implant (Figure 4.2.3.1b).  This is a striking finding, which firmly 
implicates PRSS8 in TLR4 cleavage of decidual cells.  However, these observations 
require further validation in a larger study. 
 
To validate TLR4 cleavage in response to ECM, parallel cultures were fixed in 4% 
Para-formaldehyde, but not permeabilized with Triton X-100. Confocal microscopy 
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showed abundant TLR4 expression on the surface of decidualized HESCs exposed 
to UCM. However, pre-treatment of the cells with ECM for 15 min resulted in a 
marked decrease in TLR4 immunofluorescence (Figure 4.2.3.2a). 
 
TLR4 is a toll-like receptor responsible for activating the innate immune system, 
commonly characterised by its ability to bind LPS.  Yet, alternative ligands of TLR4 
include numerous viral proteins, polysaccharide and several endogenous proteins 
such as low-density lipoprotein, beta-defensins, and heat shock proteins (Brubaker et 
al., 2015). TLR4 associates with MD-2 to form a heterodimer that identifies a common 
'pattern' amongst structurally diverse LPS molecules (Shimazu et al., 1999).  Mining 
of existing microarray data (Takano et al., 2007) revealed that MD-2 transcripts, 
coded by lymphocyte antigen 96 (LY96), are abundantly present in undifferentiated 
and decidualizing HESCs, indicating that these cells should be responsive to LPS in a 
TLR4-dependent manner.  To test this hypothesis, primary HESCs decidualized for 4 
days were treated with LPS (0.5 µg/ml).  Since IL-8 is a major cytokine induced by 
TLR4 in HESCs (Hirata et al., 2005), the induction of IL-8 transcripts was measured 
by qRT-PCR 30, 60 and 120 minutes following LPS exposure.  As shown in Figure 
4.2.3.3a, IL-8 transcript levels increased by approximately 10-fold, 120 minutes 
following exposure of decidualizing cells to LPS.  To test if this induction is mediated 
by TLR4, decidualizing cells were pre-treated with a TLR4-specific inhibitor peptide, 
VIPER.  VIPER completely repressed the induction of IL-8 in response to LPS 
treatment (Figure 4.2.3.3c).  In fact, VIPER reduced IL-8 transcript levels below those 
observed in vehicle-treated control cells, suggesting that TLR4 may be endogenously 
activated in decidualizing cells.  More importantly, pre-treatment with ECM but not 
UCM also blocked LPS-dependent induction of IL-8 in decidualizing cells (Figure 
4.2.3b). 
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Figure 4.2.3.1 Embryo conditioned medium (ECM) applied to day 4 DESCs 
inhibits TLR4 expression.  a) Confluent day 4 DESCs were exposed to UCM 
(1:100) or ECM (1:100), for 15 minutes.  Protein was extracted and  ENAC,  
ENAC, PAR2 and TLR4 levels measured via Western blot.  -actin was used as a 
loading control.  The complete blot is included in Appendix 9.  b)  Confluent day 4 
DESCs were exposed to UCM (1:100) or ECM (1:100) from single embryo 
transfers (P = Pregnant, NP = Not pregnant), for 15 minutes.  Protein was 
extracted and TLR4 levels measured via Western blot.  -actin was used as a 
loading control.  Blot is representative of 4 independent experiments using 4 
samples.  Densitometry was performed using Syngene GeneTools analysis 
software and the results are shown as % change from UCM (n = 4, P = 0.0158).  
Data are presented as mean + S.E.M and ANOVA was used for statistical 
analysis.   
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Figure 4.2.3.2 TLR4 expression in DESCs purified from mid-luteal endometrial biopsies.  Immunoflourescent labelling of purified DESCs 
(day 4), with no treatment, exposure to UCM (1:100) or exposure to ECM (1:100) from successfully implanted SET embryos (P) for 15 minutes.  
Images are representative of 3 samples.  Dr Seley Gharanei assisted with the treatment and imaging of the HESCs.
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Figure 4.2.3.3 IL-8 expression in day 4 DESCs upon exposure to LPS.  a)  Day 
4 DESCs were treated with LPS (0.5 µg/ml) for 30, 60 and 120 minutes. b)  Day 4 
DESCs were treated with ECM from successfully implanted embryos (1:100) for 30 
minutes, washed with PBS and then exposed to LPS (0.5 µg/ml) for 60 minutes (n 
= 3, P = 0.05).  c)  Day 4 DESCs were treated with VIPER (TLR4-specific inhibitor 
peptide; 500µM) for 30 minutes, washed with PBS and then exposed to LPS 
(0.5µg/ml) for 60 minutes (n = 3, P = 0.03).  In all experiments RNA was 
harvested, cDNA synthesised and IL-8 transcript levels measured using qRT-PCR.  
Transcript levels were normalised to L19.  Data are presented as means + S.E.M, 
representative of 3 replicates.  The unpaired t-test was used for statistical analysis. 
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4.2.4 TLR4 expression in mid-luteal phase endometrium  
To validate the expression of TLR4 in human endometrium, fixed endometrial 
sections from mid-luteal biopsies were analysed using immunohistochemistry (IHC).  
As shown in Figure 4.2.4.1, TLR4 expression within the stromal compartment was 
heterogeneous.  While some stromal cells displayed little staining, others showed 
intense TLR4 immunoreactivity.  Stromal cells displaying prominent staining appeared 
more abundant in areas of localised oedema (O). A whirling pattern of staining was 
observed in stromal cells adjacent to the spiral arteries (SA).  TLR4 staining was 
predominantly cytoplasmic in stromal cells. Prominent TLR4 immunoreactivity was 
also apparent in the apical border of luminal epithelial cells (LE). By contrast, the 
glandular epithelium (GE) mostly exhibited weak staining. Luminal epithelial cells 
likely constitute a minor subpopulation of isolated endometrial epithelial cells 
propagated in culture; which in turn explains the differential expression of TLR4 
expression between HEECs and HESCs. However, the finding that TLR4 is 
expressed on luminal epithelial cells does suggest a role for this receptor in pre-
implantation endometrial responses.  
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Figure 4.2.4.1 TLR4 in mid-luteal phase endometrial sections.  Fixed 
sections from endometrial biopsies, collected via pipelle, were rehydrated 
and incubated with TLR4 antibody (1:5000).  Novolink Polymer solution 
(Leica) enabled visualisation of primary antibody staining (brown) and 
haematoxylin was used to visualise nucleii (violet). Dr Katherine Fishwick 
assisted with the preparation and imaging of the slides.  Luminal epithelium 
(LE), oedema (O), glandular epithelium (GE), spiral arteries (SA). 
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4.2.5 Endometrial Expression of TLR4 in Reproductive Failure 
If TLR4 is an important determinant of endometrial responses to embryonic cues, 
deregulation of this TLR family member could contribute to reproductive failure.  To 
test this hypothesis, I examined the expression of TLR4 mRNA and protein in patients 
suffering either recurrent implantation failure (RIF) or recurrent miscarriage.  For the 
purpose of this study, RIF was defined as implantation failure (i.e. negative pregnancy 
test) in 3 or more consecutive IVF treatment cycles; and RM as 3 or more consecutive 
miscarriages.  Two RIF subjects and 3 RM patients suffered secondary infertility and 
secondary miscarriages, respectively.  Both clinical groups were matched in age and 
body mass index (BMI).  The median [range] day of biopsy was LH+9 [+7 - +12] and 
LH+9 [+7 - +11] in the RIF and RM groups, respectively.  The demographic details 
are tabulated in Appendix 5. 
Total RNA was extracted from whole tissue samples stored in RNA later solution, 
from 14 RIF subjects and 14 RM patients. The RNA was reverse transcribed and 
TLR4, F2RL1 (coding for PAR2) and SCNN1A (coding for  ENaC) transcript levels 
determined by qRT-PCR.  As shown in Figure 4.2.5.1, SCNN1A and TLR4 transcript 
levels were significantly higher in the RM patients when compared to RIF subjects (P 
= 0.0021 and P = 0.0395, respectively).  By contrast, F2RL1 mRNA levels were 
comparable between both groups (P > 0.05).  Notably, there was a positive 
correlation between TLR4 and F2RL1 transcript levels (Spearman's rank test, r = 
0.39, P = 0.03), TLR4 and SCNN1A mRNA levels (r = 0.51, P = 0.004), and F2RL1 
and SCNN1A mRNA levels (r = 0.53, P = 0.002) (Figure 4.2.5.2); suggesting 
coordinated transcriptional regulation of these protease-sensitive receptors in 
differentiating human endometrium.  
 
 139 
 
Additional analysis revealed no association between TLR4 transcript levels and uNK 
cell density, age or BMI of the patients.  Similarly, no correlation was found between 
these demographic details and expression of either F2RL1 or SCNN1A transcripts 
(Figure 4.2.5.3). 
The expression and activity of TLR4 is tightly regulated by several post-translational 
mechanisms, including ubiquitylation and proteosomal degradation (Liew et al., 2005).  
Hence, TLR4 protein levels were determined in a second cohort of snap-frozen 
biopsies by Western blot analysis.  The median [range] day of biopsy was LH+9 [+5 - 
+12] and LH+8 [+5 - +10] in the RIF and RM groups, respectively.  The demographic 
details of this cohort are tabulated in Appendix 6.  Expression was normalized to -
actin levels and quantified by densitometry using Syngene GeneTools analysis 
software.  By contrast to the mRNA analysis, TLR4 protein levels were significantly 
reduced in RM compared to RIF biopsies (P < 0.01; Figure 4.2.5.4).  Interestingly, 
TLR4 protein levels did correlate to BMI (r = 0.41, P = 0.04), and uNK cell density (r = 
0.44, P = 0.02), but not to the age of the patient (r = 0.29, P = 0.12) (Figure 4.2.5.5). 
I speculated that increased endometrial PRSS8 expression in RM subjects could 
account for the discrepancy between TLR4 mRNA and protein levels.  Although 
PRSS8 transcript levels were indeed raised in RM subjects when compared to RIF 
patients (P < 0.05), Western blot analysis showed no difference between the two 
clinical groups (P > 0.05; Figure 4.2.5.6), indicating that endogenous cleavage is 
unlikely to account for the lower TLR4 levels in RM patients.  
Taken together, the data show that endometrial TLR4 expression differs between RIF 
and RM patients.  Additional IHC studies are needed to examine the tissue 
distribution of TLR4 in these patient groups.  Furthermore, it would be interesting to 
test if endometrial TLR4 expression is predictive of subsequent pregnancy outcome in 
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women suffering from persistent reproductive failure.  
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Figure 4.2.5.1 TLR4, F2RL1 and SCNN1A transcript expression levels in patients with RIF or RM.  RNA was extracted from 28 mid-luteal 
endometrial biopsies (RIF, n = 14; RM, n = 14) and transcript expression analysed via qRT-PCR.  Selected patients were all aged between 25 and 
37 years with a healthy BMI (demographic details are tabulated in Appendix 5).  All values were normalised to L19.  Data are presented as mean 
values.  TLR4, P = 0.0395; F2RL1, P = 0.5112; SCNN1A, P = 0.0021.  The Mann Whitney test was used for statistical analysis.  *P<0.05; **P<0.01; 
***P<0.001. 
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Figure 4.2.5.2 Regression analysis of TLR4, F2RL1 and SCNN1A transcript levels in a cohort of reproductive failure patients.  RNA was 
extracted from 28 mid-luteal endometrial biopsies taken (RIF, n = 14; RM, n = 14) and transcript expression analysed via qRT-PCR.  All values 
were normalised to L19.  Patient demographic details are tabulated in Appendix 5.  Dotted lines represent 95% confidence intervals.  Spearman’s ρ 
value and probability (P) shown.  *P<0.05; **P<0.01; ***P<0.001. 
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Figure 4.2.5.3 Regression analysis of TLR4, F2RL1 and SCNN1A transcript levels and demographic details in a cohort of reproductive 
failure patients.  Correlation between uNK cell density (%), age (years), BMI and (a) TLR4, (b) F2RL1, (c) SCNN1A transcript expression.  RNA 
was extracted from 28 mid-luteal endometrial biopsies (RIF, n = 14; RM, n = 14) and transcript expression analysed via qRT-PCR.  All values were 
normalised to L19.  Patient demographic details are tabulated in Appendix 5.  Dotted lines represent 95% confidence intervals.  Spearman’s ρ 
value and probability (P) shown.  *P<0.05; **P<0.01; ***P<0.001.   
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Figure 4.2.5.4 TLR4 protein levels in patients with RIF or RM.  Protein was 
extracted from 30 endometrial biopsies (RIF, n = 15; RM, n = 15) and analysed via 
Western blot.  Patient demographic details are tabulated in Appendix 6.  -actin 
was used as a loading control.  Western blots are included in Appendix 7.  
Densitometry was performed using Syngene GeneTools analysis software and the 
results are shown as % change from UCM.  Data are presented as mean values.  
The Mann Whitney test was used for statistical analysis.  *P<0.05; **P<0.01; 
***P<0.001. 
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Figure 4.2.5.5 Regression analysis of TLR4 protein levels and demographic details in a cohort of reproductive failure patients.  Correlation 
between uNK cell density (%), age (years), BMI and TLR4 protein expression.  Protein was extracted from 30 endometrial biopsies (RIF, n = 15; 
RM, n = 15) and analysed via Western blot.  Patient demographic details are tabulated in Appendix 6.  -actin was used as a loading control.  
Dotted lines represent 95% confidence intervals.  Spearman’s ρ value and probability (P) shown.  *P<0.05; **P<0.01; ***P<0.001. 
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Figure 4.2.5.6 PRSS8 transcript and protein expression in patients with RIF or RM.  RNA was extracted from 28 endometrial biopsies (RIF, n 
= 14; RM, n = 14) and transcript expression analysed via qRT-PCR.  Patient demographic details are tabulated in Appendix 5.  All values were 
normalised to L19.  Protein was extracted from 30 endometrial biopsies (RIF, n = 15; RM, n = 15) and analysed via Western blot.  Patient 
demographic details are tabulated in Appendix 6.  -actin was used as a loading control.  Western blots are included in Appendix 7.  Densitometry 
was performed using Syngene GeneTools analysis software and the results are shown as % change from UCM.  Data are presented as mean 
values.  The Mann-Whitney test was used for statistical analysis. *P<0.05; **P<0.01; ***P<0.001. 
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4.3 Discussion 
In chapter 3, we showed that embryo-derived trypsin-like proteases can regulate cell 
signalling events in the human endometrium.  Despite evidence for ENaC cleavage 
inducing similar signalling in the mouse, I show that additional maternal receptors 
may be responsible for interpreting the conserved embryo-derived signals in 
humans. 
By measuring transcript and protein levels in endometrial cells I demonstrate that 
PAR2, TLR4 and ENaC (receptors regulated by trypsin, PRSS8 and TMPRSS2) are 
present in the endometrium and up-regulated at the time of implantation.  
Furthermore, by showing increased receptor expression in HESCs compared to 
HEECs via ICC and Western blot, I highlight a role for ENaC and TLR4 beyond initial 
breaching of the epithelium by the embryo.  The peak of protease-regulated receptor 
expression on day 4 in DESCs and co-ordinated transcriptional regulation of TLR4, 
SCNN1A and F2RL1 in endometrial biopsies indicates priming of the stromal 
compartment ready for synchronised proteolytic processing by embryo-derived 
signals.   
In order to identify the specific interactions between embryo-derived proteases and 
maternal receptors, day 4 DESCs were co-cultured with ECM.  Although preliminary, 
the data show that the presence of embryo-derived signals, specifically from 
successfully implanting embryos, directly affects the structure of TLR4 and down-
regulates TLR4 activity.  The result is a markedly diminished immune response to 
LPS, which mimicked the addition of a TLR4-specific inhibitor and could be crucial in 
permitting the implantation of a semi-allogenic embryo into the maternal decidua.   
The homogenous localisation of TLR4 across the luminal epithelia, detected via IHC 
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analysis of fixed endometrial sections, indicates a pre-implantation role of this 
receptor in addition to a post-implantation function.  This is consistent with previously 
identified TLR4 protein expression in both the epithelial and stromal compartments of 
the human endometrium (Hirata et al., 2005).  Yet, in contrast to the TLR4 
localisation observed in patients suffering from RM (Figure 4.2.4.1), IHC analysis of 
biopsies from hysterectomy patients indicates weak TLR4 staining in the apical 
epithelium and intense TLR4 staining in the endometrial glands (Fazeli et al., 2005).  
This discrepancy in TLR4 localisation may be explained by inter-patient variability 
and highlights the need for comprehensive IHC studies on phase-matched biopsies 
from larger cohorts of patients, encompassing differing aetiologies. 
To further test whether TLR4 is crucial at implantation, we assessed whether TLR4 
becomes de-regulated in cases of reproductive failure.  In agreement with evidence 
that TLR4 is under strict post-translational control (Liew et al., 2005) but in contrast 
to the transcript expression, TLR4 protein levels were decreased in RM, compared to 
RIF, samples.  Further, reduced TLR4 protein levels showed a correlation with 
increased BMI and uNK cell density.  It is important to highlight that these findings 
are limited due to a lack of samples from fertile controls, which are difficult to obtain 
in our clinical setting.  
It is foreseeable that a reduced level of active TLR4 receptors in the endometrium of 
RM patients is responsible for less stringent embryo selection at the time of 
implantation.  The resulting dampened immune response would predispose to 
pregnancy loss by permitting the implantation of developmentally incompetent 
embryos, which would require subsequent disposal at a later selection checkpoint. 
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Chapter 5 
Discussion 
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5.1 A changing implantation paradigm 
 
ART is based on a ‘double binary’ view of the drivers of reproductive success; i.e. 
implantation of a ‘normal’ but not an ‘abnormal’ embryo in a ‘receptive’ but not a 
‘non-receptive’ endometrium results in a successful pregnancy. Should these four 
variables occur randomly and combine by chance, the likelihood of successful 
pregnancy per implantation event would be 25%. This predicted incidence is 
remarkably similar to the average fecundity rate in humans. Further, the fact that 
many IVF units, including ours, now achieve ~ 50% pregnancy rates in women under 
the age of 35 years could be viewed as indirectly validating the ‘double binary’ 
paradigm. In other words, by constantly upgrading the methods and strategies for 
selection of ‘normal’ embryos and ‘receptive’ endometrium, pregnancy rates are set 
to rise further, miscarriage rates will gradually fall and, ultimately, IVF success will 
become guaranteed. 
However, the ‘double binary’ view of implantation is based upon a number of 
unsubstantiated assumptions and misleading observations. For example, the 
concept of ‘normal’ and ‘abnormal’ embryos stems from the belief that embryonic 
aneuploidies are caused solely, or at least predominately, by meiotic errors. 
Consequently, genetic analysis of one or more blastomeres from a cleavage-stage 
embryo should enable incontrovertible selection of normal embryos, thus eliminating 
one of the two obstacles that prevent total reproductive success. Despite the initial 
enthusiasm and widespread adoption of preimplantation genetic screening (PGS), 
randomized controlled trials showed that PGS not only failed to improve but actually 
diminished on-going IVF pregnancy and live birth rates (Mastenbroek et al., 2007, 
Mastenbroek et al., 2011, Staessen et al., 2004).  Undaunted by the initial failure of 
PGS, an upgraded screening procedure, designated PGS#2, is now heavily 
marketed to improve live-birth rates in IVF. PGS#2 in comparison to PGS#1 is 
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characterized by: (i) trophectoderm biopsy on day 5 or 6 embryos in place of day 3 
embryo biopsy; and (ii) fluorescence in-situ hybridization (FISH) of limited 
chromosome numbers is replaced by techniques that enable screening of all 24 
chromosome pairs (Gleicher et al., 2014). A few clinical trials have been published to 
date in support of PGS#2 (Rubio et al., 2013) but these studies have been heavily 
criticised for methodological flaws and misrepresentation of data (Gleicher et al., 
2014). 
At the heart of the PGS controversy lies the assumption that aneuploidy is always 
detrimental. This conjecture is of course highly intuitive because of the link between 
aneuploidy and disease. Aneuploidy is the leading cause of mental retardation and 
sporadic miscarriage and a key characteristic of cancer, as >90% of all solid human 
tumours harbour aneuploid genomes (Weaver and Cleveland, 2006). However, a 
wealth of data has emerged in recent years demonstrating that genomic instability is 
not pathological per se but intrinsic to the early stages of human embryo 
development.  
A systematic review of the chromosomal constitution of human embryos found, on 
average, 73% of pre-implantation embryos to be mosaic (van Echten-Arends et al., 
2011).  This high rate of mosaicism has been confirmed by subsequent analysis of 
all blastomeres in normally developing cleavage stage embryos via aCGH (71.4%) 
(Mertzanidou et al., 2013) and firmly undermines the reliability of PGS.  Despite 
extensive reports of mosaicism amongst blastocysts (Evsikov and Verlinsky, 1998, 
Magli et al., 2000, Sandalinas et al., 2001, Santos et al., 2010), the prevalence of 
these chromosomal abnormalities appears to be reduced when compared to 
cleavage stage embryos, suggesting a degree of ‘self-correction’ during embryo 
development (Fragouli et al., 2013, Vanneste et al., 2009).  The nature of such a 
mechanism remains to be identified but the shuttling of abnormal cells away from the 
ICM and towards the trophectoderm lineage has been disproved (Evsikov and 
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Verlinsky, 1998, Magli et al., 2000, Sandalinas et al., 2001, Santos et al., 2010).  
Contrary to the assumption underpinning PGS that only euploid embryos should be 
considered ‘normal’, new evidence has confirmed that mosaic embryos can result in 
the birth of healthy babies (Greco et al., 2015).   
While mosaicism may be a hallmark of human embryos, the purpose of 
chromosomally abnormal blastomeres in human embryos is a pertinent but largely 
ignored question in reproductive biology. Based on observations in yeast, aneuploidy 
has been shown to facilitate rapid phenotypic evolution and acquisition of adaptive 
traits under stress (Chen et al., 2012). When placed in an evolutionary context, 
transient aneuploidy in early development confers plasticity and adaptability to 
ecological changes. Another hypothesis is that aneuploid blastomeres, through 
mechanisms as yet not understood, contribute to the invasiveness of the embryo. 
More refined, this hypothesis purports that, depending on the degree of aneuploidy 
and the nature of chromosomal errors, mosaic embryos may either arrest, implant 
normally, or even have an implantation advantage.  
Chromosomes 15, 16, 21 and 22 are those most commonly associated with 
aneuploidy in human embryos (Gutiérrez-Mateo et al., 2011, Fragouli et al., 2011), 
with chromosomes 16 and 22 being the most frequently trisomic (Rubio et al., 2003, 
Bettio et al., 2008).  Interestingly, the aneuploidies observed amongst human 
embryos involve trisomies and monosomies in equal proportion (Fragouli et al., 
2013).  Yet, aneuploidies are differentially tolerated during pregnancy according to 
the affected chromosome and trisomies are more compatible with human life than 
monosomies.  Trisomy 16, thought to affect 1% of all conceptions, is the aneuploidy 
most strongly correlated with first trimester miscarriage (Benn, 1998).  Thus, despite 
leading to non-viable pregnancies, these trisomic embryos commonly evade the 
selection checkpoints during the implantation process.  It becomes pertinent that the 
gene encoding PRSS8, a protease more highly expressed by successfully implanting 
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embryos, is located on chromosome 16.  The increased gene dosage in trisomic 
embryos could result in an over-production of embryo-derived proteases involved at 
implantation, promoting invasion of the chromosomally ‘abnormal’ embryo (Quenby 
et al., 2002).  Measuring the levels of embryo-derived proteases in PGS embryos, to 
determine whether they correlate with gene dosage, would be an important follow-up 
study. 
5.2 Embryo selection at implantation 
Embryo ‘biosensoring’ by the endometrium was first demonstrated in cattle (Sandra 
and Renard, 2011).  Emerging evidence indicates that abnormal decidualization in 
humans causes loss of the embryo selectivity checkpoint, which renders the 
endometrium excessively permissive to implantation but unable to sustain the 
conceptus (Weimar et al., 2012a, Salker et al., 2010). This hypothesis is supported 
by in vitro studies demonstrating that RM is associated with aberrant responsiveness 
of HESCs to decidualizing signals (Weimar et al., 2012b), although the underlying 
mechanisms are unknown.  This process of embryo selection is either positive or 
negative; in other words, a decidualizing endometrium responds to embryonic 
signals in a manner that either supports further development or leads to rapid demise 
through menstruation-like shedding; thus increasing the likelihood of future 
reproductive success by safeguarding resources and expediting recovery. 
87% of miscarriages prior to 10 weeks gestation are karyotypically abnormal 
(Burgoyne 1991).  Therefore, these losses represent negative selection via a 
maternal response to abnormal embryos rather than a maternal aetiological cause.  
Various selection hurdles are imposed, predominantly within the first trimester of 
pregnancy, in order to obstruct non-viable pregnancies in a timely manner, which 
restrict the level of detriment to the mother and enable maximal reproductive 
success.  The importance of these quality control mechanisms are highlighted by 
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the high rates of early pregnancy loss observed in humans (Teklenburg et al., 
2010a).   
Firstly, a prolonged gestational interval following implantation relies upon corpus 
luteal rescue by the embryo in order to maintain progesterone levels for the 
maintenance of pregnancy (Baird et al., 2003).  Secondly, the onset of maternal 
arterial circulation, notably between 9 and 10 weeks gestation, poses a transient 
phase of placental oxidative stress, representing an additional selective challenge 
(Jaffe et al., 1997).  Prior to this, plugging of distal portions of spiral arteries by 
cytotrophoblast aggregates restricts arterial circulation to intracellular spaces, 
resulting in low oxygen tension within the placenta (Jauniaux et al., 2000).  If the 
level of oxidative stress rises too sharply or becomes too great during this phase 
the cellular defenses become overwhelmed and normal cellular function becomes 
impaired (Watson et al., 1998) resulting in trophoblastic degeneration, and 
pregnancy failure (Jauniaux et al., 1994). 
5.3 The molecular harbingers of embryonic developmental 
competence 
 
SGK1 plays an important role in embryo implantation by protecting the feto-maternal 
interface from oxidative cell death.  Further, SGK1 is up- and down- regulated in mid-
secretory endometrial biopsies taken from women with unexplained infertility and 
RM, respectively (Salker et al., 2011).  The effects of SGK1 are mediated both by 
direct activation of ENaC and the ability to enhance ENaC expression via NEDD4-2 
inhibition.  ENaC not only regulates PGE2 release during mouse implantation but 
uterine expression levels of ENaC have also been associated with pregnancy 
outcome in humans (Ruan et al., 2012).  As ENaC is regulated via proteolytic 
processing we focused on identifying embryo-derived proteases that may function at 
implantation. 
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For the first time, we provide evidence that human embryos generate trypsin and 
tryptic activity, with enhanced expression at the blastocyst stage.  Furthermore, we 
identify a conserved up-regulation of two serine proteases, TMPRSS2 and PRSS8, 
in mice and human blastocysts.  PRSS8 is produced by human placental 
trophoblasts and has been implicated in early pregnancy establishment (Ma et al., 
2009).  Prss8 knockout mice display lethality due to placental insufficiency (Hummler 
et al., 2013) and a PRSS8 polymorphism has been related to severe pre-eclampsia 
and shallow trophoblast invasion (Luo et al., 2014).  Although Tmprss2 double 
knockout mice develop normally, TMPRSS2 is thought to play important roles in 
embryo development, cell growth, proliferation, differentiation, migration, 
angiogenesis and inflammation via regulation of target genes (Kim et al., 2006).  
TMPRSS2 drives ETS-related gene (ERG) over-expression through gene fusion, 
resulting in more aggressive prostate tumour phenotypes and poorer prognoses 
(Demichelis et al., 2007, Tomlins et al., 2005).  PRSS8 and TMPRSS2 are 
membrane-bound proteases that become cleaved upon activation (Jack et al., 
1995), display trypsin-like activity and are able to regulate membrane bound 
receptors, such as ENaC (Donaldson et al., 2002).  PRSS8 and TMPRSS2 are both 
encoded by genes located on chromosomes commonly associated with aneuploidy 
in human embryos, 16 and 21, respectively. 
We provide evidence that the levels of these embryo-derived proteases relate to 
implantation outcome upon embryo transfer, with PRSS8 and TMPRSS2 being more 
highly expressed in successful and unsuccessful implantation events, respectively.  
Yet the complexity of the embryonic protease signal must not be disregarded and 
further investigations must be done in order to more closely characterise embryo-
secreted products at implantation.  It is important to highlight that measurements of 
ECM are not straightforward, require optimization and include confounding factors, 
such as the components of embryo culture medium itself.    
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5.4 Protease-sensitive receptors in the human endometrium 
Following a systematic literature search of putative targets of TMPRSS2 and PRSS8, 
we focused on the in vivo and in vitro expression of three transmembrane receptors 
able to regulate cell signalling within the endometrium (ENAC, PAR2 and TLR4).  We 
included both  and subunits of ENaC in our experiments as these contain the 
receptor’s key sites of proteolytic processing.  Increasing ENaC, TLR4 and PAR2 
transcript levels were identified within the endometrium during the mid-secretory 
phase, with heightened expression of ENaC and TLR4 in HESCs compared to 
HEECs.  Crucially, decidualization revealed a dynamic phenotype of receptor 
expression, with a distinctive peak at day 4, in line with the transient pro-
inflammatory response in HESCs, which regulates the expression of receptivity 
genes. 
Co-culture of ECM and day 4 DESCs failed to demonstrate cleavage and activation 
of ENaC or PAR2.  This may be explained by the high dilution factor (1:100) required 
to permit the analysis of individual embryos on DESC monolayers and could possibly 
be overcome by direct co-cultures of embryos and DESCs. 
We did identify TLR4 cleavage upon co-culture with ECM, particularly from 
successfully implanting embryos, suggesting an increased sensitivity of this receptor 
to embryo-derived proteases in comparison to ENaC and PAR2.  Further, we 
demonstrated that this inactivation by ECM renders the receptor unable to induce an 
inflammatory response upon activation by its cognate ligand, LPS.  PRSS8 is the 
most likely embryo-derived protease involved in TLR4 cleavage, as it can directly 
cleave and inactivate the receptor (Uchimura et al., 2014), is detectable in ECM and 
increased PRSS8 levels were associated with successful implantation.  Strategies to 
formally test this PRSS8-TLR4 interaction at implantation could involve the 
application of recombinant PRSS8, PRSS8 blocking antibodies or inhibitors and 
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endogenous PRSS8 knockdown.   
5.5 Summary 
In view of the incidence of genetic instability in human embryos, it is remarkable that 
little if anything is known about the fate of developmentally incompetent embryos at 
implantation. The reason for this lack of insight is obvious. On the one hand, our 
understanding of the implantation process is largely based on animal models, such 
as mouse, with a low incidence of chromosomally aberrant embryos. On the other, 
the prevailing belief is that most aberrant embryos cannot breach the luminal 
epithelium and disintegrate in the uterine cavity. Obvious exceptions on this rule are 
embryos with numeric aneuplodies, such as trisomies, which cause clinical 
miscarriages. 
My observations challenge this view and suggest that embryos generate complex 
soluble signals that either lead to active maternal rejection or induce an immune-
privileged and supportive environment. My studies uncovered the importance of the 
PRSS8-TLR4 pathway in maternal selection of implanting embryos. Silencing of 
TLR4 directly couples implantation to an innate immune response in the 
endometrium. Importantly, I showed that embryos that fail to secrete sufficient 
PRSS8 are less likely to implant, which may relate to partial or incomplete TLR4 
inactivation. Conversely, lack of endometrial TLR4 expression may impair the 
selectivity checkpoint at implantation, thus predisposing for recurrent miscarriage 
and superfertility. The complexity of embryonic protease signals, combined with the 
expression of multiple responsive receptors in the endometrium, renders 
implantation exceptionally dynamic. Nevertheless, an in-depth understanding of the 
mechanisms that control selection is poised to lead to effective strategies for the 
detection and prevention of persistent reproductive failure.  
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Appendix 1: qRT-PCR primers 
 
Gene Forward Primer Reverse Primer 
F2RL1 5'-ATCCTGCTAGCAGCCTCTC-3' 5'-GTGGGATGTGCCATCAACCTT -3' 
IL8 5'-CCAAGGAAAACTGGGTGCAGA-3' 5'-TTCACTGATTCTTGGATACCACAG-3' 
L19   5'-GCGGAAGGGTACAGCCAA-3' 5'-GCAGCCGGGCGCAAA-3' 
PRSS8 5'-CCTGACTTGAGCCACTCCTT-3' 5'-AAAGCACACCCAGAAGAATGG-3' 
PTGS2 5'-CCAGCACTTCACGCATCAGT-3' 5'-GGGTGGACTTAAATCATATTTACGGT-3' 
SCNN1A 5'-CATCCCTGGAGGAGGACA-3' 5'-TGGTGGAAGTGAGAGTAATTCG-3' 
TLR4 5'-AGCCATGGCCTTCCTCTC-3' 5'-ACTTCAGCTCCATGCATTGATAA-3' 
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Appendix 2: Up-regulated human genes: Fold Change >2.0 
 
Dev. Stage Gene Classification Fold change P value 
1 cell ECE2 Metalloproteases 136.67 0.17 
  ANPEP Metalloproteases 111.03 0.17 
  USP13 Cysteine Proteases 102.47 0.01 
  USP2 Cysteine Proteases 93.82 0.01 
  PSEN2 Aspartic Proteases 93.18 0.01 
  ENPEP Metalloproteases 86.64 0.03 
  USP35 Cysteine Proteases 60.86 0.05 
  BRCC3 (C6.1A) Metalloproteases 53.72 0.02 
  TMPRSS2 Serine Proteases 47.39 0.02 
  CAPN13 Cysteine Proteases 37.84 0.01 
  RISC/SCPEP1 Serine Proteases 34.46 0.06 
  PA2G4 Metalloproteases 33.15 0.01 
  TFRC Metalloproteases 31.52 0.00 
  PRSS8 Serine Proteases 30.56 0.10 
  SENP8 Cysteine Proteases 20.95 0.01 
  CAPN7 Cysteine Proteases 20.31 0.13 
  PRSS23 Serine Proteases 19.49 0.00 
  CYLD1 (CYLD) Cysteine Proteases 18.44 0.00 
  ADAM22 Metalloproteases 17.93 0.17 
  BEM46L1/ABHD13 Serine Proteases 17.10 0.19 
  PRSS15/LONP1 Serine Proteases 17.07 0.16 
  UCHL1 Cysteine Proteases 16.72 0.00 
  PMPCB Metalloproteases 16.54 0.00 
  UQCRC1 Metalloproteases 15.36 0.08 
  BACE2 Aspartic Proteases 15.08 0.06 
  ADAMTS1 Metalloproteases 14.82 0.49 
  NRD1 Metalloproteases 14.60 0.00 
  CPVL Serine Proteases 13.29 0.00 
  USP44 Cysteine Proteases 11.63 0.12 
  PGA4 Aspartic Proteases 11.62 0.16 
  CAPN3 Cysteine Proteases 10.67 0.00 
  USP45 Cysteine Proteases 10.25 0.02 
  SENP6 Cysteine Proteases 10.20 0.16 
  PSEN1 Aspartic Proteases 10.19 0.05 
  GGTL4 (GGTLC2) Threonine Proteases 9.69 0.25 
  USP34 Cysteine Proteases 9.57 0.01 
  USP10 Cysteine Proteases 8.77 0.00 
  KLKB1 Serine Proteases 8.71 0.29 
  DPP4 Serine Proteases 8.34 0.13 
  ADAM9 Metalloproteases 8.13 0.12 
  PCOLN3 (CHMP1A) Metalloproteases 7.84 0.00 
  APEH Serine Proteases 7.58 0.03 
  TRA1/TRRAP Serine Proteases 7.41 0.01 
  USP20 Cysteine Proteases 7.36 0.04 
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  THOP1 Metalloproteases 7.27 0.00 
  PIM2 Serine Proteases 6.81 0.05 
  USP15 Cysteine Proteases 6.67 0.02 
  PPGB/CATHEPSIN A Serine Proteases 6.47 0.26 
  PRCP Serine Proteases 6.21 0.13 
  CASP9 Cysteine Proteases 6.06 0.00 
  LGMN Cysteine Proteases 5.99 0.03 
  METAP1 Metalloproteases 5.78 0.21 
  USP21 Cysteine Proteases 5.59 0.05 
  ABHD4 Serine Proteases 5.53 0.00 
  PGPEP1 Cysteine Proteases 5.40 0.03 
  PEPD Metalloproteases 5.31 0.00 
  AQPEP Metalloproteases 5.18 0.00 
  C1S Serine Proteases 5.16 0.29 
  CLN2/TPP1 Serine Proteases 5.00 0.06 
  YME1L1 Metalloproteases 4.89 0.02 
  AUTL1 (ATG4C) Cysteine Proteases 4.87 0.20 
  DPP7 Serine Proteases 4.85 0.01 
  PSH1 (SPPL3) Aspartic Proteases 4.80 0.08 
  CAPN14 Cysteine Proteases 4.68 0.25 
  CLPP Serine Proteases 4.67 0.27 
  PLG Serine Proteases 4.67 0.06 
  CEZANNE (OTUD7B) Cysteine Proteases 4.59 0.01 
  PSMB9 Threonine Proteases 4.30 0.01 
  ABHD12/BEM46L3 Serine Proteases 4.25 0.00 
  USP9X Cysteine Proteases 4.18 0.05 
  ADAMTS16 Metalloproteases 4.15 0.23 
  ASPA Metalloproteases 4.09 0.09 
  SUP16H Metalloproteases 3.95 0.02 
  ADAM1A Metalloproteases 3.84 0.16 
  GFPT1 Cysteine Proteases 3.80 0.00 
  TMPRSS4 Serine Proteases 3.75 0.56 
  MEP1A Metalloproteases 3.63 0.85 
  XPNPEPL (XPNPEP1) Metalloproteases 3.53 0.00 
  USP4 Cysteine Proteases 3.45 0.01 
  CG1 58/ABHD5 Serine Proteases 3.31 0.13 
  KLK8 Serine Proteases 3.29 0.38 
  MMP20 Metalloproteases 3.18 0.23 
  COPS6 Metalloproteases 3.17 0.00 
  GZMM Serine Proteases 3.16 0.93 
  OSGEP Metalloproteases 3.13 0.17 
  PROC Serine Proteases 3.12 0.82 
  PROCL Serine Proteases 3.12 0.82 
  USP30 Cysteine Proteases 3.12 0.03 
  CAPN10 Cysteine Proteases 3.09 0.22 
  ESPL1 Cysteine Proteases 3.03 0.09 
  CFD/ADIPSIN Serine Proteases 3.01 0.13 
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  USP47 Cysteine Proteases 2.93 0.16 
  CTRL Serine Proteases 2.91 0.34 
  SPC18/SEC11A Serine Proteases 2.88 0.56 
  USP25 Cysteine Proteases 2.84 0.02 
  SPC21/SEC11C Serine Proteases 2.80 0.27 
  AUTL2 (ATG4A) Cysteine Proteases 2.79 0.01 
  EPHXRP/EPHX4 Serine Proteases 2.79 0.44 
  RHBDL4/RHBDL3 Serine Proteases 2.78 0.01 
  ADAM32 Metalloproteases 2.69 0.05 
  LAP3 Metalloproteases 2.67 0.10 
  USP52 (PAN2) Cysteine Proteases 2.66 0.03 
  PSMA5 Threonine Proteases 2.61 0.02 
  AFG3L2 Metalloproteases 2.59 0.03 
  USP5 Cysteine Proteases 2.57 0.18 
  TFR2 Metalloproteases 2.57 0.00 
  HGF/SOS1 Serine Proteases 2.56 0.09 
  RNPEP Metalloproteases 2.52 0.01 
  PRSS7 Serine Proteases 2.51 0.06 
  MMP24 Metalloproteases 2.51 0.05 
  ADAM7 Metalloproteases 2.45 0.04 
  MMP13 Metalloproteases 2.44 0.08 
  HTRA2 Serine Proteases 2.42 0.00 
  ADAMDEC1 Metalloproteases 2.38 0.15 
  PIP Aspartic Proteases 2.38 0.01 
  KLK14 Serine Proteases 2.37 0.15 
  PRPF8 Metalloproteases 2.33 0.02 
  ADAM18 Metalloproteases 2.33 0.57 
  USP1 Cysteine Proteases 2.33 0.28 
  PSMD7 Metalloproteases 2.32 0.16 
  GGH Cysteine Proteases 2.29 0.05 
  HPN Serine Proteases 2.28 0.48 
  EGFR-RS/RHBDF1 Serine Proteases 2.27 0.07 
  PRSS27/MARAPSIN Serine Proteases 2.25 0.89 
  LPA Serine Proteases 2.25 0.43 
  TRAP1 Serine Proteases 2.23 0.04 
  GGT5 (GGTLA1) Threonine Proteases 2.21 0.42 
  ADAMTS19 Metalloproteases 2.19 0.42 
  ADAMTS18 Metalloproteases 2.18 0.03 
  USP16 Cysteine Proteases 2.17 0.02 
  DNPEP Metalloproteases 2.16 0.23 
  LTF Serine Proteases 2.14 0.61 
  USP37 Cysteine Proteases 2.12 0.07 
  PSMA2 Threonine Proteases 2.12 0.00 
  ADAM30 Metalloproteases 2.12 0.64 
  ELA1 Serine Proteases 2.08 0.41 
  USP31 Cysteine Proteases 2.04 0.04 
  USP48 Cysteine Proteases 2.04 0.04 
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  USP18 Cysteine Proteases 2.03 0.15 
 
  
        
2 Cell ANPEP Metalloproteases 115.04 0.17 
  USP13 Cysteine Proteases 103.60 0.06 
  USP2 Cysteine Proteases 88.60 0.01 
  ENPEP Metalloproteases 75.41 0.03 
  PSEN2 Aspartic Proteases 66.44 0.01 
  BRCC3 (C6.1A) Metalloproteases 65.10 0.02 
  PRSS8 Serine Proteases 48.27 0.10 
  USP35 Cysteine Proteases 43.37 0.03 
  TFRC Metalloproteases 40.01 0.00 
  ADAM22 Metalloproteases 38.77 0.16 
  PRSS23 Serine Proteases 34.89 0.01 
  CAPN13 Cysteine Proteases 33.29 0.10 
  PA2G4 Metalloproteases 28.84 0.01 
  TMPRSS2 Serine Proteases 26.24 0.02 
  RISC/SCPEP1 Serine Proteases 26.22 0.07 
  ECE2 Metalloproteases 25.48 0.18 
  BACE2 Aspartic Proteases 20.69 0.03 
  CYLD1 (CYLD) Cysteine Proteases 19.50 0.00 
  PMPCB Metalloproteases 19.13 0.01 
  PRSS15/LONP1 Serine Proteases 18.58 0.16 
  SENP8 Cysteine Proteases 16.09 0.09 
  NRD1 Metalloproteases 14.96 0.00 
  CPVL Serine Proteases 14.91 0.00 
  ADAMTS1 Metalloproteases 14.20 0.49 
  UQCRC1 Metalloproteases 14.14 0.08 
  UCHL1 Cysteine Proteases 14.03 0.00 
  CAPN7 Cysteine Proteases 12.94 0.31 
  CAPN3 Cysteine Proteases 12.15 0.01 
  PGA4 Aspartic Proteases 11.76 0.04 
  DPP4 Serine Proteases 10.30 0.13 
  USP44 Cysteine Proteases 10.12 0.23 
  PIM2 Serine Proteases 9.78 0.06 
  ADAM9 Metalloproteases 8.78 0.11 
  SENP6 Cysteine Proteases 8.67 0.38 
  USP20 Cysteine Proteases 8.66 0.10 
  PSEN1 Aspartic Proteases 8.02 0.10 
  PCOLN3 (CHMP1A) Metalloproteases 7.72 0.00 
  APEH Serine Proteases 7.68 0.02 
  USP45 Cysteine Proteases 7.54 0.08 
  USP10 Cysteine Proteases 7.42 0.01 
  PEPD Metalloproteases 7.39 0.00 
  USP34 Cysteine Proteases 7.35 0.27 
  THOP1 Metalloproteases 7.29 0.01 
  BEM46L1/ABHD13 Serine Proteases 7.04 0.22 
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  HPN Serine Proteases 6.98 0.19 
  YME1L1 Metalloproteases 6.97 0.01 
  PPGB/CATHEPSIN A Serine Proteases 6.94 0.26 
  USP15 Cysteine Proteases 6.46 0.12 
  USP21 Cysteine Proteases 6.08 0.08 
  PRCP Serine Proteases 6.02 0.13 
  CAPN14 Cysteine Proteases 5.98 0.46 
  METAP1 Metalloproteases 5.57 0.21 
  GGTL4 (GGTLC2) Threonine Proteases 5.52 0.51 
  PLG Serine Proteases 5.41 0.03 
  TRA1/TRRAP Serine Proteases 5.22 0.01 
  KLKB1 Serine Proteases 5.22 0.33 
  USP4 Cysteine Proteases 5.14 0.06 
  CLN2/TPP1 Serine Proteases 4.93 0.06 
  CASP9 Cysteine Proteases 4.79 0.07 
  PSMD7 Metalloproteases 4.62 0.07 
  PSMB9 Threonine Proteases 4.42 0.01 
  DPP7 Serine Proteases 4.38 0.00 
  PGPEP1 Cysteine Proteases 4.36 0.06 
  XPNPEPL (XPNPEP1) Metalloproteases 4.33 0.00 
  AFG3L2 Metalloproteases 4.29 0.00 
  SUP16H Metalloproteases 4.20 0.03 
  PSH1 (SPPL3) Aspartic Proteases 4.06 0.01 
  USP9X Cysteine Proteases 3.81 0.14 
  USP11 Cysteine Proteases 3.80 0.40 
  ABHD4 Serine Proteases 3.78 0.01 
  SPC18/SEC11A Serine Proteases 3.74 0.51 
  MEP1A Metalloproteases 3.67 0.85 
  KLK8 Serine Proteases 3.61 0.36 
  COPS6 Metalloproteases 3.61 0.01 
  CLPP Serine Proteases 3.58 0.31 
  AQPEP Metalloproteases 3.56 0.00 
  TMPRSS4 Serine Proteases 3.56 0.58 
  CEZANNE (OTUD7B) Cysteine Proteases 3.42 0.09 
  RHBDL4/RHBDL3 Serine Proteases 3.42 0.12 
  USP37 Cysteine Proteases 3.40 0.09 
  USP47 Cysteine Proteases 3.32 0.30 
  SPC21/SEC11C Serine Proteases 3.28 0.24 
  LAP3 Metalloproteases 3.28 0.06 
  GZMM Serine Proteases 3.26 0.92 
  GFPT1 Cysteine Proteases 3.17 0.22 
  AUTL1 (ATG4C) Cysteine Proteases 3.11 0.49 
  USP25 Cysteine Proteases 3.11 0.00 
  USP52 (PAN2) Cysteine Proteases 3.11 0.08 
  LGMN Cysteine Proteases 3.08 0.32 
  USP30 Cysteine Proteases 3.05 0.04 
  GGT5 (GGTLA1) Threonine Proteases 3.05 0.27 
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  ASPA Metalloproteases 3.02 0.09 
  TRHDE Metalloproteases 3.02 0.91 
  CTRL Serine Proteases 2.91 0.34 
  C1S Serine Proteases 2.82 0.40 
  TRAP1 Serine Proteases 2.78 0.01 
  USP5 Cysteine Proteases 2.72 0.14 
  ESPL1 Cysteine Proteases 2.71 0.08 
  ADAM1A Metalloproteases 2.68 0.21 
  CG1 58/ABHD5 Serine Proteases 2.68 0.16 
  PRPF8 Metalloproteases 2.61 0.02 
  CFD/ADIPSIN Serine Proteases 2.60 0.12 
  ELA1 Serine Proteases 2.60 0.31 
  CAPN10 Cysteine Proteases 2.52 0.04 
  CAPN12 Cysteine Proteases 2.50 0.08 
  OSGEP Metalloproteases 2.48 0.20 
  HGF/SOS1 Serine Proteases 2.47 0.17 
  ADAM3B Metalloproteases 2.43 0.25 
  POH1 (PSMD14) Metalloproteases 2.43 0.01 
  DNPEP Metalloproteases 2.41 0.20 
  KLK6 Serine Proteases 2.41 0.56 
  RELN Serine Proteases 2.39 0.30 
  PIP Aspartic Proteases 2.39 0.00 
  ADAM7 Metalloproteases 2.35 0.03 
  PRTN3 Serine Proteases 2.35 0.90 
  ADAM18 Metalloproteases 2.34 0.61 
  RNPEP Metalloproteases 2.33 0.01 
  MMP24 Metalloproteases 2.30 0.06 
  PCSK2 Serine Proteases 2.28 0.63 
  PSMA5 Threonine Proteases 2.27 0.14 
  ADAMTS18 Metalloproteases 2.22 0.03 
  CPGL (CNDP2) Metalloproteases 2.20 0.20 
  HTRA2 Serine Proteases 2.19 0.01 
  CASP2 Cysteine Proteases 2.17 0.51 
  PCSK6 Serine Proteases 2.16 0.31 
  TFR2 Metalloproteases 2.16 0.02 
  CPA5 Metalloproteases 2.11 0.02 
  FACE1 (ZMPSTE24) Metalloproteases 2.08 0.01 
  OTUB2 Cysteine Proteases 2.07 0.57 
  EPHXRP/EPHX4 Serine Proteases 2.06 0.57 
  PRSS7 Serine Proteases 2.03 0.09 
  AUTL2 (ATG4A) Cysteine Proteases 2.01 0.23 
  ADAMTS5 Metalloproteases 2.00 0.60 
          
4 Cell ENPEP Metalloproteases 144.46 0.03 
  ANPEP Metalloproteases 141.93 0.17 
  USP2 Cysteine Proteases 92.92 0.01 
  USP13 Cysteine Proteases 88.81 0.06 
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  PSEN2 Aspartic Proteases 54.98 0.03 
  CAPN13 Cysteine Proteases 34.92 0.01 
  USP35 Cysteine Proteases 32.39 0.08 
  ECE2 Metalloproteases 27.54 0.18 
  TMPRSS2 Serine Proteases 27.09 0.02 
  PRSS8 Serine Proteases 26.16 0.10 
  BRCC3 (C6.1A) Metalloproteases 24.87 0.02 
  PA2G4 Metalloproteases 22.49 0.00 
  CPVL Serine Proteases 19.54 0.00 
  CAPN7 Cysteine Proteases 16.61 0.02 
  CYLD1 (CYLD) Cysteine Proteases 14.63 0.01 
  CAPN3 Cysteine Proteases 14.37 0.12 
  SENP8 Cysteine Proteases 14.12 0.09 
  UCHL1 Cysteine Proteases 14.06 0.00 
  RISC/SCPEP1 Serine Proteases 11.46 0.06 
  ADAM22 Metalloproteases 11.39 0.18 
  BACE2 Aspartic Proteases 11.35 0.03 
  PGA4 Aspartic Proteases 10.97 0.02 
  USP10 Cysteine Proteases 10.57 0.04 
  KLKB1 Serine Proteases 9.03 0.29 
  USP34 Cysteine Proteases 8.82 0.00 
  PRSS23 Serine Proteases 8.70 0.00 
  USP20 Cysteine Proteases 8.59 0.03 
  TRA1/TRRAP Serine Proteases 8.49 0.00 
  THOP1 Metalloproteases 8.48 0.00 
  USP45 Cysteine Proteases 8.07 0.06 
  PIM2 Serine Proteases 7.95 0.05 
  UQCRC1 Metalloproteases 7.90 0.08 
  USP44 Cysteine Proteases 7.83 0.07 
  PSEN1 Aspartic Proteases 7.80 0.04 
  BEM46L1/ABHD13 Serine Proteases 7.68 0.21 
  ASPA Metalloproteases 7.43 0.06 
  GGTL4 (GGTLC2) Threonine Proteases 6.65 0.33 
  PMPCB Metalloproteases 6.51 0.01 
  SENP6 Cysteine Proteases 6.34 0.19 
  USP21 Cysteine Proteases 6.26 0.04 
  USP15 Cysteine Proteases 6.16 0.00 
  ADAM9 Metalloproteases 6.11 0.12 
  NRD1 Metalloproteases 6.07 0.01 
  METAP1 Metalloproteases 6.01 0.20 
  DPP4 Serine Proteases 5.91 0.12 
  PCOLN3 (CHMP1A) Metalloproteases 5.76 0.01 
  USP4 Cysteine Proteases 5.50 0.16 
  USP29 Cysteine Proteases 5.07 0.21 
  TFRC Metalloproteases 4.83 0.06 
  PSMB9 Threonine Proteases 4.73 0.08 
  USP9X Cysteine Proteases 4.71 0.03 
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  AQPEP Metalloproteases 4.68 0.02 
  PEPD Metalloproteases 4.65 0.00 
  MEP1A Metalloproteases 4.64 0.81 
  GZMM Serine Proteases 4.38 0.89 
  ABHD12/BEM46L3 Serine Proteases 4.35 0.02 
  HPN Serine Proteases 4.00 0.23 
  APEH Serine Proteases 3.99 0.02 
  TMPRSS4 Serine Proteases 3.88 0.56 
  USP11 Cysteine Proteases 3.83 0.16 
  AFG3L2 Metalloproteases 3.77 0.01 
  USP37 Cysteine Proteases 3.75 0.06 
  RHBDL4/RHBDL3 Serine Proteases 3.72 0.02 
  MMP20 Metalloproteases 3.69 0.20 
  CEZANNE (OTUD7B) Cysteine Proteases 3.67 0.04 
  DPP7 Serine Proteases 3.63 0.03 
  CASP9 Cysteine Proteases 3.59 0.01 
  CAPN14 Cysteine Proteases 3.57 0.19 
  YME1L1 Metalloproteases 3.56 0.01 
  PRCP Serine Proteases 3.56 0.15 
  XPNPEPL (XPNPEP1) Metalloproteases 3.46 0.00 
  CLPP Serine Proteases 3.39 0.32 
  ADAM30 Metalloproteases 3.31 0.44 
  KLK8 Serine Proteases 3.28 0.38 
  PSMD7 Metalloproteases 3.27 0.12 
  LGMN Cysteine Proteases 3.18 0.03 
  PLG Serine Proteases 3.12 0.07 
  USP47 Cysteine Proteases 3.04 0.05 
  GFPT1 Cysteine Proteases 3.03 0.01 
  PSH1 (SPPL3) Aspartic Proteases 3.01 0.04 
  ELA1 Serine Proteases 3.01 0.28 
  OSGEP Metalloproteases 2.97 0.16 
  PPGB/CATHEPSIN A Serine Proteases 2.97 0.38 
  HGF/SOS1 Serine Proteases 2.95 0.01 
  USP5 Cysteine Proteases 2.95 0.00 
  PRSS15/LONP1 Serine Proteases 2.92 0.41 
  USP52 (PAN2) Cysteine Proteases 2.84 0.06 
  RNPEP Metalloproteases 2.78 0.01 
  PROC Serine Proteases 2.76 0.84 
  PROCL Serine Proteases 2.76 0.84 
  GGT5 (GGTLA1) Threonine Proteases 2.65 0.05 
  MMP13 Metalloproteases 2.63 0.07 
  USP25 Cysteine Proteases 2.60 0.07 
  CG1 58/ABHD5 Serine Proteases 2.57 0.15 
  CFD/ADIPSIN Serine Proteases 2.56 0.16 
  USP30 Cysteine Proteases 2.55 0.10 
  CPA5 Metalloproteases 2.55 0.01 
  SUP16H Metalloproteases 2.53 0.05 
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  ADAM1A Metalloproteases 2.46 0.23 
  CAPN10 Cysteine Proteases 2.45 0.01 
  PRSS7 Serine Proteases 2.44 0.04 
  ADAMTS16 Metalloproteases 2.42 0.43 
  ABHD4 Serine Proteases 2.37 0.05 
  ADAM7 Metalloproteases 2.35 0.00 
  EPHXRP/EPHX4 Serine Proteases 2.34 0.51 
  FACE1 (ZMPSTE24) Metalloproteases 2.32 0.01 
  AUTL1 (ATG4C) Cysteine Proteases 2.31 0.28 
  PGPEP1 Cysteine Proteases 2.31 0.10 
  MMP21 Metalloproteases 2.31 0.78 
  CAPN12 Cysteine Proteases 2.30 0.07 
  PIP Aspartic Proteases 2.27 0.00 
  SPC18/SEC11A Serine Proteases 2.27 0.66 
  TMPRSS6 Serine Proteases 2.26 0.40 
  ESPL1 Cysteine Proteases 2.25 0.12 
  AOPEP (C9ORF3) Metalloproteases 2.25 0.12 
  AUTL2 (ATG4A) Cysteine Proteases 2.18 0.06 
  SPC21/SEC11C Serine Proteases 2.17 0.37 
  C1S Serine Proteases 2.16 0.53 
  CPGL (CNDP2) Metalloproteases 2.13 0.15 
  PRPF8 Metalloproteases 2.05 0.10 
  PSMA5 Threonine Proteases 2.05 0.04 
  GGT7 (GGTL3) Threonine Proteases 2.04 0.14 
  LPA Serine Proteases 2.01 0.34 
  ADAMDEC1 Metalloproteases 2.01 0.21 
          
8 Cell ENPEP Metalloproteases 59.43 0.03 
  PRSS8 Serine Proteases 46.68 0.10 
  ANPEP Metalloproteases 42.61 0.17 
  CPVL Serine Proteases 23.14 0.00 
  BRCC3 (C6.1A) Metalloproteases 20.68 0.01 
  CAPN13 Cysteine Proteases 19.44 0.02 
  PSEN2 Aspartic Proteases 15.19 0.21 
  USP13 Cysteine Proteases 13.59 0.27 
  USP2 Cysteine Proteases 11.60 0.13 
  RISC/SCPEP1 Serine Proteases 11.52 0.06 
  MMP20 Metalloproteases 9.12 0.16 
  UCHL1 Cysteine Proteases 8.65 0.00 
  BACE2 Aspartic Proteases 8.29 0.15 
  BEM46L1/ABHD13 Serine Proteases 7.90 0.22 
  PSMD7 Metalloproteases 7.81 0.05 
  PSMB9 Threonine Proteases 7.02 0.51 
  ADAM9 Metalloproteases 6.87 0.09 
  USP35 Cysteine Proteases 6.87 0.14 
  TMPRSS2 Serine Proteases 6.70 0.00 
  PSMB8 Threonine Proteases 6.51 0.73 
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  AFG3L2 Metalloproteases 6.17 0.01 
  METAP1 Metalloproteases 6.10 0.20 
  ACE2 Metalloproteases 6.02 0.13 
  UQCRC1 Metalloproteases 5.93 0.07 
  ECE2 Metalloproteases 5.81 0.23 
  PEPD Metalloproteases 5.44 0.02 
  SUP16H Metalloproteases 5.26 0.02 
  XPNPEPL (XPNPEP1) Metalloproteases 5.12 0.03 
  CAPN3 Cysteine Proteases 5.06 0.01 
  THOP1 Metalloproteases 4.95 0.05 
  PIM2 Serine Proteases 4.78 0.06 
  SENP5 Cysteine Proteases 4.57 0.28 
  PMPCB Metalloproteases 4.53 0.03 
  NRD1 Metalloproteases 4.47 0.03 
  DESC1/TMPRSS11E Serine Proteases 4.35 0.29 
  HGF/SOS1 Serine Proteases 4.35 0.01 
  CYLD1 (CYLD) Cysteine Proteases 4.32 0.03 
  TFRC Metalloproteases 4.19 0.06 
  CPGL (CNDP2) Metalloproteases 3.98 0.71 
  USP29 Cysteine Proteases 3.92 0.40 
  PLG Serine Proteases 3.74 0.07 
  KLK8 Serine Proteases 3.72 0.36 
  ABHD12/BEM46L3 Serine Proteases 3.66 0.01 
  ADAM10 Metalloproteases 3.59 0.21 
  FACE1 (ZMPSTE24) Metalloproteases 3.45 0.04 
  PA2G4 Metalloproteases 3.45 0.00 
  RNPEP Metalloproteases 3.33 0.01 
  TAF2 Metalloproteases 3.33 0.15 
  CAD Metalloproteases 3.30 0.06 
  PRSS23 Serine Proteases 3.21 0.23 
  TRAP1 Serine Proteases 3.15 0.06 
  LGMN Cysteine Proteases 3.15 0.58 
  AOPEP (C9ORF3) Metalloproteases 3.13 0.05 
  PGA4 Aspartic Proteases 3.10 0.02 
  APEH Serine Proteases 3.09 0.12 
  ASPA Metalloproteases 2.93 0.08 
  CTRL Serine Proteases 2.93 0.35 
  USP20 Cysteine Proteases 2.76 0.13 
  HPN Serine Proteases 2.72 0.31 
  AFG3L1 (AFG3L1P) Metalloproteases 2.65 0.13 
  POH1 (PSMD14) Metalloproteases 2.62 0.07 
  MBTPS2 Metalloproteases 2.61 0.29 
  USP10 Cysteine Proteases 2.55 0.31 
  CAPN14 Cysteine Proteases 2.52 0.33 
  AQPEP Metalloproteases 2.48 0.25 
  HSPCA/HSP90AA1 Serine Proteases 2.41 0.18 
  MIPEP Metalloproteases 2.40 0.13 
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  ADAM33 Metalloproteases 2.38 0.43 
  HTRA2 Serine Proteases 2.37 0.01 
  SPC21/SEC11C Serine Proteases 2.35 0.43 
  IMP1L Serine Proteases 2.35 0.48 
  CAPN12 Cysteine Proteases 2.34 0.04 
  GZMM Serine Proteases 2.33 0.96 
  ADAMTS2 Metalloproteases 2.30 0.25 
  SPC18/SEC11A Serine Proteases 2.19 0.75 
  PCSK1 Serine Proteases 2.19 0.90 
  CAPN11 Cysteine Proteases 2.19 0.30 
  GGT1 Threonine Proteases 2.19 0.34 
  EGFR-RS/RHBDF1 Serine Proteases 2.13 0.21 
  USP34 Cysteine Proteases 2.08 0.56 
  PRSS16 Serine Proteases 2.07 0.19 
  ADAM1A Metalloproteases 2.07 0.39 
  TPSB1 Serine Proteases 2.04 0.72 
  DPP4 Serine Proteases 2.00 0.35 
          
Morula ENPEP Metalloproteases 28.97 0.03 
  PRSS8 Serine Proteases 22.58 0.10 
  TMPRSS2 Serine Proteases 15.44 0.00 
  CPVL Serine Proteases 13.48 0.00 
  ACE2 Metalloproteases 12.10 0.13 
  LTA4H Metalloproteases 9.64 0.00 
  ADAM9 Metalloproteases 8.15 0.12 
  PIM2 Serine Proteases 8.11 0.06 
  ADAMTS1 Metalloproteases 7.50 0.53 
  LACTB Serine Proteases 7.49 0.12 
  MBTPS2 Metalloproteases 6.15 0.15 
  XPNPEPL (XPNPEP1) Metalloproteases 6.09 0.01 
  GZMM Serine Proteases 5.49 0.87 
  CPGL (CNDP2) Metalloproteases 5.47 0.85 
  LGMN Cysteine Proteases 5.47 0.21 
  MBTPS1 Serine Proteases 5.34 0.14 
  ANPEP Metalloproteases 5.02 0.22 
  PSMB9 Threonine Proteases 5.02 0.14 
  CLN2/TPP1 Serine Proteases 4.51 0.07 
  BRCC3 (C6.1A) Metalloproteases 4.21 0.02 
  SENP5 Cysteine Proteases 4.14 0.24 
  BEM46L1/ABHD13 Serine Proteases 4.02 0.28 
  ABHD4 Serine Proteases 3.83 0.01 
  PRCP Serine Proteases 3.71 0.16 
  HSPCA/HSP90AA1 Serine Proteases 3.71 0.11 
  TMPRSS4 Serine Proteases 3.67 0.56 
  IMMP2L Serine Proteases 3.54 0.02 
  PSMD7 Metalloproteases 3.46 0.10 
  KLK14 Serine Proteases 3.28 0.08 
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  CG1 58/ABHD5 Serine Proteases 3.13 0.14 
  CAPN13 Cysteine Proteases 3.09 0.02 
  USP13 Cysteine Proteases 3.05 0.26 
  TRAP1 Serine Proteases 2.95 0.02 
  INPP5E Metalloproteases 2.85 0.01 
  AQPEP Metalloproteases 2.80 0.00 
  TPP2 Serine Proteases 2.78 0.03 
  ABHD12/BEM46L3 Serine Proteases 2.74 0.01 
  AOPEP (C9ORF3) Metalloproteases 2.64 0.09 
  ADAM10 Metalloproteases 2.58 0.28 
  RNPEP Metalloproteases 2.53 0.01 
  CAPN14 Cysteine Proteases 2.52 0.66 
  AFG3L2 Metalloproteases 2.41 0.02 
  UQCRC1 Metalloproteases 2.38 0.19 
  METAP1 Metalloproteases 2.36 0.37 
  SPC21/SEC11C Serine Proteases 2.31 0.33 
  RISC/SCPEP1 Serine Proteases 2.28 0.16 
  TRHDE Metalloproteases 2.27 0.95 
  USP7 Cysteine Proteases 2.27 0.00 
  ADAM6 Metalloproteases 2.26 0.81 
  PEPD Metalloproteases 2.23 0.06 
  POH1 (PSMD14) Metalloproteases 2.22 0.02 
  TAF2 Metalloproteases 2.20 0.24 
  CTSF Cysteine Proteases 2.19 0.22 
  ECEL1 Metalloproteases 2.16 0.87 
  TPSG1 Serine Proteases 2.16 0.47 
  THOP1 Metalloproteases 2.13 0.01 
  MIPEP Metalloproteases 2.12 0.18 
  TPSB1 Serine Proteases 2.11 0.70 
  DPP3 Metalloproteases 2.10 0.56 
  PCSK1 Serine Proteases 2.06 0.92 
  HGF/SOS1 Serine Proteases 2.05 0.01 
  KLK6 Serine Proteases 2.01 0.66 
  BACE2 Aspartic Proteases 2.00 0.39 
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Appendix 3: Up-regulated mouse genes: Fold Change >2.0 
 
Dev. Stage Gene Classification Fold change P value 
Oocyte Enpep Metalloproteases 117.18 0.00 
 Uchl1 Cysteine Proteases 60.96 0.01 
 Cathepsin A Serine Proteases 32.15 0.00 
 Ctsh Cysteine Proteases 30.39 0.00 
 CpnCpn1 Metalloproteases 29.04 0.02 
 Usp2 Cysteine Proteases 24.58 0.01 
 Lap3 Metalloproteases 20.38 0.01 
 Xpnpep1 Metalloproteases 17.68 0.00 
 Bace2 Aspartic Proteases 16.30 0.01 
 Otub2 Cysteine Proteases 16.16 0.00 
 Prss8 Serine Proteases 14.71 0.00 
 Osgep Metalloproteases 14.04 0.00 
 Uqcrc1 Metalloproteases 13.69 0.01 
 Dpp4 Serine Proteases 12.26 0.01 
 Yme1L1 Metalloproteases 11.35 0.03 
 Sva Aspartic Proteases 11.26 0.05 
 Pepd Metalloproteases 9.77 0.04 
 St14 Serine Proteases 9.74 0.01 
 Psen2 Aspartic Proteases 9.37 0.00 
 Clpp Serine Proteases 9.01 0.00 
 Spg7 Metalloproteases 8.90 0.18 
 Casp8 Cysteine Proteases 8.88 0.02 
 Lta4H Metalloproteases 8.47 0.01 
 NpeppsPsa Metalloproteases 7.46 0.05 
 Tmprss2 Serine Proteases 7.00 0.09 
 Hsp841 Serine Proteases 6.70 0.01 
 Usp21 Cysteine Proteases 6.70 0.06 
 Metap1 Metalloproteases 6.43 0.06 
 Klk7 Serine Proteases 6.35 0.04 
 C2 Serine Proteases 6.28 0.07 
 Dpp7 Serine Proteases 5.89 0.02 
 Cad Metalloproteases 5.69 0.01 
 Usp3 Cysteine Proteases 5.61 0.00 
 Usp9X Cysteine Proteases 5.51 0.02 
 Afg3L1 Metalloproteases 5.47 0.00 
 Pga5 (Pepf) Aspartic Proteases 5.35 0.00 
 Usp19 Cysteine Proteases 5.13 0.00 
 Cela3B Ii Serine Proteases 5.10 0.24 
 Prtn3 Serine Proteases 4.81 0.08 
 TrfrTrfrc Metalloproteases 4.68 0.03 
 Senp6 Cysteine Proteases 4.57 0.01 
 Dnpep Metalloproteases 4.52 0.00 
 Capn9 Cysteine Proteases 4.45 0.20 
 Dpp3 Metalloproteases 4.36 0.00 
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 Eif3S5Eif3F Metalloproteases 4.23 0.00 
 Pgpi (Pgpep1) Cysteine Proteases 4.20 0.02 
 Ctsf Cysteine Proteases 4.12 0.16 
 Adam19 Metalloproteases 3.98 0.00 
 Acy1 Metalloproteases 3.79 0.26 
 Rhbdd2 Serine Proteases 3.69 0.16 
 Tpp1 Serine Proteases 3.53 0.00 
 Pcsk4 Serine Proteases 3.49 0.22 
 Senp1 Cysteine Proteases 3.46 0.01 
 Pcsk1 Serine Proteases 3.34 0.30 
 Rnpep Metalloproteases 3.33 0.01 
 Tranb1 (Trabid) Cysteine Proteases 3.25 0.01 
 Mst1 Serine Proteases 3.24 0.20 
 Cpxm1Cpx1 Metalloproteases 3.18 0.00 
 Pan2 (Usp52) Cysteine Proteases 3.13 0.01 
 Psmd7 Metalloproteases 3.05 0.03 
 Psmd14Poh1 Metalloproteases 3.01 0.01 
 Usp4 Cysteine Proteases 3.01 0.05 
 Anpep Metalloproteases 2.97 0.69 
 Usp15 Cysteine Proteases 2.95 0.08 
 Aspa Metalloproteases 2.95 0.05 
 Usp20 Cysteine Proteases 2.86 0.01 
 Pa2G4 Metalloproteases 2.83 0.11 
 Capn7 Cysteine Proteases 2.82 0.00 
 Mep1B Metalloproteases 2.77 0.01 
 Prss28 Serine Proteases 2.74 0.25 
 Ctrb1 Serine Proteases 2.65 0.39 
 Pmpcb Metalloproteases 2.65 0.01 
 Cflar Cysteine Proteases 2.61 0.20 
 Usp16 Cysteine Proteases 2.57 0.01 
 Shh Cysteine Proteases 2.56 0.67 
 Lgmn Cysteine Proteases 2.53 0.00 
 Pcsk6 Serine Proteases 2.52 0.01 
 Ide Metalloproteases 2.48 0.02 
 Cts6 Cysteine Proteases 2.41 0.69 
 Atg4B (Autl1) Cysteine Proteases 2.34 0.01 
 Mbtps1 Serine Proteases 2.33 0.00 
 Rhbdl3 Serine Proteases 2.31 0.19 
 Usp11 Cysteine Proteases 2.31 0.02 
 Adam34 Metalloproteases 2.31 0.44 
 Usp-Ps (Dub2) Cysteine Proteases 2.30 0.60 
 Face1 Metalloproteases 2.29 0.08 
 Usp18 Cysteine Proteases 2.22 0.41 
 Psen1 Aspartic Proteases 2.17 0.01 
 Ggh Cysteine Proteases 2.16 0.27 
 Eif3S3 Metalloproteases 2.08 0.08 
 Capn12 Cysteine Proteases 2.05 0.01 
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1 Cell Enpep Metalloproteases 92.45 0.00 
 Uchl1 Cysteine Proteases 65.01 0.04 
 Clpp Serine Proteases 61.46 0.00 
 Osgep Metalloproteases 53.35 0.00 
 Cathepsin A Serine Proteases 52.12 0.01 
 Usp2 Cysteine Proteases 46.19 0.00 
 CpnCpn1 Metalloproteases 45.20 0.02 
 Mep1B Metalloproteases 36.36 0.01 
 Psen2 Aspartic Proteases 28.95 0.00 
 Lap3 Metalloproteases 27.79 0.01 
 Eif3S5Eif3F Metalloproteases 25.25 0.00 
 Psmd14Poh1 Metalloproteases 20.59 0.01 
 Ctsh Cysteine Proteases 18.65 0.02 
 Usp21 Cysteine Proteases 17.86 0.00 
 Xpnpep1 Metalloproteases 15.77 0.00 
 Cad Metalloproteases 13.89 0.01 
 Dnpep Metalloproteases 13.87 0.00 
 Casp8 Cysteine Proteases 13.54 0.02 
 Uqcrc1 Metalloproteases 12.96 0.01 
 Yme1L1 Metalloproteases 11.78 0.03 
 Tmprss2 Serine Proteases 9.68 0.08 
 Pmpcb Metalloproteases 9.32 0.01 
 Klk7 Serine Proteases 9.14 0.05 
 Bace2 Aspartic Proteases 9.08 0.25 
 St14 Serine Proteases 8.74 0.00 
 Senp6 Cysteine Proteases 8.69 0.03 
 Senp1 Cysteine Proteases 8.64 0.02 
 Otub2 Cysteine Proteases 8.22 0.01 
 Lta4H Metalloproteases 8.15 0.01 
 Capn9 Cysteine Proteases 7.98 0.07 
 Dpp7 Serine Proteases 7.75 0.01 
 Usp15 Cysteine Proteases 7.63 0.01 
 Usp19 Cysteine Proteases 7.49 0.00 
 Dpp4 Serine Proteases 7.47 0.01 
 Cts6 Cysteine Proteases 7.43 0.26 
 Prss8 Serine Proteases 7.41 0.00 
 Pepd Metalloproteases 7.18 0.04 
 Pitrm1 Metalloproteases 7.06 0.01 
 Usp9X Cysteine Proteases 6.68 0.00 
 Eif3S3 Metalloproteases 6.65 0.02 
 Cops6 Metalloproteases 6.17 0.01 
 NpeppsPsa Metalloproteases 6.00 0.05 
 Prtn3 Serine Proteases 5.46 0.07 
 Mmp23 Metalloproteases 5.29 0.20 
 Pan2 (Usp52) Cysteine Proteases 5.03 0.00 
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 Cops5 Metalloproteases 4.91 0.00 
 Afg3L1 Metalloproteases 4.83 0.00 
 Rhbdd2 Serine Proteases 4.83 0.13 
 Capn7 Cysteine Proteases 4.76 0.02 
 Shh Cysteine Proteases 4.73 0.47 
 Dpp3 Metalloproteases 4.44 0.01 
 Hsp841 Serine Proteases 4.27 0.02 
 TrfrTrfrc Metalloproteases 4.21 0.03 
 Cflar Cysteine Proteases 4.19 0.03 
 Usp-Ps (Dub2) Cysteine Proteases 3.92 0.31 
 Metap1 Metalloproteases 3.88 0.09 
 Usp3 Cysteine Proteases 3.84 0.07 
 Usp38 Cysteine Proteases 3.55 0.00 
 Acy1 Metalloproteases 3.51 0.27 
 Sva Aspartic Proteases 3.49 0.81 
 Prss28 Serine Proteases 3.49 0.19 
 Cela3B Ii Serine Proteases 3.47 0.32 
 Cpxm1Cpx1 Metalloproteases 3.46 0.00 
 Ctsf Cysteine Proteases 3.41 0.74 
 Mst1 Serine Proteases 3.40 0.19 
 Aspa Metalloproteases 3.27 0.03 
 Spg7 Metalloproteases 3.26 0.30 
 Usp18 Cysteine Proteases 3.11 0.14 
 Adam21 Metalloproteases 3.04 0.10 
 Adam19 Metalloproteases 2.97 0.01 
 Usp20 Cysteine Proteases 2.88 0.02 
 Ide Metalloproteases 2.80 0.01 
 C2 Serine Proteases 2.79 0.14 
 Usp27X Cysteine Proteases 2.74 0.00 
 Psmd7 Metalloproteases 2.68 0.03 
 Usp47 Cysteine Proteases 2.63 0.00 
 Tpp1 Serine Proteases 2.53 0.01 
 Capn12 Cysteine Proteases 2.52 0.01 
 Face1 Metalloproteases 2.49 0.06 
 Nrd1 Metalloproteases 2.48 0.01 
 Ctsr Cysteine Proteases 2.47 0.53 
 Pgpi (Pgpep1) Cysteine Proteases 2.45 0.32 
 Casp14 Cysteine Proteases 2.43 0.17 
 Prss30 Serine Proteases 2.42 0.76 
 Tmprss8 Serine Proteases 2.42 0.76 
 Dpep3 Metalloproteases 2.41 0.51 
 Pcsk6 Serine Proteases 2.38 0.01 
 Klk11 Serine Proteases 2.37 0.76 
 Usp7 Cysteine Proteases 2.36 0.00 
 Rnpep Metalloproteases 2.35 0.00 
 Sval2 Aspartic Proteases 2.29 0.29 
 Adam7 Metalloproteases 2.24 0.08 
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 Trap1 Serine Proteases 2.16 0.01 
 Pga5 (Pepf) Aspartic Proteases 2.16 0.02 
 Ctse Aspartic Proteases 2.14 0.26 
 Trrap Serine Proteases 2.14 0.00 
 Pcsk1 Serine Proteases 2.11 0.50 
 Usp11 Cysteine Proteases 2.08 0.04 
 Rhbdl3 Serine Proteases 2.04 0.26 
 Usp45 Cysteine Proteases 2.03 0.18 
 Prpf8 Metalloproteases 2.02 0.01 
     
2 Cell Enpep Metalloproteases 112.68 0.00 
 Sva Aspartic Proteases 47.66 0.04 
 Uchl1 Cysteine Proteases 19.90 0.02 
 Lta4H Metalloproteases 12.21 0.01 
 Gfpt1 Cysteine Proteases 11.70 0.01 
 Usp-Ps (Dub2) Cysteine Proteases 11.45 0.00 
 Ctsh Cysteine Proteases 10.81 0.00 
 Usp2 Cysteine Proteases 10.03 0.04 
 Klk7 Serine Proteases 9.72 0.04 
 Ctss Cysteine Proteases 9.71 0.02 
 Usp21 Cysteine Proteases 8.73 0.04 
 Lap3 Metalloproteases 7.82 0.01 
 Usp12 (Ubh1) Cysteine Proteases 7.79 0.00 
 Senp6 Cysteine Proteases 7.52 0.00 
 Prep Serine Proteases 7.50 0.11 
 Dpp4 Serine Proteases 7.22 0.02 
 Afg3L1 Metalloproteases 7.21 0.00 
 St14 Serine Proteases 7.18 0.01 
 Dpp7 Serine Proteases 7.17 0.02 
 Usp15 Cysteine Proteases 6.92 0.01 
 Uqcrc1 Metalloproteases 6.77 0.01 
 Usp16 Cysteine Proteases 6.49 0.01 
 Shh Cysteine Proteases 6.44 0.45 
 Htra2 Serine Proteases 6.34 0.00 
 Prss8 Serine Proteases 5.74 0.00 
 Pepd Metalloproteases 5.63 0.05 
 Tpp1 Serine Proteases 5.63 0.00 
 Rhbdd2 Serine Proteases 5.61 0.12 
 Hsp841 Serine Proteases 5.59 0.02 
 Tmprss2 Serine Proteases 5.47 0.10 
 Pmpcb Metalloproteases 5.46 0.01 
 Uqcrc2 Metalloproteases 5.41 0.02 
 Usp38 Cysteine Proteases 5.31 0.01 
 Cflar Cysteine Proteases 5.29 0.03 
 Capn9 Cysteine Proteases 4.83 0.14 
 Brcc3C61A Metalloproteases 4.83 0.00 
 Ide Metalloproteases 4.71 0.01 
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 Pitrm1 Metalloproteases 4.68 0.01 
 Cops5 Metalloproteases 4.15 0.00 
 Casp3 Cysteine Proteases 4.08 0.00 
 Otub2 Cysteine Proteases 3.96 0.02 
 Usp33 Cysteine Proteases 3.82 0.01 
 Osgep Metalloproteases 3.73 0.00 
 Spg7 Metalloproteases 3.67 0.27 
 Tranb1 (Trabid) Cysteine Proteases 3.65 0.02 
 Mep1B Metalloproteases 3.62 0.01 
 Usp18 Cysteine Proteases 3.60 0.03 
 Ctsb Cysteine Proteases 3.52 0.07 
 Dpp3 Metalloproteases 3.26 0.01 
 Apeh Serine Proteases 3.16 0.00 
 Usp1 Cysteine Proteases 3.14 0.02 
 Metap1 Metalloproteases 3.07 0.11 
 Usp9X Cysteine Proteases 3.05 0.01 
 Cpxm1Cpx1 Metalloproteases 3.01 0.00 
 Prss28 Serine Proteases 2.99 0.23 
 Scaf11 (Casp11) Cysteine Proteases 2.96 0.02 
 Prtn3 Serine Proteases 2.92 0.13 
 Acy1 Metalloproteases 2.90 0.32 
 Aspa Metalloproteases 2.83 0.04 
 Cts6 Cysteine Proteases 2.81 0.77 
 Psmd14Poh1 Metalloproteases 2.81 0.01 
 Pcsk6 Serine Proteases 2.78 0.01 
 Psen2 Aspartic Proteases 2.75 0.04 
 Spc21 Serine Proteases 2.75 0.01 
 Prss30 Serine Proteases 2.74 0.71 
 Tmprss8 Serine Proteases 2.74 0.71 
 Senp1 Cysteine Proteases 2.55 0.01 
 Eif3S5Eif3F Metalloproteases 2.51 0.00 
 Dnpep Metalloproteases 2.42 0.00 
 Adam19 Metalloproteases 2.41 0.01 
 Hspca Serine Proteases 2.41 0.00 
 Usp47 Cysteine Proteases 2.36 0.00 
 Mmp11 Metalloproteases 2.32 0.49 
 Casp8 Cysteine Proteases 2.32 0.20 
 Rnpepl1 Metalloproteases 2.31 0.05 
 Pcsk1 Serine Proteases 2.30 0.46 
 Cts3 Cysteine Proteases 2.29 0.43 
 Adam9 Metalloproteases 2.28 0.00 
 Usp20 Cysteine Proteases 2.28 0.09 
 Capn8 Cysteine Proteases 2.23 0.01 
 CpnCpn1 Metalloproteases 2.23 0.12 
 Ctsf Cysteine Proteases 2.21 0.39 
 Ggh Cysteine Proteases 2.18 0.10 
 Mmp23 Metalloproteases 2.15 0.45 
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 Prpf8 Metalloproteases 2.14 0.01 
 Anpep Metalloproteases 2.13 0.82 
 Trap1 Serine Proteases 2.13 0.02 
 Ctsq Cysteine Proteases 2.03 0.87 
 Folh1 Metalloproteases 2.02 0.61 
 Clpp Serine Proteases 2.00 0.04 
     
8 cell Htra1 Serine Proteases 73.41 0.03 
 Enpep Metalloproteases 29.96 0.00 
 Prss8 Serine Proteases 13.37 0.00 
 Tpp1 Serine Proteases 12.76 0.00 
 CpnCpn1 Metalloproteases 11.33 0.02 
 Cts6 Cysteine Proteases 10.02 0.14 
 Gfpt1 Cysteine Proteases 7.91 0.06 
 Klk7 Serine Proteases 7.52 0.05 
 Ctsz Cysteine Proteases 7.38 0.05 
 Apeh Serine Proteases 6.71 0.00 
 Capn9 Cysteine Proteases 6.63 0.09 
 Tmprss2 Serine Proteases 5.47 0.11 
 Lta4H Metalloproteases 5.44 0.01 
 Ctsh Cysteine Proteases 5.44 0.05 
 Spg7 Metalloproteases 4.45 0.23 
 Psmb8 Threonine Proteases 4.41 0.79 
 Usp33 Cysteine Proteases 4.37 0.13 
 Lap3 Metalloproteases 4.32 0.01 
 Ctsb Cysteine Proteases 3.88 0.07 
 Pitrm1 Metalloproteases 3.80 0.01 
 St14 Serine Proteases 3.79 0.02 
 Abhd5 Serine Proteases 3.46 0.02 
 Prep Serine Proteases 3.45 0.17 
 Usp16 Cysteine Proteases 3.25 0.00 
 Usp1 Cysteine Proteases 3.23 0.00 
 Ggh Cysteine Proteases 3.07 0.02 
 Adam19 Metalloproteases 3.00 0.02 
 Usp10 Cysteine Proteases 2.92 0.03 
 Parl Serine Proteases 2.90 0.08 
 Usp12 (Ubh1) Cysteine Proteases 2.87 0.10 
 Tmprss5 Serine Proteases 2.85 0.32 
 Bace2 Aspartic Proteases 2.76 0.47 
 Ctsk Cysteine Proteases 2.64 0.24 
 Ide Metalloproteases 2.58 0.01 
 Htra2 Serine Proteases 2.58 0.01 
 Usp38 Cysteine Proteases 2.55 0.06 
 Ctsc Cysteine Proteases 2.53 0.01 
 Usp20 Cysteine Proteases 2.52 0.07 
 Pcsk6 Serine Proteases 2.48 0.01 
 Pepd Metalloproteases 2.46 0.12 
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 Cpxm1Cpx1 Metalloproteases 2.40 0.02 
 Ctsl Cysteine Proteases 2.40 0.00 
 Psh1 (Sppl3) Aspartic Proteases 2.39 0.13 
 Ctsg Serine Proteases 2.39 0.64 
 Sva Aspartic Proteases 2.35 0.28 
 Rnpepl1 Metalloproteases 2.33 0.17 
 Afg3L2 Metalloproteases 2.33 0.01 
 Acy3 Metalloproteases 2.31 0.03 
 Casp3 Cysteine Proteases 2.31 0.02 
 Xpnpep1 Metalloproteases 2.29 0.00 
 Uqcrc1 Metalloproteases 2.27 0.03 
 Pcsk4 Serine Proteases 2.27 0.38 
 NpeppsPsa Metalloproteases 2.23 0.14 
 Afg3L1 Metalloproteases 2.21 0.00 
 Mmp12 Metalloproteases 2.20 0.65 
 Ctss Cysteine Proteases 2.18 0.94 
 Proc Serine Proteases 2.15 0.20 
 Procl Serine Proteases 2.15 0.20 
 Usp18 Cysteine Proteases 2.12 0.66 
 Psmb10 Threonine Proteases 2.10 0.17 
 Ppat Cysteine Proteases 2.09 0.00 
 Dpp3 Metalloproteases 2.09 0.01 
 Dnpep Metalloproteases 2.05 0.00 
 Usp14 Cysteine Proteases 2.04 0.00 
 Pga5 (Pepf) Aspartic Proteases 2.03 0.15 
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Appendix 4: Total number of embryos used for ICC 
 
 
Mouse Human 
ENTK 8 21 
AMBP 8 24 
PRSS8 9 19 
TMPRSS2 9 11 
Total 34 75 
 
 
Appendix 5: Patient characteristics (Figures 4.2.5.1, 4.2.5.2, 
4.2.5.3, 4.2.5.6) 
 
(median [range]) 
RIF 
n=14 
RM 
n=14 
Age (years): 30 [25-37] 33 [29-37] 
Body Mass Index (BMI): 23 [18-30] 23.5 [18-29] 
uNK Density (%): 2.17% 3.35% 
 
Appendix 6: Patient characteristics (Figures 4.2.5.4, 4.2.5.5, 
4.2.5.6) 
 
(median [range]) 
RIF 
n=15 
RM 
n=15 
Age (years): 31 [24-38] 33 [25-38] 
Body Mass Index (BMI): 22.5 [16-35] 22.5 [19-32] 
uNK Density (%): 4.37% 2.76% 
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Appendix 7: Western blots (Figures 4.2.5.4 and 4.2.5.6) 
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Appendix 8: Western blots (Figure 4.2.2.3) 
 
 
 
 
 
 
 
 
Protein extracted from decidualizing HESCs.   
Bands from left to right; day 0, day 2, day 4, day 8 of treatment. 
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Appendix 9: Western blots (Figure 4.2.3.1a) 
 
 
 
 
 
 
 
 
Protein extracted from day 4 DESCs treated with UCM (left band) or ECM (right 
band). 
 184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
 185 
 
 
 
 
Achache, H. and Revel, A. (2006) 'Endometrial receptivity markers, the journey to 
successful embryo implantation', Human reproduction update, 12(6), pp. 731-
746. 
Aplin, J., Hey, N. and Li, T. (1996) 'MUC1 as a cell surface and secretory component of 
endometrial epithelium: reduced levels in recurrent miscarriage', American 
Journal of Reproductive Immunology, 35(3), pp. 261-266. 
Aplin, J. D. (1997) 'Adhesion molecules in implantation', Reviews of Reproduction, 2(2), 
pp. 84-93. 
Arici, A., Engin, O., Attar, E. and Olive, D. L. (1995) 'Modulation of leukemia inhibitory 
factor gene expression and protein biosynthesis in human endometrium', The 
Journal of Clinical Endocrinology & Metabolism, 80(6), pp. 1908-1915. 
Baird, D. D., Weinberg, C. R., McConnaughey, D. R. and Wilcox, A. J. (2003) 'Rescue of 
the corpus luteum in human pregnancy', Biology of reproduction, 68(2), pp. 448-
456. 
Baranao, R., Piazza, A., Rumi, L. and Fried, E. (1997) 'Determination of IL‐1 and IL‐6 
Levels in Human Embryo Culture‐Conditioned Media', American journal of 
reproductive immunology, 37(2), pp. 191-194. 
Beaujean, N., Taylor, J., Gardner, J., Wilmut, I., Meehan, R. and Young, L. (2004) 'Effect 
of limited DNA methylation reprogramming in the normal sheep embryo on 
somatic cell nuclear transfer', Biology of reproduction, 71(1), pp. 185-193. 
Bell, C. E., Calder, M. D. and Watson, A. J. (2008) 'Genomic RNA profiling and the 
programme controlling preimplantation mammalian development', Molecular 
human reproduction, 14(12), pp. 691-701. 
Benn, P. (1998) 'Trisomy 16 and trisomy 16 mosaicism: a review', American journal of 
medical genetics, 79(2), pp. 121-133. 
Bentin-Ley, U. (2000) 'Relevance of endometrial pinopodes for human blastocyst 
implantation', Human reproduction (Oxford, England), 15, pp. 67. 
Bettio, D., Venci, A. and Setti, P. L. (2008) 'Chromosomal abnormalities in miscarriages 
after different assisted reproduction procedures', Placenta, 29, pp. 126-128. 
Bhatt, H., Brunet, L. J. and Stewart, C. L. (1991) 'Uterine expression of leukemia 
inhibitory factor coincides with the onset of blastocyst implantation', Proceedings 
of the National Academy of Sciences, 88(24), pp. 11408-11412. 
Bird, G. S., DeHaven, W. I., Smyth, J. T. and Putney, J. W. (2008) 'Methods for studying 
store-operated calcium entry', Methods, 46(3), pp. 204-212. 
Blaszkowska, J. (2005) 'Effect of Ascaris trypsin inhibitor on fetal development of mice', 
Wiadomości Parazytologiczne, 51(2). 
Boomsma, C., Kavelaars, A., Eijkemans, M., Lentjes, E., Fauser, B., Heijnen, C. and 
 186 
 
Macklon, N. (2009) 'Endometrial secretion analysis identifies a cytokine profile 
predictive of pregnancy in IVF', Human Reproduction, 24(6), pp. 1427-1435. 
Bowman, P. and McLaren, A. (1970) 'The reaction of the mouse blastocyst and its zona 
pellucida to enzymes in vitro', Journal of Embryology and Experimental 
Morphology, 24(2), pp. 331-334. 
Braude, P., Bolton, V. and Moore, S. (1988) 'Human gene expression first occurs 
between the four-and eight-cell stages of preimplantation development', Nature, 
332(6163), pp. 459-461. 
Braude, P., Pelham, H., Flach, G. and Lobatto, R. (1979) 'Post-transcriptional control in 
the early mouse embryo'. 
Brosens, J. J., Parker, M. G., McIndoe, A., Pijnenborg, R. and Brosens, I. A. (2009) 'A 
role for menstruation in preconditioning the uterus for successful pregnancy', 
American journal of obstetrics and gynecology, 200(6), pp. 615. e1-615. e6. 
Brosens, J. J., Pijnenborg, R. and Brosens, I. A. (2002) 'The myometrial junctional zone 
spiral arteries in normal and abnormal pregnancies: a review of the literature', 
American journal of obstetrics and gynecology, 187(5), pp. 1416-1423. 
Brosens, J. J., Salker, M. S., Teklenburg, G., Nautiyal, J., Salter, S., Lucas, E. S., Steel, 
J. H., Christian, M., Chan, Y.-W. and Boomsma, C. M. (2014) 'Uterine selection 
of human embryos at implantation', Scientific reports, 4. 
Brubaker, S. W., Bonham, K. S., Zanoni, I. and Kagan, J. C. (2015) 'Innate immune 
pattern recognition: a cell biological perspective', Annual review of immunology, 
33, pp. 257-290. 
Bruns, J. B., Carattino, M. D., Sheng, S., Maarouf, A. B., Weisz, O. A., Pilewski, J. M., 
Hughey, R. P. and Kleyman, T. R. (2007) 'Epithelial Na+ channels are fully 
activated by furin-and prostasin-dependent release of an inhibitory peptide from 
the γ-subunit', Journal of Biological Chemistry, 282(9), pp. 6153-6160. 
Burton, G. J., Jauniaux, E. and Watson, A. L. (1999) 'Maternal arterial connections to the 
placental intervillous space during the first trimester of human pregnancy: the 
Boyd collection revisited', American journal of obstetrics and gynecology, 181(3), 
pp. 718-724. 
Burton, G. J., Watson, A. L., Hempstock, J., Skepper, J. N. and Jauniaux, E. (2002) 
'Uterine glands provide histiotrophic nutrition for the human fetus during the first 
trimester of pregnancy', The Journal of Clinical Endocrinology & Metabolism, 
87(6), pp. 2954-2959. 
Caldwell, R. A., Boucher, R. C. and Stutts, M. J. (2004) 'Serine protease activation of 
near-silent epithelial Na+ channels', American Journal of Physiology-Cell 
Physiology, 286(1), pp. C190-C194. 
Cha, J., Sun, X. and Dey, S. K. (2012) 'Mechanisms of implantation: strategies for 
successful pregnancy', Nature medicine, 18(12), pp. 1754-1767. 
 187 
 
Chan, R. W., Schwab, K. E. and Gargett, C. E. (2004) 'Clonogenicity of human 
endometrial epithelial and stromal cells', Biology of reproduction, 70(6), pp. 1738-
1750. 
Chard, T. (1991) 'Frequency of implantation and early pregnancy loss in natural cycles', 
Baillieres Clin Obstet Gynaecol, 5(1), pp. 179-89. 
Charnock-Jones, D., Sharkey, A., Fenwick, P. and Smith, S. (1994) 'Leukaemia 
inhibitory factor mRNA concentration peaks in human endometrium at the time of 
implantation and the blastocyst contains mRNA for the receptor at this time', 
Journal of Reproduction and Fertility, 101(2), pp. 421-426. 
Chen, G., Bradford, W. D., Seidel, C. W. and Li, R. (2012) 'Hsp90 stress potentiates 
rapid cellular adaptation through induction of aneuploidy', Nature, 482(7384), pp. 
246-250. 
Chraïbi, A., Vallet, V., Firsov, D., Hess, S. K. and Horisberger, J.-D. (1998) 'Protease 
modulation of the activity of the epithelial sodium channel expressed in Xenopus 
oocytes', The Journal of general physiology, 111(1), pp. 127-138. 
Christian, M., Mak, I., White, J. O. and Brosens, J. J. (2002) 'Mechanisms of 
decidualization', Reproductive BioMedicine Online, 4, pp. 24-30. 
Clarke, G. N. (2006) 'ART and history, 1678–1978', Human Reproduction, 21(7), pp. 
1645-1650. 
Corcoran, D., Fair, T., Park, S., Rizos, D., Patel, O., Smith, G., Coussens, P., Ireland, J., 
Boland, M. and Evans, A. (2006) 'Suppressed expression of genes involved in 
transcription and translation in in vitro compared with in vivo cultured bovine 
embryos', Reproduction, 131(4), pp. 651-660. 
Cork, B., Tuckerman, E., Warren, M., Li, T. and Laird, S. 'Expression of LIF and IL-6 in 
endometrial epithelial cells of normal fertile women and women who suffer 
unexplained recurrent miscarriage'. Human Reproduction: OXFORD UNIV 
PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, 228-228. 
COWELL, T. P. (1969) 'Implantation and development of mouse eggs transferred to the 
uteri of non-progestational mice', Journal of reproduction and fertility, 19(2), pp. 
239-245. 
Crosby, I., Gandolfi, F. and Moor, R. (1988) 'Control of protein synthesis during early 
cleavage of sheep embryos', Journal of reproduction and fertility, 82(2), pp. 769-
775. 
De Neubourg, D., Gerris, J., Mangelschots, K., Van Royen, E., Vercruyssen, M. and 
Elseviers, M. (2004) 'Single top quality embryo transfer as a model for prediction 
of early pregnancy outcome', Human Reproduction, 19(6), pp. 1476-1479. 
Demichelis, F., Fall, K., Perner, S., Andrén, O., Schmidt, F., Setlur, S., Hoshida, Y., 
Mosquera, J., Pawitan, Y. and Lee, C. (2007) 'TMPRSS2: ERG gene fusion 
associated with lethal prostate cancer in a watchful waiting cohort', Oncogene, 
 188 
 
26(31), pp. 4596-4599. 
Dobson, A. T., Raja, R., Abeyta, M. J., Taylor, T., Shen, S., Haqq, C. and Pera, R. A. R. 
(2004) 'The unique transcriptome through day 3 of human preimplantation 
development', Human Molecular Genetics, 13(14), pp. 1461-1470. 
Dominguez, F., Yanez-Mo, M., Sanchez-Madrid, F. and Simon, C. (2005) 'Embryonic 
implantation and leukocyte transendothelial migration: different processes with 
similar players?', The FASEB journal, 19(9), pp. 1056-1060. 
Donaldson, S. H., Hirsh, A., Li, D. C., Holloway, G., Chao, J., Boucher, R. C. and 
Gabriel, S. E. (2002) 'Regulation of the epithelial sodium channel by serine 
proteases in human airways', Journal of Biological Chemistry, 277(10), pp. 8338-
8345. 
Dunglison, G., Barlow, D. and Sargent, I. (1996) 'Leukaemia inhibitory factor significantly 
enhances the blastocyst formation rates of human embryos cultured in serum-
free medium', Human Reproduction, 11(1), pp. 191-196. 
Déry, O., Corvera, C. U., Steinhoff, M. and Bunnett, N. W. (1998) 'Proteinase-activated 
receptors: novel mechanisms of signaling by serine proteases', American Journal 
of Physiology-Cell Physiology, 274(6), pp. C1429-C1452. 
Edgar, R., Domrachev, M. and Lash, A. E. (2002) 'Gene Expression Omnibus: NCBI 
gene expression and hybridization array data repository', Nucleic acids research, 
30(1), pp. 207-210. 
Edwards, R., Steptoe, P. and Purdy, J. (1970) 'Fertilization and cleavage in vitro of 
preovulator human oocytes', Nature, 227(5265), pp. 1307-1309. 
Edwards, R., Steptoe, P. and Purdy, J. (1980) 'ESTABLISHING FULL‐TERM HUMAN 
PREGNANCIES USING CLEAVING EMBRYOS GROWN IN VITRO*', BJOG: An 
International Journal of Obstetrics & Gynaecology, 87(9), pp. 737-756. 
Edwards, R. G., Bavister, B. D. and Steptoe, P. C. (1969) 'Early stages of fertilization in 
vitro of human oocytes matured in vitro', Nature, 221, pp. 632-35. 
Emera, D., Romero, R. and Wagner, G. (2012) 'The evolution of menstruation: A new 
model for genetic assimilation', Bioessays, 34(1), pp. 26-35. 
Evsikov, S. and Verlinsky, Y. (1998) 'Mosaicism in the inner cell mass of human 
blastocysts', Human Reproduction, 13(11), pp. 3151-3155. 
Ferretti, C., Bruni, L., Dangles-Marie, V., Pecking, A. and Bellet, D. (2007) 'Molecular 
circuits shared by placental and cancer cells, and their implications in the 
proliferative, invasive and migratory capacities of trophoblasts', Human 
reproduction update, 13(2), pp. 121-141. 
Finn, C. (1966) 'Endocrine control of endometrial sensitivity during the induction of the 
decidual cell reaction in the mouse', Journal of Endocrinology, 36(3), pp. 239-
248. 
Flach, G., Johnson, M., Braude, P., Taylor, R. and Bolton, V. (1982) 'The transition from 
 189 
 
maternal to embryonic control in the 2-cell mouse embryo', The EMBO journal, 
1(6), pp. 681. 
Foote, R. H. and Carney, E. W. (1988) 'Factors limiting reproductive efficiency in 
selected laboratory animals', Ann N Y Acad Sci, 541, pp. 683-96. 
Fragouli, E., Alfarawati, S., Daphnis, D. D., Goodall, N.-n., Mania, A., Griffiths, T., 
Gordon, A. and Wells, D. (2011) 'Cytogenetic analysis of human blastocysts with 
the use of FISH, CGH and aCGH: scientific data and technical evaluation', 
Human Reproduction, 26(2), pp. 480-490. 
Fragouli, E., Alfarawati, S., Spath, K., Jaroudi, S., Sarasa, J., Enciso, M. and Wells, D. 
(2013) 'The origin and impact of embryonic aneuploidy', Human genetics, 132(9), 
pp. 1001-1013. 
Frank (1994) 'Prostaglandin E2 enhances human endometrial stromal cell 
differentiation', Endocrinology, 134(1), pp. 258-263. 
Fronius, M. and Clauss, W. G. (2008) 'Mechano-sensitivity of ENaC: may the (shear) 
force be with you', Pflügers Archiv-European Journal of Physiology, 455(5), pp. 
775-785. 
Fulka, H., Mrazek, M., Tepla, O. and Fulka, J. (2004) 'DNA methylation pattern in human 
zygotes and developing embryos', Reproduction, 128(6), pp. 703-708. 
Gardner, D. K., Lane, M., Stevens, J., Schlenker, T. and Schoolcraft, W. B. (2000) 
'Blastocyst score affects implantation and pregnancy outcome: towards a single 
blastocyst transfer', Fertility and sterility, 73(6), pp. 1155-1158. 
Gargett, C. E. and Masuda, H. (2010) 'Adult stem cells in the endometrium', Molecular 
human reproduction, 16(11), pp. 818-834. 
Gargett, C. E., Schwab, K. E. and Deane, J. A. (2015) 'Endometrial stem/progenitor 
cells: the first 10 years', Human reproduction update, pp. dmv051. 
Garty, H. and Palmer, L. G. (1997) 'Epithelial sodium channels: function, structure, and 
regulation', Physiological reviews, 77(2), pp. 359-396. 
Gee, K. R., Brown, K., Chen, W. U., Bishop-Stewart, J., Gray, D. and Johnson, I. (2000) 
'Chemical and physiological characterization of fluo-4 Ca 2+-indicator dyes', Cell 
calcium, 27(2), pp. 97-106. 
Gellersen, B., Brosens, I. A. and Brosens, J. J. (2007) 'Decidualization of the human 
endometrium: mechanisms, functions, and clinical perspectives', Seminars In 
Reproductive Medicine, 25(6), pp. 445-453. 
Gellersen, B. and Brosens, J. (2003) 'Cyclic AMP and progesterone receptor cross-talk 
in human endometrium: a decidualizing affair', Journal of Endocrinology, 178(3), 
pp. 357-372. 
Gellersen, B. and Brosens, J. J. (2014) 'Cyclic decidualization of the human 
endometrium in reproductive health and failure', Endocrine reviews, 35(6), pp. 
851-905. 
 190 
 
Genbacev, O. D., Prakobphol, A., Foulk, R. A., Krtolica, A. R., Ilic, D., Singer, M. S., 
Yang, Z.-Q., Kiessling, L. L., Rosen, S. D. and Fisher, S. J. (2003) 'Trophoblast 
L-selectin-mediated adhesion at the maternal-fetal interface', Science Signaling, 
299(5605), pp. 405. 
Gleicher, N., Kushnir, V. A. and Barad, D. H. (2014) 'Preimplantation genetic screening 
(PGS) still in search of a clinical application: a systematic review', Reprod Biol 
Endocrinol, 12(1), pp. 22. 
Gray, C. A., Bartol, F. F., Tarleton, B. J., Wiley, A. A., Johnson, G. A., Bazer, F. W. and 
Spencer, T. E. (2001) 'Developmental biology of uterine glands', Biology of 
reproduction, 65(5), pp. 1311-1323. 
Greco, E., Minasi, M. G. and Fiorentino, F. (2015) 'Healthy Babies after Intrauterine 
Transfer of Mosaic Aneuploid Blastocysts', New England Journal of Medicine, 
373(21), pp. 2089-2090. 
Grewal, S., Carver, J. G., Ridley, A. J. and Mardon, H. J. (2008) 'Implantation of the 
human embryo requires Rac1-dependent endometrial stromal cell migration', 
Proceedings of the National Academy of Sciences, 105(42), pp. 16189-16194. 
Groothuis, P. G., Dassen, H. H. N. M., Romano, A. and Punyadeera, C. (2007) 
'Estrogen and the endometrium: lessons learned from gene expression profiling 
in rodents and human', Human Reproduction Update, 13(4), pp. 405-417. 
Gutiérrez-Mateo, C., Colls, P., Sánchez-García, J., Escudero, T., Prates, R., Ketterson, 
K., Wells, D. and Munné, S. (2011) 'Validation of microarray comparative 
genomic hybridization for comprehensive chromosome analysis of embryos', 
Fertility and sterility, 95(3), pp. 953-958. 
Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield, C., Natanson-Yaron, 
S., Prus, D., Cohen-Daniel, L., Arnon, T. I. and Manaster, I. (2006) 'Decidual NK 
cells regulate key developmental processes at the human fetal-maternal 
interface', Nature medicine, 12(9), pp. 1065-1074. 
Hassold, T. and Hunt, P. (2001) 'To err (meiotically) is human: the genesis of human 
aneuploidy', Nature Reviews Genetics, 2(4), pp. 280-291. 
Henriet, P., Chevronnay, H. P. G. and Marbaix, E. (2012) 'The endocrine and paracrine 
control of menstruation', Molecular and cellular endocrinology, 358(2), pp. 197-
207. 
Hertig, A. T., Rock, J. and Adams, E. C. (1956) 'A description of 34 human ova within 
the first 17 days of development', American Journal of Anatomy, 98(3), pp. 435-
493. 
Hertig, A. T., Rock, J., Adams, E. C. and Mulligan, W. J. (1954) 'ON THE 
PREIMPLANTATION STAGES OF THE HUMAN OVUM-A DESCRIPTION OF 4 
NORMAL AND 4 ABNORMAL SPECIMENS RANGING FROM THE 2ND TO 
THE 5TH DAY OF DEVELOPMENT', Contributions to Embryology, 35(240), pp. 
 191 
 
201-&. 
Hirata, T., Osuga, Y., Hamasaki, K., Hirota, Y., Nose, E., Morimoto, C., Harada, M., 
Takemura, Y., Koga, K. and Yoshino, O. (2007) 'Expression of toll-like receptors 
2, 3, 4, and 9 genes in the human endometrium during the menstrual cycle', 
Journal of reproductive immunology, 74(1), pp. 53-60. 
Hirata, T., Osuga, Y., Hirota, Y., Koga, K., Yoshino, O., Harada, M., Morimoto, C., Yano, 
T., Nishii, O. and Tsutsumi, O. (2005) 'Evidence for the presence of toll-like 
receptor 4 system in the human endometrium', The Journal of Clinical 
Endocrinology & Metabolism, 90(1), pp. 548-556. 
Hirota, Y., Osuga, Y., Hirata, T., Koga, K., Yoshino, O., Harada, M., Morimoto, C., Nose, 
E., Yano, T. and Tsutsumi, O. (2005) 'Evidence for the presence of protease-
activated receptor 2 and its possible implication in remodeling of human 
endometrium', The Journal of Clinical Endocrinology & Metabolism, 90(3), pp. 
1662-1669. 
Holm, P., Booth, P. and Callesen, H. (2002) 'Kinetics of early in vitro development of 
bovine in vivo-and in vitro-derived zygotes produced and/or cultured in 
chemically defined or serum-containing media', Reproduction, 123(4), pp. 553-
565. 
Holmes, P. and Gordashko, B. (1980) 'Evidence of prostaglandin involvement in 
blastocyst implantation', Journal of embryology and experimental morphology, 
55(1), pp. 109-122. 
Holmes, P., Sjögren, A. and Hamberger, L. (1990) 'Prostaglandin-E2 released by pre-
implantation human conceptuses', Journal of reproductive immunology, 17(1), 
pp. 79-86. 
Huang, J.-C., Wun, W.-S. A., Goldsby, J. S., Matijevic-Aleksic, N. and Wu, K. K. (2004) 
'Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo 
hatching', Human Reproduction, 19(12), pp. 2900-2906. 
Hummler, E., Dousse, A., Rieder, A., Stehle, J.-C., Rubera, I., Osterheld, M.-C., 
Beermann, F., Frateschi, S. and Charles, R.-P. (2013) 'The channel-activating 
protease CAP1/Prss8 is required for placental labyrinth maturation', PloS one, 
8(2). 
Hustin, J. and Schaaps, J.-P. (1987) 'Echocardiograhic and anatomic studies of the 
maternotrophoblastic border during the first trimester of pregnancy', American 
journal of obstetrics and gynecology, 157(1), pp. 162-168. 
Ichikawa, S., Shibata, T., Takehara, Y., Tamada, H., Oda, K. and Murao, S. (1985) 
'Effects of proteinase inhibitors on preimplantation embryos in the rat', Journal of 
reproduction and fertility, 73(2), pp. 385-390. 
Ir, S. T. A., Toskess, P. P., Liddle, R. and McGrath, K. (1996) 'Hereditary pancreatitis is 
caused by a mutation in the cationic trypsinogen gene', Nature genetics, 14. 
 192 
 
Itoh, H., Tomita, M., Kobayashi, T., Uchino, H., Maruyama, H. and Nawa, Y. (1996) 
'Expression of inter-α-trypsin inhibitor light chain (bikunin) in human pancreas', 
Journal of biochemistry, 120(2), pp. 271-275. 
Jack, X. Y., Chao, L. and Chao, J. (1995) 'Molecular cloning, tissue-specific expression, 
and cellular localization of human prostasin mRNA', Journal of Biological 
Chemistry, 270(22), pp. 13483-13489. 
Jaffe, R., Jauniaux, E. and Hustin, J. (1997) 'Maternal circulation in the first-trimester 
human placenta—myth or reality?', American journal of obstetrics and 
gynecology, 176(3), pp. 695-705. 
Jauniaux, E., Farquharson, R. G., Christiansen, O. B. and Exalto, N. (2006) 'Evidence-
based guidelines for the investigation and medical treatment of recurrent 
miscarriage', Human reproduction, 21(9), pp. 2216-2222. 
Jauniaux, E., Watson, A. L., Hempstock, J., Bao, Y.-P., Skepper, J. N. and Burton, G. J. 
(2000) 'Onset of maternal arterial blood flow and placental oxidative stress: a 
possible factor in human early pregnancy failure', The American journal of 
pathology, 157(6), pp. 2111-2122. 
Jauniaux, E., Zaidi, J., Jurkovic, D., Campbell, S. and Hustin, J. (1994) 'Pregnancy: 
Comparison of colour Doppler features and pathological findings in complicated 
early pregnancy', Human reproduction, 9(12), pp. 2432-2437. 
Jiang, Y.-h., Shi, Y., He, Y.-p., Du, J., Li, R.-s., Shi, H.-j., Sun, Z.-g. and Wang, J. (2011) 
'Serine protease inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF) inhibits the rat embryo implantation in vivo and interferes with cell 
adhesion in vitro', Contraception, 84(6), pp. 642-648. 
Jones, H. W. (2003) 'IVF: past and future', Reproductive biomedicine online, 6(3), pp. 
375-381. 
Jurisicova, A., Antenos, M., Kapasi, K., Meriano, J. and Casper, R. F. (1999) 'Variability 
in the expression of trophectodermal markers β-human chorionic gonadotrophin, 
human leukocyte antigen-G and pregnancy specific β-1 glycoprotein by the 
human blastocyst', Human Reproduction, 14(7), pp. 1852-1858. 
Kane, M. (1986) 'A survey of the effects of proteases and glycosidases on culture of 
rabbit morulae to blastocysts', Journal of reproduction and fertility, 78(1), pp. 225-
230. 
Kauma, S. W. and Matt, D. W. (1995) 'Coculture cells that express leukemia inhibitory 
factor (LIF) enhance mouse blastocyst developmentin vitro', Journal of assisted 
reproduction and genetics, 12(2), pp. 153-156. 
Kellenberger, S. and Schild, L. (2002) 'Epithelial sodium channel/degenerin family of ion 
channels: a variety of functions for a shared structure', Physiological reviews, 
82(3), pp. 735-767. 
Kim, T. S., Heinlein, C., Hackman, R. C. and Nelson, P. S. (2006) 'Phenotypic analysis 
 193 
 
of mice lacking the Tmprss2-encoded protease', Molecular and cellular biology, 
26(3), pp. 965-975. 
Klentzeris, L., Bulmer, J., Trejdosiewicz, L., Morrison, L. and Cooke, I. (1993) 'Infertility: 
Beta-1 integrin cell adhesion molecules in the endometrium of fertile and infertile 
women', Human Reproduction, 8(8), pp. 1223-1230. 
Kleyman, T. R., Carattino, M. D. and Hughey, R. P. (2009) 'ENaC at the cutting edge: 
regulation of epithelial sodium channels by proteases', Journal of Biological 
Chemistry, 284(31), pp. 20447-20451. 
Knijn, H. M., Wrenzycki, C., Hendriksen, P. J., Vos, P. L., Zeinstra, E. C., van der 
Weijden, G. C., Niemann, H. and Dieleman, S. J. (2006) 'In vitro and in vivo 
culture effects on mRNA expression of genes involved in metabolism and 
apoptosis in bovine embryos', Reproduction, Fertility and Development, 17(8), 
pp. 775-784. 
Knobil, E. (2013) 'The neuroendocrine control of the menstrual cycle', Recent progress 
in hormone research, 36, pp. 53-88. 
Kojima, K., Kanzaki, H., Iwai, M., Hatayama, H., Fujimoto, M., Inoue, T., Horie, K., 
Nakayama, H., Fujita, J. and Mori, T. (1994) 'Expression of leukemia inhibitory 
factor in human endometrium and placenta', Biology of Reproduction, 50(4), pp. 
882-887. 
Komatsu, H., Shimose, A., Shimizu, T., Mukai, Y., Kobayashi, J., Ohama, T. and Sato, 
K. (2012) 'Trypsin inhibits lipopolysaccharide signaling in macrophages via toll-
like receptor 4 accessory molecules', Life sciences, 91(3), pp. 143-150. 
Koot, Y., Boomsma, C., Eijkemans, M., Lentjes, E. and Macklon, N. 'Is pre-clinical 
pregnancy loss a ëcauseí of unexplained infertility?'. HUMAN REPRODUCTION: 
OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, 
ENGLAND, I29-I30. 
Koot, Y. E., van Hooff, S. R., Boomsma, C. M., van Leenen, D., Koerkamp, M. J. G., 
Goddijn, M., Eijkemans, M. J., Fauser, B. C., Holstege, F. C. and Macklon, N. S. 
(2016) 'An endometrial gene expression signature accurately predicts recurrent 
implantation failure after IVF', Scientific Reports, 6, pp. 19411. 
Koot, Y. E. M., Teklenburg, G., Salker, M. S., Brosens, J. J. and Macklon, N. S. (2012) 
'Molecular aspects of implantation failure', Biochimica et biophysica acta, 
1822(12). 
Kubo, H., Spindle, A. and Pedersen, R. A. (1981) 'Inhibition of mouse blastocyst 
attachment and outgrowth by protease inhibitors', Journal of Experimental 
Zoology, 216(3), pp. 445-451. 
Kunitz, M. (1939) 'Formation of trypsin from crystalline trypsinogen by means of 
enterokinase', The Journal of general physiology, 22(4), pp. 429-446. 
Kuokkanen, S., Chen, B., Ojalvo, L., Benard, L., Santoro, N. and Pollard, J. W. (2010) 
 194 
 
'Genomic profiling of microRNAs and messenger RNAs reveals hormonal 
regulation in microRNA expression in human endometrium', Biology of 
reproduction, 82(4), pp. 791-801. 
Laird, S., Tuckerman, E., Cork, B., Linjawi, S., Blakemore, A. and Li, T. (2003) 'A review 
of immune cells and molecules in women with recurrent miscarriage', Human 
reproduction update, 9(2), pp. 163-174. 
Laird, S., Tuckerman, E., Dalton, C., Dunphy, B., Li, T. and Zhang, X. (1997) 'The 
production of leukaemia inhibitory factor by human endometrium: presence in 
uterine flushings and production by cells in culture', Human Reproduction, 12(3), 
pp. 569-574. 
Laird, S., Tuckerman, E., Li, T. and Bolton, A. (1994) 'Implantation: Stimulation of human 
endometrial epithelial cell interleukin 6 production by interleukin 1 and placental 
protein 14', Human Reproduction, 9(7), pp. 1339-1343. 
Lalitkumar, S., Boggavarapu, N. R., Menezes, J., Dimitriadis, E., Zhang, J.-G., Nicola, N. 
A., Gemzell-Danielsson, K. and Lalitkumar, L. P. (2013) 'Polyethylene glycated 
leukemia inhibitory factor antagonist inhibits human blastocyst implantation and 
triggers apoptosis by down-regulating embryonic AKT', Fertility and sterility, 
100(4), pp. 1160-1169. e2. 
Leitao, B., Jones, M. C., Fusi, L., Higham, J., Lee, Y., Takano, M., Goto, T., Christian, 
M., Lam, E. W.-F. and Brosens, J. J. (2010) 'Silencing of the JNK pathway 
maintains progesterone receptor activity in decidualizing human endometrial 
stromal cells exposed to oxidative stress signals', The FASEB Journal, 24(5), pp. 
1541-1551. 
Lejeune, B., Lecocq, R., Lamy, F. and Leroy, F. (1982) 'Changes in the pattern of 
endometrial protein synthesis during decidualization in the rat', Journal of 
reproduction and fertility, 66(2), pp. 519-523. 
Lejeune, B., Van Hoeck, J. and Leroy, F. (1981) 'Transmitter role of the luminal uterine 
epithelium in the induction of decidualization in rats', Journal of reproduction and 
fertility, 61(1), pp. 235-240. 
Lessey, B., Castelbaum, A., Sawin, S. and Sun, J. (1995) 'Integrins as markers of 
uterine receptivity in women with primary unexplained infertility', Fertility and 
sterility, 63(3), pp. 535-542. 
Li, Q., Wang, J., Armant, D. R., Bagchi, M. K. and Bagchi, I. C. (2002) 'Calcitonin down-
regulates E-cadherin expression in rodent uterine epithelium during implantation', 
Journal of Biological Chemistry, 277(48), pp. 46447-46455. 
Liew, F. Y., Xu, D., Brint, E. K. and O'Neill, L. A. (2005) 'Negative regulation of toll-like 
receptor-mediated immune responses', Nature Reviews Immunology, 5(6), pp. 
446-458. 
Lim, H. and Dey, S. (1997) 'Prostaglandin E2 Receptor Subtype EP2 Gene Expression 
 195 
 
in the Mouse Uterus Coincides with Differentiation of the Luminal Epithelium for 
Implantation 1', Endocrinology, 138(11), pp. 4599-4606. 
Lim, H., Gupta, R. A., Ma, W.-g., Paria, B. C., Moller, D. E., Morrow, J. D., DuBois, R. 
N., Trzaskos, J. M. and Dey, S. K. (1999) 'Cyclo-oxygenase-2-derived 
prostacyclin mediates embryo implantation in the mouse via PPARδ', Genes & 
development, 13(12), pp. 1561-1574. 
Lim, K. J., Odukoya, O. A., Ajjan, R. A., Li, T.-C., Weetman, A. P. and Cooke, I. D. 
(2000) 'The role of T-helper cytokines in human reproduction', Fertility and 
sterility, 73(1), pp. 136-142. 
Lin, H. Y., Zhang, H., Yang, Q., Wang, H. X., Wang, H. M., Chai, K. X., Chen, L. M. and 
Zhu, C. (2006) 'Expression of prostasin and protease nexin-1 in rhesus monkey 
(Macaca mulatta) endometrium and placenta during early pregnancy', J 
Histochem Cytochem, 54(10), pp. 1139-47. 
Lindsay, L. L. and Hedrick, J. L. (1998) 'Treatment of Xenopus laevis coelomic eggs with 
trypsin mimics pars recta oviductal transit by selectively hydrolyzing envelope 
glycoprotein gp43, increasing sperm binding to the envelope, and rendering eggs 
fertilizable', Journal of Experimental Zoology, 281(2), pp. 132-138. 
Liu, Y., Yin, H., Zhao, M. and Lu, Q. (2014) 'TLR2 and TLR4 in autoimmune diseases: a 
comprehensive review', Clinical reviews in allergy & immunology, 47(2), pp. 136-
147. 
Lonergan, P. and Fair, T. (2008) 'In vitro-produced bovine embryos—Dealing with the 
warts', Theriogenology, 69(1), pp. 17-22. 
Lopes, A., Madsen, S., Ramsing, N., Løvendahl, P., Greve, T. and Callesen, H. (2007) 
'Investigation of respiration of individual bovine embryos produced in vivo and in 
vitro and correlation with viability following transfer', Human Reproduction, 22(2), 
pp. 558-566. 
Lopes, F. L., Desmarais, J. A. and Murphy, B. D. (2004) 'Embryonic diapause and its 
regulation', Reproduction, 128(6), pp. 669-678. 
Lu, Y.-C., Yeh, W.-C. and Ohashi, P. S. (2008) 'LPS/TLR4 signal transduction pathway', 
Cytokine, 42(2), pp. 145-151. 
Lucas, E. S., Dyer, N. P., Murakami, K., Hou Lee, Y., Chan, Y. W., Grimaldi, G., Muter, 
J., Brighton, P. J., Moore, J. D. and Patel, G. (2015) 'Loss of Endometrial 
Plasticity in Recurrent Pregnancy Loss', STEM CELLS. 
Lucas, E. S., Salker, M. S. and Brosens, J. J. (2013) 'Uterine plasticity and reproductive 
fitness', Reproductive biomedicine online, 27(5), pp. 506-514. 
Luo, D., Zhang, Y., Bai, Y., Liu, X., Gong, Y., Zhou, B., Zhang, L., Luo, L. and Zhou, R. 
(2014) 'Prostasin gene polymorphism at rs12597511 is associated with severe 
preeclampsia in Chinese Han women', Chin Med J (Engl), 127(11), pp. 2048-52. 
Ma, X. J., Fu, Y. Y., Li, Y. X., Chen, L. M., Chai, K. and Wang, Y. L. (2009) 'Prostasin 
 196 
 
inhibits cell invasion in human choriocarcinomal JEG-3 cells', Histochem Cell 
Biol, 132(6), pp. 639-46. 
Macklon, N. S. and Brosens, J. J. (2014) 'The human endometrium as a sensor of 
embryo quality', Biology of reproduction, 91(4), pp. 98. 
Macklon, N. S., Geraedts, J. P. and Fauser, B. C. (2002) 'Conception to ongoing 
pregnancy: the ‘black box’of early pregnancy loss', Human Reproduction Update, 
8(4), pp. 333-343. 
Magli, M., Jones, G., Gras, L., Gianaroli, L., Korman, I. and Trounson, A. (2000) 
'Chromosome mosaicism in day 3 aneuploid embryos that develop to 
morphologically normal blastocysts in vitro', Human Reproduction, 15(8), pp. 
1781-1786. 
Markee, J. (1978) 'Menstruation in intraocular endometrial transplants in the Rhesus 
monkey', American journal of obstetrics and gynecology, 131(5), pp. 558-559. 
Mastenbroek, S., Twisk, M., van der Veen, F. and Repping, S. (2011) 'Preimplantation 
genetic screening: a systematic review and meta-analysis of RCTs', Human 
reproduction update, 17(4), pp. 454-466. 
Mastenbroek, S., Twisk, M., van Echten-Arends, J., Sikkema-Raddatz, B., Korevaar, J. 
C., Verhoeve, H. R., Vogel, N. E., Arts, E. G., De Vries, J. W. and Bossuyt, P. M. 
(2007) 'In vitro fertilization with preimplantation genetic screening', New England 
Journal of Medicine, 357(1), pp. 9-17. 
Masuda, H., Matsuzaki, Y., Hiratsu, E., Ono, M., Nagashima, T., Kajitani, T., Arase, T., 
Oda, H., Uchida, H. and Asada, H. (2010) 'Stem cell-like properties of the 
endometrial side population: implication in endometrial regeneration', PloS one, 
5(4), pp. e10387. 
Matsumoto, H., Ma, W.-g., Smalley, W., Trzaskos, J., Breyer, R. M. and Dey, S. K. 
(2001) 'Diversification of Cyclooxygenase-2-Derived Prostaglandins in Ovulation 
and Implantation', Biology of Reproduction, 64(5), pp. 1557-1565. 
McHughes, C., Springer, G., Spate, L., Li, R., Woods, R., Green, M., Korte, S., Murphy, 
C., Green, J. and Prather, R. (2009) 'Identification and quantification of 
differentially represented transcripts in in vitro and in vivo derived preimplantation 
bovine embryos', Molecular reproduction and development, 76(1), pp. 48-60. 
Mertzanidou, A., Wilton, L., Cheng, J., Spits, C., Vanneste, E., Moreau, Y., Vermeesch, 
J. and Sermon, K. (2013) 'Microarray analysis reveals abnormal chromosomal 
complements in over 70% of 14 normally developing human embryos', Human 
Reproduction, 28(1), pp. 256-264. 
Meseguer, M., Aplin, J. D., Caballero-Campo, P., O'Connor, J. E., Martín, J. C., Remohí, 
J., Pellicer, A. and Simón, C. (2001) 'Human endometrial mucin MUC1 is up-
regulated by progesterone and down-regulated in vitro by the human blastocyst', 
Biology of reproduction, 64(2), pp. 590-601. 
 197 
 
Mishra, A. and Seshagiri, P. (2000) 'Evidence for the involvement of a species-specific 
embryonic protease in zona escape of hamster blastocysts', Molecular human 
reproduction, 6(11), pp. 1005-1012. 
Miyazaki, K., Maruyama, T., Masuda, H., Yamasaki, A., Uchida, S., Oda, H., Uchida, H. 
and Yoshimura, Y. (2012) 'Stem cell-like differentiation potentials of endometrial 
side population cells as revealed by a newly developed in vivo endometrial stem 
cell assay'. 
Moffett, A. and Loke, C. (2006) 'Immunology of placentation in eutherian mammals', 
Nature Reviews Immunology, 6(8), pp. 584-594. 
Moor, R. and Cragle, R. (1971) 'The sheep egg: enzymatic removal of the zona pellucida 
and culture of eggs in vitro', Journal of reproduction and fertility, 27(3), pp. 401-
409. 
Mor, G., Cardenas, I., Abrahams, V. and Guller, S. (2011) 'Inflammation and pregnancy: 
the role of the immune system at the implantation site', Annals of the New York 
Academy of Sciences, 1221(1), pp. 80-87. 
Muter, J. 2015. Uncoupling of circadian and other maternal cues in decidualizing 
endometrial cells. PhD thesis, University of Warwick. 
Muter, J., Lucas, E. S., Chan, Y.-W., Brighton, P. J., Moore, J. D., Lacey, L., Quenby, S., 
Lam, E. W.-F. and Brosens, J. J. (2015) 'The clock protein period 2 synchronizes 
mitotic expansion and decidual transformation of human endometrial stromal 
cells', The FASEB Journal, 29(4), pp. 1603-1614. 
Nachtigall, M. J., Kliman, H. J., Feinberg, R. F., Olive, D. L., Engin, O. and Arici, A. 
(1996) 'The effect of leukemia inhibitory factor (LIF) on trophoblast differentiation: 
a potential role in human implantation', The Journal of Clinical Endocrinology & 
Metabolism, 81(2), pp. 801-806. 
Niakan, K. K., Han, J., Pedersen, R. A., Simon, C. and Pera, R. A. R. (2012) 'Human 
pre-implantation embryo development', Development, 139(5), pp. 829-841. 
Nikas, G., Drakakis, P., Loutradis, D., Mara-Skoufari, C., Koumantakis, E., Michalas, S. 
and Psychoyos, A. (1995) 'Implantation: Uterine pinopodes as markers of the 
‘nidation window’in cycling women receiving exogenous oestradiol and 
progesterone', Human Reproduction, 10(5), pp. 1208-1213. 
Nikas, G. and Psychoyos, A. (1997) 'Uterine Pinopodes in Peri‐implantation Human 
Endometrium Clinical Relevance', Annals of the New York Academy of Sciences, 
816(1), pp. 129-142. 
Norwitz, E. R., Schust, D. J. and Fisher, S. J. (2001) 'Implantation and the survival of 
early pregnancy', New England Journal of Medicine, 345(19), pp. 1400-1408. 
Noyes, R., Hertig, A. and Rock, J. (1950) 'Dating the endometrial biopsy', Obstetrical & 
Gynecological Survey, 5(4), pp. 561-564. 
Nystedt, S., Emilsson, K., Larsson, A. K., Strömbeck, B. and Sundelin, J. (1995) 
 198 
 
'Molecular Cloning and Functional Expression of the Gene Encoding the Human 
Proteinase‐Activated Receptor 2', European Journal of Biochemistry, 232(1), pp. 
84-89. 
O'Sullivan, C. M., Rancourt, S. L., Liu, S. Y. and Rancourt, D. E. (2001) 'A novel murine 
tryptase involved in blastocyst hatching and outgrowth', Reproduction, 122(1), 
pp. 61-71. 
Panter, G. and Jerala, R. (2011) 'The ectodomain of the Toll-like receptor 4 prevents 
constitutive receptor activation', Journal of Biological Chemistry, 286(26), pp. 
23334-23344. 
Patel, A. N., Park, E., Kuzman, M., Benetti, F., Silva, F. J. and Allickson, J. G. (2008) 
'Multipotent menstrual blood stromal stem cells: isolation, characterization, and 
differentiation', Cell transplantation, 17(3), pp. 303-311. 
Patrizio, P. and Sakkas, D. (2009) 'From oocyte to baby: a clinical evaluation of the 
biological efficiency of in vitro fertilization', Fertility and sterility, 91(4), pp. 1061-
1066. 
Peng, Q., Yang, H., Xue, S., Shi, L., Yu, Q. and Kuang, Y. (2012) 'Secretome profile of 
mouse oocytes after activation using mass spectrum', Journal of assisted 
reproduction and genetics, 29(8), pp. 765-771. 
Perona, R. M. and Wassarman, P. M. (1986) 'Mouse blastocysts hatch< i> in vitro</i> by 
using a trypsin-like proteinase associated with cells of mural trophectoderm', 
Developmental biology, 114(1), pp. 42-52. 
Puente, X. S., Sánchez, L. M., Overall, C. M. and López-Otín, C. (2003) 'Human and 
mouse proteases: a comparative genomic approach', Nature Reviews Genetics, 
4(7), pp. 544-558. 
Quenby, S., Anim-Somuah, M., Kalumbi, C., Farquharson, R. and Aplin, J. D. (2007) 
'Different types of recurrent miscarriage are associated with varying patterns of 
adhesion molecule expression in endometrium', Reproductive biomedicine 
online, 14(2), pp. 224-234. 
Quenby, S., Vince, G., Farquharson, R. and Aplin, J. (2002) 'Recurrent miscarriage: a 
defect in nature’s quality control?', Human reproduction, 17(8), pp. 1959-1963. 
Quinn, C., Ryan, E., Claessens, E. A., Greenblatt, E., Hawrylyshyn, P., Cruickshank, B., 
Hannam, T., Dunk, C. and Casper, R. F. (2007) 'The presence of pinopodes in 
the human endometrium does not delineate the implantation window', Fertility 
and sterility, 87(5), pp. 1015-1021. 
Rai, R. and Regan, L. (2006) 'Recurrent miscarriage', The Lancet, 368(9535), pp. 601-
611. 
Revel, A., Achache, H., Stevens, J., Smith, Y. and Reich, R. (2011) 'MicroRNAs are 
associated with human embryo implantation defects', Human reproduction, 
26(10), pp. 2830-2840. 
 199 
 
Robertson, S. A., Chin, P. Y., Glynn, D. J. and Thompson, J. G. (2011) 'Peri‐Conceptual 
Cytokines–Setting the Trajectory for Embryo Implantation, Pregnancy and 
Beyond', American Journal of Reproductive Immunology, 66(s1), pp. 2-10. 
Rogers, P. A. (1996) 'Structure and function of endometrial blood vessels', Human 
reproduction update, 2(1), pp. 57-62. 
Ruan, Y. C., Guo, J. H., Liu, X., Zhang, R., Tsang, L. L., Da Dong, J., Chen, H., Yu, M. 
K., Jiang, X. and Zhang, X. H. (2012) 'Activation of the epithelial Na+ channel 
triggers prostaglandin E2 release and production required for embryo 
implantation', Nature medicine, 18(7), pp. 1112-1117. 
Ruan, Y. C., Wang, Z., Du, J. Y., Zuo, W. L., Guo, J. H., Zhang, J., Wu, Z. L., Wong, H. 
Y., Chung, Y. W. and Chan, H. C. (2008) 'Regulation of smooth muscle 
contractility by the epithelium in rat vas deferens: role of ATP‐induced release of 
PGE2', The Journal of physiology, 586(20), pp. 4843-4857. 
Ruan, Y. C., Zhou, W. and Chan, H. C. (2011) 'Regulation of smooth muscle contraction 
by the epithelium: role of prostaglandins', Physiology, 26(3), pp. 156-170. 
Rubio, C., Bellver, J., Rodrigo, L., Bosch, E., Mercader, A., Vidal, C., De los Santos, M. 
J., Giles, J., Labarta, E. and Domingo, J. (2013) 'Preimplantation genetic 
screening using fluorescence in situ hybridization in patients with repetitive 
implantation failure and advanced maternal age: two randomized trials', Fertility 
and sterility, 99(5), pp. 1400-1407. 
Rubio, C., Simon, C., Vidal, F., Rodrigo, L., Pehlivan, T., Remohi, J. and Pellicer, A. 
(2003) 'Chromosomal abnormalities and embryo development in recurrent 
miscarriage couples', Human Reproduction, 18(1), pp. 182-188. 
Saboia-Vahia, L., Borges-Veloso, A., Mesquita-Rodrigues, C., Cuervo, P., Dias-Lopes, 
G., Britto, C., de Barros Silva, A. P. and De Jesus, J. B. (2013) 'Trypsin-like 
serine peptidase profiles in the egg, larval, and pupal stages of Aedes 
albopictus', Parasites & vectors, 6(1), pp. 1-11. 
Sakoff, J. and Murdoch, R. (1996) 'The role of calcium in the artificially induced decidual 
cell reaction in pseudopregnant mice', Biochemical and molecular medicine, 
57(2), pp. 81-90. 
Salamonsen, L. A. and Nie, G. (2002) 'Proteases at the endometrial–trophoblast 
interface: their role in implantation', Reviews in Endocrine and Metabolic 
Disorders, 3(2), pp. 133-143. 
Salamonsen, L. A., Zhang, J. and Brasted, M. (2002) 'Leukocyte networks and human 
endometrial remodelling', Journal of reproductive immunology, 57(1), pp. 95-108. 
Salker, M., Teklenburg, G., Molokhia, M., Lavery, S., Trew, G., Aojanepong, T., Mardon, 
H. J., Lokugamage, A. U., Rai, R. and Landles, C. (2010) 'Natural selection of 
human embryos: impaired decidualization of endometrium disables embryo-
maternal interactions and causes recurrent pregnancy loss', PloS one, 5(4), pp. 
 200 
 
e10287. 
Salker, M. S., Christian, M., Steel, J. H., Nautiyal, J., Lavery, S., Trew, G., Webster, Z., 
Al-Sabbagh, M., Puchchakayala, G. and Föller, M. (2011) 'Deregulation of the 
serum-and glucocorticoid-inducible kinase SGK1 in the endometrium causes 
reproductive failure', Nature medicine, 17(11), pp. 1509-1513. 
Salker, M. S., Nautiyal, J., Steel, J. H., Webster, Z., Šućurović, S., Nicou, M., Singh, Y., 
Lucas, E. S., Murakami, K. and Chan, Y.-W. (2012) 'Disordered IL-33/ST2 
activation in decidualizing stromal cells prolongs uterine receptivity in women 
with recurrent pregnancy loss', PLoS One, 7(12), pp. e52252. 
Sandalinas, M., Sadowy, S., Alikani, M., Calderon, G., Cohen, J. and Munné, S. (2001) 
'Developmental ability of chromosomally abnormal human embryos to develop to 
the blastocyst stage', Human Reproduction, 16(9), pp. 1954-1958. 
Sandra, O. and Renard, J.-P. (2011) 'The endometrium is an early biosensor of the 
embryo capacity to develop to term'. 
Santos, M. A., Teklenburg, G., Macklon, N. S., Van Opstal, D., Schuring-Blom, G. H., 
Krijtenburg, P.-J., de Vreeden-Elbertse, J., Fauser, B. C. and Baart, E. B. (2010) 
'The fate of the mosaic embryo: chromosomal constitution and development of 
Day 4, 5 and 8 human embryos', Human Reproduction, 25(8), pp. 1916-1926. 
Sawada, H., Yamazaki, K. and Hoshi, M. (1990) 'Trypsin‐like hatching protease from 
mouse embryos: evidence for the presence in culture medium and its enzymatic 
properties', Journal of Experimental Zoology, 254(1), pp. 83-87. 
Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Fukudome, K., Miyake, K. and Kimoto, M. 
(1999) 'MD-2, a molecule that confers lipopolysaccharide responsiveness on 
Toll-like receptor 4', The Journal of experimental medicine, 189(11), pp. 1777-
1782. 
Simmons, D. G., Fortier, A. L. and Cross, J. C. (2007) 'Diverse subtypes and 
developmental origins of trophoblast giant cells in the mouse placenta', 
Developmental biology, 304(2), pp. 567-578. 
Simon, C., Frances, A., Piquette, G., El Danasouri, I., Zurawski, G., Dang, W. and 
Polan, M. (1994) 'Embryonic implantation in mice is blocked by interleukin-1 
receptor antagonist', Endocrinology, 134(2), pp. 521-528. 
Simón, C., Gimeno, M. J., Mercader, A., O’Connor, J. E., RemohÍ, J., Polan, M. L. and 
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Human embryos frequently harbor large-scale complex chromosomal errors that impede normal
development. Affected embryos may fail to implant although many first breach the endometrial epithelium
and embed in the decidualizing stroma before being rejected via mechanisms that are poorly understood.
Here we show that developmentally impaired human embryos elicit an endoplasmic stress response in
human decidual cells. A stress response was also evident upon in vivo exposure of mouse uteri to culture
medium conditioned by low-quality human embryos. By contrast, signals emanating from developmentally
competent embryos activated a focused gene network enriched in metabolic enzymes and implantation
factors. We further show that trypsin, a serine protease released by pre-implantation embryos, elicits Ca21
signaling in endometrial epithelial cells. Competent human embryos triggered short-lived oscillatory Ca21
fluxes whereas low-quality embryos caused a heightened and prolonged Ca21 response. Thus, distinct
positive and negative mechanisms contribute to active selection of human embryos at implantation.
R
eproduction in humans is marred by early pregnancy failure. Approximately 15% of clinically recognized
pregnancies miscarry. When combined with pre-clinical losses, the true incidence is closer to 50%, ren-
dering miscarriage by far the most common complication of pregnancy1,2. This exceptional attrition rate is
attributed to the intrinsic invasiveness of human embryos and the high prevalence of chromosomal errors. Based
on genome-wide screening of individual blastomeres, in excess of 70% of high-quality cleavage-stage IVF
embryos reportedly harbor cells with complex large-scale structural chromosomal imbalances, some caused by
meiotic aneuploidies but most by mitotic non-disjunction3–5. The incidence of aneuploidy in human embryos is
estimated to be an order of magnitude higher than in other mammalian species. Further, a vast array of
chromosomal errors has been detected in human embryos throughout all stages of pre-implantation develop-
ment. Many of the chromosomal abnormalities observed in blastocysts have never been recorded in clinical
miscarriage samples3, suggesting that these embryos either fail to implant or are rejected soon after breaching the
endometrial luminal epithelium2,6–8.
Evidence from several mammalian species indicates that the endometrium is intrinsically capable of mounting
an implantation response that is tailored to individual embryos. For example, microarray analysis of bovine
endometrium has identified gene signatures that are dependent on the origins (e.g. somatic cell nuclear transfer,
IVF, or artificial insemination) and developmental potential of the attaching embryo9. Using a co-culture system,
we reported previously that human endometrial stromal cells (HESCs) become sensitive to embryonic signals upon
differentiation into decidual cells and respond selectively to low-quality human embryos by inhibiting the secretion
of key implantation factors, including interleukin-1 beta, heparin-binding EGF-like growth factor, and leukemia
inhibitory factor10. Furthermore, aberrant decidualization of HESCs and lack of embryo sensoring are strongly
associated with recurrent pregnancy loss11–14. These observations led to the hypothesis that active embryo selection
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at implantation is essential for reproductive success11–14, although the
underlying mechanisms remain as yet poorly characterized.
A major obstacle is that human implantation events cannot be
studied directly. In culture, the developmental potential of human
embryos can only be assessed indirectly, foremost on morphological
criteria, and over a legally restricted period. To overcome these hur-
dles, we prospectively collected conditioned medium of individually
cultured human pre-implantation embryos and then characterized
the maternal response, in vitro as well as in a heterologous in vivo
model, to soluble factors produced by low-quality human embryos
and embryos of proven developmental competence. We report that
human embryos presage their developmental competence even prior
to implantation. The spectrumof endometrial responses to cues from
different embryos ranges widely, from enhanced expression of key
implantation factors to overt endoplasmic reticulum (ER) stress. We
also provide evidence that embryo-derived serine proteases are
involved in eliciting a maternal response tailored to the devel-
opmental potential of the conceptus.
Results
Developmentally impaired human embryos induce ER stress
response in decidualizing HESCs. We systematically collected the
conditioned medium of day 4 human IVF embryos, which had been
cultured individually for 72 h in microdroplets overlaid with mineral
oil. Next, we incubated primary decidualizing HESCs with pooled
culture supernatants from developmentally impaired embryos
(DIEs), which were deemed unsuitable for transfer15, and from
embryos that resulted in ongoing pregnancies after single embryo
transfer (developmentally competent embryos, DCEs; Table S1).
Control cultures consisted of decidualizing HESCs incubated with
unconditioned embryo culture medium (ECM). Incubation of
primary cultures was repeated three times with separate pools of
conditioned media from DCEs and DIEs. RNA was isolated from
decidualizing HESCs after 12 h of incubation and analyzed by
genome-wide expression profiling using DNA microarrays. Surpri-
singly, only 15 decidual genes were found to respond significantly
(P , 0.01) to signals emanating from DCEs. In contrast, 449
maternal genes were perturbed in response to medium conditioned
by DIEs (Fig. 1A; Table S1). Gene ontology annotation categorized
half of these maternal genes into three broad biological processes:
transport (20%), translation (17%), and cell cycle (13%) (Fig. 1B).
To investigate further the response of decidual cells to compro-
mised embryos, we focused onHSPA8, themost downregulated gene
in the array analysis (Table S2). This gene encodes HSC70, a ubiqui-
tously and constitutively expressedmember of the heat shock protein
70 family of molecular chaperones involved in the assembly ofmulti-
protein complexes, transport of nascent polypeptides and regulation
of protein folding16,17. HSC70 levels increased in primary HESCs
decidualized for 4 or more days (Fig. 1C). Small interfering
(si)RNA-mediated knockdown of this molecular chaperone reduced
the secretion of prolactin (PRL) and insulin-like growth factor-bind-
ing protein 1 (IGFBP1) (Fig. 1D and E), two highly sensitive differ-
entiation markers18. Cell viability was not affected significantly
(Fig. 1F).
Because of its role in protein homeostasis19,20, we postulated that
loss of HSC70 causes ER stress in decidual cells. In fact, decidualizing
HESCs mount a physiological unfolded protein response (UPR)
associated with ER expansion and acquisition of a secretory pheno-
type21. This UPR was characterized by synchronous induction of
various chaperones, including protein disulfide isomerase (PDI),
BIP (GRP78), endoplasmic oxidoreductin-1a (ERO1a), and cal-
nexin (Fig. 2A). In addition, differentiating HESCs upregulate the
expression of the three key ER signaling proteins, the serine/threo-
nine kinase inositol-requiring enzyme 1a (IRE1a), PKR-like
ER-localized eIF2a kinase (PERK), and the protease-activated tran-
scription factor ATF6, which collectively determine the cellular res-
ponse to ER stress signals21. Interestingly, HSC70 knockdown had
little or no effect on the expression of other ER chaperones or ATF6
Figure 1 | Decidualizing endometrial cells are biosensors of embryo quality. (a) Venn diagram presenting the number of transcripts regulated in
decidualizing HESCs significantly (P , 0.01) regulated in response to signals from developmentally competent embryos (DCE) and developmentally
impaired embryos (DIE). (b) Gene Ontology classification of decidual genes regulated in response to soluble factors secreted by DIE. (c) Western blot
analysis demonstrating the kinetics of HSC70 induction in primary HESC cultures decidualized with cAMP and MPA in a time-course lasting 8 d. b-
ACTIN served as a loading control. A representative result from three different primary cultures is shown. Full length images are presented as
Supplementary Information. (d) Primary HESCs were transfected with non-targeting (NT) siRNA or siRNA targeting HSC70, decidualized for 5 d, and
then immunoblotted for HSC70. b-ACTIN served as a loading control. Full length images are presented as Supplementary Information. (e) HSC70
knockdown inhibits the secretion of decidualmarkers, PRL and IGFBP1, in primaryHESC cultures differentiated in vitro for 5 d. The data representmean
(6SD) of triplicate experiments. * indicates P, 0.05, and *** P, 0.001. (f ) The percentage of viable HESCs, transfected first with non-targeting (NT)
siRNA or HSC70 targeting siRNA and then decidualized for 5 d, is presented relative to the number of viable cells in mock-transfected, undifferentiated
cells (dotted line). The data represent the mean (6SD) of three biological repeat experiments.
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but further enhanced the induction of IRE1a and PERK. In addition,
silencing of this molecular chaperone protein in decidualizing cells
markedly upregulated the levels of X-box binding protein 1 (XBP1)
and C/EBP-homologous protein (CHOP), downstream transcrip-
tion factors that couple ER stress to translational inhibition, induc-
tion of ER chaperones, cell cycle arrest and death21. We speculated
that lack of overt cell death upon HSC70 knockdown could be
accounted for by augmented autophagy21. In keeping with this
notion, the abundance of the microtubule-associated protein light
chain 3B (LC3B), a marker of autophagic activity22, increased mark-
edly upon HSC70 knockdown in decidualizing cells (Fig. 2A).
Confocalmicroscopy showed that the pattern of LC3B staining chan-
ged from being punctate and finely granular in undifferentiated and
decidualizing cells to immunoreactive aggregates upon HSC70 silen-
cing (Fig. 2B).
To test further the assertion that decidualizing HESCs mount an
ER stress response uponHSC70 knockdown, we transfected primary
cultures with pcDNA3/XBP1-luc, a plasmid in which human XBP1
cDNA is fused upstream of luciferase cDNA23. Under non-ER stress
conditions, the presence of an in-frame stop codon prevents the
expression of the downstream luciferase gene. Under ER stress con-
ditions, however, activated IRE1a splices the XBP1-luc transcript,
allowing translation of the luciferase cDNA. As shown in Fig. 2C,
decidualization of HESCs transfected with pcDNA3/XBP1-luc only
marginally enhanced luciferase levels whereas simultaneous HSC70
knockdown elicited a 5-fold induction.We then reasoned that decid-
ualizing HESCs transfected with pcDNA3/XBP1-luc could serve as a
bioassay to monitor ER stress responses induced by limited amounts
of ECM. Primary cells seeded in 96-well plates were first transfected
with the reporter construct, decidualized for 5 d, and then exposed
for 12 h to either unconditioned ECMor pooled spent medium from
DCEs or DIEs. In keeping with the array findings, soluble factors
derived from DIEs strongly induced luciferase expression whereas
this response was entirely absent upon incubation with uncon-
ditioned ECM or medium conditioned by DCEs (Fig. 2D).
Developmentally competent human embryos signal to promote
implantation. We next explored if the developmental potential of
human embryos impacts on the expression of uterine implantation
genes in vivo. Female C57BL/6 mice were hormonally stimulated to
Figure 2 | HSC70 knockdown induces ER stress in decidualizing stromal cells. (a) Total cell lysates from primary HESC cultures, transfected first with
non-targeting (NT) siRNA or siRNA targeting HSC70 and then decidualized with cAMP and MPA for 5 d, were immunoprobed for various proteins
involved in UPR, ER stress, and autophagy as indicated. b-ACTIN served as a loading control. Full length images are presented as Supplementary
Information. (b) HSC70 knockdown in HESCs promotes autophagosome formation. Primary cells cultured on chamber slides were transfected with
either non-targeting (NT) or HSC70 targeting siRNA, decidualized for 5 d, stained for LC3B expression (green) and subjected to confocal microscopy.
The nuclei were visualized with DAPI (blue). (c) Primary cultures were co-transfected with pcDNA3/XBP1-luc, pRL-sv40 and either siRNA targeting
HSC70 or NT siRNA. The cells were left untreated or differentiated for 5 d before measuring luciferase activity. The results show the normalized mean
firefly luciferase activity (6SD), expressed in relative light units (RLU), of four biological repeat experiments. *** indicates P , 0.001. (d) Confluent
cultures were transfected as described in (c), left untreated (control) or decidualized for 5 d, and then exposed to 30 ml of unconditioned embryo culture
medium (ECM) or media conditioned by DCEs or DIEs for 12 h. The results show normalized mean luciferase activity (6SD), expressed in relative light
units (RLU), of three biological repeat experiments. *** indicates P , 0.001.
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induce uterine receptivity and the lumen flushed with 50 ml of
unconditioned ECM or pooled conditioned culture medium from
humanDCEs or DIEs. The animals were sacrificed 24 h later and the
uterine transcriptome sequenced. As in the experiments with
primary HESCs, many more genes (,63) were altered in response
to exposure of the uterine lumen to DIE versus DCE conditioned
medium (Fig. 3A). However, the extent and amplitude of the
transcriptional response to DCE was much more pronounced in
vivo when compared to decidualizing primary HESC cultures.
Strikingly, 27 of 90 (30%) uterine genes solely responsive to DCE
signals code factors that have already been implicated in the
implantation process (Table S3), including COX-2 (Ptgs2),
Cytochrome P450 26a1 (Cyp26a1), and osteopontin (Spp1)24–26. In
addition, exposure to DCE signals strongly upregulated a group of
metabolic genes, which included Fabp4, Plin1, Cidec, Adipoq, Retn,
and Car3 (Fig. S1). Fatty acid binding protein 4 (Fabp4) is a widely
used marker of differentiating adipocytes27. Cell death-inducing
DFF45-like effector c (Cidec) promotes lipid droplet expansion
whereas perilipin 1 (Plin1) prevents lipase-dependent breakdown
of lipid droplets under basal conditions28. Further, adiponectin
(Adipoq) and resistin (Retn) are key adipokines involved in regulat-
ing energy intake and expenditure as well as insulin sensitivity29.
Taken together, the data point towards the existence of an evolu-
tionarily conserved network of maternal genes that is responsive to
embryonic signals and contributes to post-implantation develop-
ment. By contrast, the response to DIE signals had the hallmarks
of a stress response (Fig. S2). This was confirmed by Western blot
analysis demonstrating strong uterine expression of Xbp1, Chop and
Lc3b in response to DIE signals (Fig. S3). Notably, a modest stress-
like response was also apparent upon flushing of the uterine lumen
with medium conditioned by DCEs, which may point towards the
induction of a decidual response and associated UPR.
The role of embryo-derived trypsin in maternal embryo recogni-
tion. A surprising observation was the induction of Prss28 (68-fold)
and Prss29 (6-fold) mRNAs in the mouse uterus in response to DCE
signals (Table S3). Prss28 and Prss29 are implantation-specific serine
proteases that exhibit trypsin-like substrate specificity30,31. Embryo-
nic tryptases activate Ca21 signaling and upregulate COX-2 levels in
murine endometrial epithelial cells (EECs), leading to prostaglandin
production required for implantation26. Prss28 and Prss29 have no
functional homologs in humans32, suggesting a compensatory role
for other serine proteases or, perhaps, that tryptic activity is no longer
involved in embryo-EEC signaling. Comparative analysis of gene
expression data showed that (Fig. S4 & S5), unlike their murine
counterparts, developing human embryos up- and down-regulate
the expression of TMPRSS15 and AMBP coding for the trypsi-
nogen activator (enterokinase) and trypsin inhibitor (trypstatin/
bikunin precursor), respectively (Fig. S5). Trypsin activity was
detectable in culture medium conditioned by human embryos
(Fig. 3B). Furthermore, exposure of Ishikawa cells (a cell line
model for human EECs) to spent embryo medium induced
Figure 3 | Competent pre-implantation human embryos actively induce a supportive uterine environment. (a) Venn diagram presenting the number of
maternal genes significantly (P, 0.01) altered 24 h after exposure ofmouse uterus to unconditioned embryo culturemediumormedium conditioned by
either developmentally competent or impaired human embryos (DCE and DIE, respectively). (b) Tryptic activity was measured in 16 cultures
containing a total of 163 human embryos between day 4 to 6 of development. Activity in unconditionedmediumwas below dotted line. (c) Application of
embryo-conditioned medium induces [Ca21]i oscillations in Ishikawa cells. Black traces show [Ca
21]i recordings from individual cells in response to
application of 1520 diluted culturemediumobtained fromDCE (top panel) orDIE (bottompanel). Red traces represent average of all individual traces in
each panel. (d) Total protein lysates obtained from Ishikawa cells 24 h after treatment with trypsin (10 nM) for 5 min were subjected to western blot
analysis and immunoprobed for COX2. b-ACTIN served as a loading control. Full length images are presented as Supplementary Information.
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oscillatory increases in intracellular Ca21 ([Ca21]i). Interestingly,
[Ca21]i oscillations were discrete, lasting approximately 5 min, in
response to DCE medium (Fig. 3C, upper panel). This contrasted
to more pronounced and much longer oscillations when cells were
exposed to DIE signals (Fig. 3C, lower panel). The [Ca21]i fluxes
induced by embryonic cues bore a striking similarity to [Ca21]i
oscillations induced upon application of trypsin (Fig. S6A and D).
Soybean trypsin inhibitor dramatically decreased [Ca21]i signals
induced by spent embryo medium (Fig. S6B and D). Conversely,
embryo-induced [Ca21]i oscillations greatly attenuated the
subsequent [Ca21]i responses to trypsin (Fig. S6C and D). Finally,
short exposure to trypsin (5 min) was sufficient to upregulate COX-2
expression in Ishikawa cells (Fig. 3D). These data indicate that EECs
serve to amplify discrete embryonic protease signals that induce a
supportive maternal environment.
Discussion
Conflict between parent and offspring is thought to drive reproduct-
ive evolution and innovation33. This hypothesis predicts that the
embryonic genome evolves to extract as much as possible from the
mother to ensure its propagation whereas maternal genes will adapt
to safeguard the success of current as well as future offspring. Thus,
reproductive success in different species depends on balancing evol-
ving embryonic and maternal traits34–36. A singular feature of the
reproductive cycle in humans, shared with very few other mam-
malian species, is menstruation, a process triggered by ‘spontaneous’
decidualization of the endometrium in an embryo-independent
manner36,37. When placed in the context of fetal-maternal con-
flict33,38, our findings indicate that cyclic decidualization coupled to
menstruation emerged as a strategy for early detection and active
rejection of developmentally abnormal embryos that have breached
the luminal epithelium.We show that decidual cells mount an extra-
ordinarily polarized transcriptional response to embryonic signals,
ranging from being exceptionally discrete in case of a competent
embryo to extensive and complex in the presence of a low-quality
embryo.We further demonstrate thatHSPA8 is particularly sensitive
to signals from DIEs. Down-regulation of this molecular chaperone
in decidual cells converts the differentiation-associated UPR into an
overt ER stress response, which in turn compromises secretion of
decidual factors, including PRL and IGFBP1, essential for placental
formation and fetal development.
Conversely, this study shows that competent pre-implantation
human embryos have retained the ability to actively enhance the
uterine environment for implantation. This response to DCE signals
is characterized by the induction of 29 known implantation factors,
including COX-2, as well as various metabolic enzymes involved in
lipid accumulation, glucose uptake, and energy expenditure (Table
S3). Interestingly, several of these metabolic genes (e.g. Cidec, Plin1,
Adipoq, Retn and Fabp4) are transcriptionally regulated by peroxi-
some proliferator-activated receptor gamma (PPARc) in adipo-
cytes39–41, suggesting that embryonic signals activate this nuclear
receptor in the endometrium, perhaps indirectly via induction of
COX-2-dependent prostaglandin production42. In mice, initiation
of implantation requires release of embryonic serine proteases, which
in turn activate epithelial Na1 channel (ENaC) in EECs, triggering
Ca21 influx and induction of COX-226. Several lines of evidence
indicate that this implantation pathway is not only conserved in
humans but also important for embryo sensoring. We found that
tryptic activity is detectable in medium conditioned by human
embryos even before hatching. Incubation of EECs with ECM eli-
cited [Ca21]i oscillations, a response markedly blunted by soybean
trypsin inhibitor and recapitulated upon treatment of cells with low
concentrations of trypsin. Further, brief exposure of EECs to trypsin
was sufficient to induce COX-2 expression. In silico analysis showed
that progression to the blastocyst stage is associated with gene
changes predictive of increased expression and activation of various
proteases implicated in ENaC activation, although the pattern of
expression of individual genes during pre-implantation development
frequently differs between mouse and human embryos (Fig. S4 & S5
and data not shown). Remarkably, cues from competent human
embryos strongly induced two non-conserved implantation-specific
serine proteinases, Prss28 (also known as implantation serine prote-
ase 1 or ISP1) and Prss29 (ISP2), in the mouse uterus. These prote-
ases are also co-expressed in pre-implantation murine embryos30,31.
ISP1 and 2 heterodimerize and form an enzymatic complex essential
for blastocyst hatching, outgrowth and implantation in mice. Taken
together, these observations suggest that endometrial protease pro-
duction accelerates as the embryo approaches the surface epithelium,
perhaps aligning hatching of the blastocyst with implantation. By
contrast, low-quality human embryos triggered prolonged and dis-
organized [Ca21]i oscillations in EECs and an uterine stress response
in vivo. The mechanism that couples these events warrants further
investigations, although it is likely to involve illicit, excessive or
unopposed activation of embryonic proteases, leading to proteotoxic
stress in both the conceptus and surrounding maternal cells. This
conjecture is supported by the observation that DCE but not DIE
signals strongly enhance uterine expression of Spink3, which codes
for the secreted serine protease inhibitor Kazal type 3 (SPINK3). The
human homolog SPINK1 critically protects the pancreas from auto-
digestion by preventing premature protease activation43,44.
In summary, reproductive success in humans depends on sus-
tained maternal investment in one - occasionally two - implanting
embryos. Genomic instability, giving rise to a vast array of chromo-
somal errors of variable complexity3, is prevalent in human embryos
throughout all stages of pre-implantation development. This
engrained diversity in embryo quality poses an obvious maternal
challenge. Our observations show that both positive and negative
selection mechanisms govern implantation (Fig. 4), rendering this
process intrinsically dynamic and adaptable to individual embryos.
Methods
Experimental ethics policy. This study was approved by the Medical Review Ethics
Committee of the University Medical Center Utrecht, the Central Committee for
Research on Human Subjects in The Netherlands (NL 12481.000.06), and the
Hammersmith and Queen Charlotte’s & Chelsea Research Ethics Committee (1997/
5065). Written informed consent was obtained from all participating subjects.
Primary cultures. Endometrial samples were obtained during the secretory phase at
the time of hysterectomy for benign indications or as an outpatient procedure using
using a Wallach EndocellTM sampler (Wallach, USA) under ultrasound guidance.
HESC cultures were established, passaged once and decidualized with 0.5 mM 8-
Bromo-cAMP (Sigma, UK) and 1026 Mmedroxyprogesterone acetate (MPA; Sigma,
UK) as previously described45.
Embryo conditioned media. All patients underwent ovarian stimulation with
recombinant FSH and final oocyte maturation was triggered with hCG. Human
embryos were cultured in microdroplets (30 ml) of Human Tubal Fluid medium,
supplemented with 5% GPO (40 g/l pasteurized plasma protein, containing 95%
albumin) under mineral oil from the second day after oocyte retrieval until day 4
(morula stage). The supernatants were collected from individually cultured embryo
that resulted in pregnancy after transfer of a single fresh embryo (n 5 40) and from
embryos deemed of poor quality (n 5 49), and unsuitable for embryo transfer based
on standard morphological criteria15. In parallel, microdroplets not containing
embryos were collected for control experiments.
Microarray analysis of primary HESC cultures and gene ontology. Primary HESCs
were plated in 48-well tissue culture-grade plates, decidualized with 8-Bromo-cAMP
and MPA for 5 d, and then incubated for 12 h with 100 ml of separately pooled
supernatants, each derived from 10 individually cultured embryos. Three pools of
conditioned media used were from DCEs and three from DIEs. Total RNA from
HESCs in individual wells was subjected to microarray analysis. Human 70-mer
oligos (Operon, Human V2 AROS) spotted onto Codelink Activated slides
(Surmodics USA) were used for genome-wide expression profiling. RNA
amplifications, labeling and hybridizations were performed as described46. Briefly,
500 ng of each amplified cRNAwas coupled to Cy3 or Cy5 fluorophores (Amersham,
UK) and subsequently hybridized on aTecanHS4800PRO and scanned on anAgilent
G2565BA microarray scanner. After data extraction using Imagene 8.0
(BioDiscovery), print-tip Loess normalization was performed on mean spot-
intensities without background subtraction 30. Data were analyzed using ANOVA (R
version 2.2.1/MAANOVA version 0.98-7) (http://www.r-project.org/). Genes with a
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P, 0.01 after false discovery rate correction were considered significant. In addition,
a 1.2 fold-change cutoff was applied and the resulting gene lists used for gene ontology
(GO) analysis. Regulated genes were mapped to GO-slim categories according to the
Gene Ontology Consortium: (http://www.geneontology.org/GO_slims/goslim_
generic.obo). Microarray data have been submitted to ArrayExpress under accession
number E-TABM-1064.
Animal experiments. C57BL/6 mice were purchased from Charles River Ltd
(Margate, UK) and all experiments were carried out in accordance with the UKHome
Office Project Licence (PPL70/6867). Immature female (3-week old) mice received a
single dose of 1 mg progesterone and 10 mg/kg/day b-estradiol (Sigma) for a total of
3 d to prime the uterus for embryo transfer. The uterine horns of control and study
mice were injected with an equal volume (50 ml) of either unconditioned embryo
culture medium (ECM), serving as controls, or pooled conditioned media from DCE
(n5 9) or DIE embryos (n5 18). The cervix was not clamped. Then, the incision was
closed to allow recovery of themice. The control and treatment groups each consisted
of three animals. Themice were sacrificed 24 h later and uteri either fixed in formalin
or snap-frozen and stored at 280uC for RNAseq and protein analyses. Both uterine
horns of each animal were analyzed individually.
RNAseq analysis of mouse uteri. Uterine mRNA profiles of 25-day old wild-type
(WT) mice were generated by deep sequencing, in triplicate, using Illumina HiSeq
2000 platform. The sequence reads that passed quality filters were analyzed with the
following methods: Bowtie Alignment followed by TopHat (splice junctions mapper)
and Cufflinks (transcript abundance). Sequence data have been submitted to GEO
(GSE47019).
Transfections of primary endometrial cells. Primary HESCs at 80% confluency
were transfected with DNA vectors or small interfering RNA (siRNA)
oligonucleotides by the calcium phosphate co-precipitation method using the
ProFection mammalian transfection kit (Promega, Madison, WI) according to the
manufacturer’s instructions. Reporter assays were done in 96-well plates. The X-box
binding protein 1 (pcDNA3/XBP1-luc) reporter construct was a kind gift from Dr.
Etsu Tashiro (Keio University, Tokyo, Japan). A constitutively active renilla
expression vector (pRL-sv40) served as an internal transfection control. The plates
were washed twice in phosphate-buffered saline (PBS) and firefly and Renilla
activities were measured using the Luclite luciferase reporter assay system (Luclite,
PerkinElmer, Boston, MA) and the luminescence was measured on a Victor II plate
reader (PerkinElmer). For gene-silencing studies, HESCs were cultured in 6-well
plates until 80% confluency and transiently transfected with 100 nM of the following
siRNA reagents (Dharmacon, Lafayette, CO): siCONTROL non-targeting (NT)
siRNA pool and HSPA8 siGENOME SMARTpool. All experiments were performed
on three or more primary cultures from different endometrial biopsies.
Figure 4 | Positive and negativemechanisms contribute to active selection of human embryos at implantation. (A) Developmentally competent human
embryos secrete evolutionary conserved serine proteases that activate epithelial Na1 channel (ENaC) expressed on luminal epithelial cells26, triggering
Ca21 signalling and, ultimately, induction of genes involved in implantation and post-implantation embryo development. In concert, the decidualizing
endometrium secretes serine protease inhibitors, such as murine SPINK3 and the human homolog SPINK1, to limit embryo-derived proteolytic activity.
Note that acquisition of a secretory phenotype upon decidualization depends on massive expansion of the ER in HESCs. (B) By contrast, excessive
protease activity emanating from developmentally compromised embryos that have breached the luminal epithelium down-regulates the expression of
molecular chaperones in surrounding decidual cells, leading to accumulation ofmisfolded proteins and ER stress. This in turn compromises decidual cell
functions and triggers tissue breakdown and early maternal rejection.
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Western blot analysis. Protein extracts were prepared by lysing cells in RIPA buffer.
Protein yield was quantified using the Bio-Rad DC protein assay kit (Bio-Rad, USA).
Equal amounts of protein were separated by 10% SDS-Polyacrylamide Gel
Electrophoresis (SDS-PAGE) before wet-transfer onto PVDFmembrane (Amersham
Biosciences, UK). Nonspecific binding sites were blocked by overnight incubation
with 5% nonfat dry milk in Tris-buffered saline with 1% Tween (TBS-T; 130 mmol/L
NaCl, 20 mmol/L Tris, pH7.6 and 1% Tween). Primary antibodies used were anti-
HSC70 (Abcam, UK), anti-BiP, anti-Calnexin, anti-ERo1a, anti-CHOP, anti-PERK,
anti-PDI, anti-LC3B, anti-COX2 (Cell Signaling, USA) and b-ACTIN (Abcam, UK)
which was used as a loading control. All primary antibodies were diluted 151000;
except for the anti-b-ACTIN, which was diluted 15100,000. Full length scans are
presented as supplementary information. Note that some images were reflected for
consistency in the sequence of presentation.
PRL, IGFBP1, and trypsin activity measurements. PRL and IGFBP-1 levels in the
HESC culture media were determined using an amplified two-step sandwich-type
immunoassay (R&D Systems, UK) according to the manufacturer’s protocol. The
Trypsin Activity Assay Kit (ABCAM) was used according to the manufacturer’s
instructions tomeasure trypsin activity in undiluted ECM and unconditioned culture
medium (control). Trypsin activity in ECM was measured between day 4–6 of
embryo development in 16 cultures (containing a total of 163 embryos). The ECM
and unconditioned control medium were stored at 280uc until analysis.
Cell viability assays. Cultured HESCs were seeded in 96-well black plates with clear
bases and maintained in 10% DCC/DMEM until they become confluent. Cells were
transfected with or without siRNA targeting HSPA8 and then subsequently
decidualized or left untreated for a total of 6 d. Cell viability was evaluated using the
ApoTox-GloTM Triplex Assay (Promega, USA) according to the manufacturer’s
instructions.
Confocal microscopy and immunohistochemistry. Primary HESCs cultured on
chamber slides were transfected with either siRNA targetingHSPA8 or non-targeting
siRNA and then either remained untreated or were decidualized with 8-Bromo-
cAMP and MPA for 5 d. ER stress in control cultures was induced by treating cells
with thapsigargin for 12 h (Sigma, UK). Cells were then fixed in 4% para-
formaldehyde and permeabilized in 0.5% Triton. Primary antibodies, incubated
overnight at 4uC in a humidified chamber (anti-LC3B 15400). The secondary
antibody used was labeled with Alexa FluorH 488 (15200; Invitrogen). Slides were
mounted with proGOLD (Invitrogen) and stained with 49,6-diamidino-2-
phenylindole (DAPI) to visualize nuclei. Images were captured using a Leica SP5 II
confocal microscope.
Confocal imaging of intracellular calcium ([Ca21]i). Experiments were performed
on Ishikawa cells cultured in glass bottomed 35 mm Petri dishes as described. For
imaging of [Ca21]i, cells were incubated for 40 min at room temperature in
physiological saline solution (PSS) containing 5 mM Fluo-4/AM (Invitrogen, UK).
Non-ionic detergent Pluronic F127 (0.025%, w/v) was included to aid the dye loading.
After incubation with Fluo-4/AM, the cells were washed with PSS and the dish was
mounted in a temperature-controlled environmental chamber on the stage of a
confocal microscope (LSM 510 META, Carl Zeiss, UK). The cells were superfused
with pre-warmed (35uC) Krebs solution for 20–30 min to ensure complete de-
esterification of Fluo-4/AM. For image acquisition, perfusion was stopped and
solution volume in the Petri dish adjusted to 200 ml. Fluo-4 fluorescence was excited
using 488 nm line of argon ion laser. Images were recorded at 1 frame per second
through the C-Apochromat 633/1.20 W objective lens. Two time series were
acquired from each Petri dish. During the first time series, baseline activity was
recorded for 2 min, then 10 ml of conditioned embryo culture medium was added to
the Petri dish and the recording continued for another 5 min. The second time series
was acquired from the same viewing field after 10 min break. In control experiments,
10 ml of unconditioned instead of conditioned ECM was added. Experiments with
trypsin and trypsin inhibitor were conducted in a similar manner. Trypsin (TRLS,
Cat# LS003734) and soybean trypsin inhibitor (SI, Cat# LS003570) were purchased
fromWorthington Biochemical Corp., Lakewood, NJ, USA). Off-line image analysis
was performed using ImageJ (NIH, http://imagej.nih.gov/ij/). Regions of interest
(ROI) were drawn around each cell within the field of view. The Multi Measure
function in the ImageJ ROI Manager was used to extract intensity profiles over time
for each ROI. Intensity profiles were imported into Origin 8.5 (OriginLab
Corporation, USA) for further processing, graphing and statistical analysis. Each
trace was normalized to its corresponding baseline to yield a self-ratio trace (F/F0).
The [Ca21]i signals induced by embryo-conditioned media were quantified as area
under the curve (AUC) calculated above the base line (DF/F0) for the first and the last
5 min time periods of the conditioned medium treatment.
Statistical analysis. Statistical analysis was performed by ANOVA with Bonferroni
correction, Student t-test or Mann Whitney U test, as appropriate.
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